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Abstract 
 
Cytochrome P450s (CYPs) are a superfamily of enzymes involved in the phase I 
metabolism of endogenous and exogenous substances. They are present in almost 
all forms of life and have been studied extensively, particularly in relation to human 
medicine, where knowledge of their activities is essential for predicting drug-drug 
interactions. In the horse, little is currently known about CYP-specific drug 
metabolism, which holds importance for animal welfare and for doping control within 
the horseracing industry where drug-specific metabolites are tested for on race days. 
Recently the first recombinant equine CYPs have been produced, allowing specific 
data on equine P450 activity to be gathered for the first time. During the current 
study,46 full-length P450 sequences were identified from the equine genome. RT-
PCR analysis was then carried out on equine liver in order to detect hepatic 
expression of P450s across various families. After this, cold-induction (pCold) E. coli 
were used for production of recombinant P450 proteins for subsquent functional 
testing. Four recombinant equine P450s were successfully expressed (CYP1A1, 
CYP2A13, CYP2C92 and CYP2D50). Due to being the isoforms most likely to be 
involved in drug metabolism, rCYP2D50 and rCYP2C92 were selected to be 
screened against ten of the most commonly used horse drugs to identify potential 
substrates. rCYP2C92 appeared to metabolise all four NSAIDs tested (flunixin, 
ketoprofen, phenylbutazone and diclofenac), however presence of the known 
hydroxylated metabolites of diclofenac and phenylbutazone (4-hydroxydiclofenac 
and oxyphenbutazone, respectively) could not be confirmed despite being present 
within equine liver microsome and human recombinant CYP2C9 samples. In spite of 
the apparant acivity displayed by rCYP2C92 towards all four NSAIDs, no 
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conclussions can be made about this enzyme’s role in NSAID metabolism due to a 
lack of known hydroxylated metabolite production.  
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Chapter 1: Introduction 
 
1.1: Overview 
 
The study of what happens to exogenous substances when they enter the body can 
be traced back as far as the middle ages (Brater and Daly, 2000), however the field 
of pharmacology and evidence-based medicine did not fully develop until the 19th 
century, with the establishment of the first pharmacology department and, 
subsequently, the theory that drugs interact with receptors within the body (Rang, 
2006). From here, the field grew exponentially, with the establishment of 
pharmacology departments throughout the world along with a focus on the actions of 
drugs on organs (Scheindlin, 2001).  
Today, pharmacology can be separated into two main branches – 
pharmacodynamics and pharmacokinetics (PD and PK, respectively). 
Pharmacodynamics is the study of how a drug affects the body while 
pharmacokinetics relates to how the body affects the drug (Lees et al, 2004). 
Combined PK/PD models are used in clinical pharmacology as a critical part of the 
drug development process, allowing clinical effects and optimal dosing regimens to 
be determined (Derendorf et al, 2000).  
PK can be further sub-divided using the acronym ADME – absorption, disposition, 
metabolism and excretion (Balani et al, 2005). ADME is an integral part of the drug 
development process and improvements in pharmacokinetic methods have resulted 
in less than 10% of New Chemical Entities (NCEs) failing at this stage by the 2000s 
(Kola and Landis, 2004). This is in contrast to almost 40% of NCEs failing due to 
ADME problems at this stage in the 1980s (Prentis et al, 1988). 
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1.2: The liver 
 
The majority of drug metabolism takes place in the liver and as such it plays a 
central role in the study of drug metabolism (Sahi et al, 2010). As the largest internal 
organ, the liver carries out many vital roles within the body. Synthesis, metabolism 
and excretion are all essential liver functions, some examples of which are the 
storage of glycogen, the synthesis of various essential biological compounds such as 
cholesterol and glucose, breakdown of both ingested and exogenous substances 
and biliary excretion (Dias et al, 2009).  
1.2.1: Liver architecture 
 
Figure 1.2.1 displays an outline of liver anatomy. The liver is divided into lobes and 
has blood supply from the hepatic artery and portal vein, which provide the organ with 
nutrients and oxygen (Ishibashi et al, 2009). The liver can be further sub-divided into 
lobules, and figure 1.2.2 displays a schematic representation of a lobule while figure 
1.2.3 shows a section of a lobule, highlighting the anatomical features. Lobules are 
the smallest structural component of the liver and within them hepatocytes line the 
capillaries in order to absorb materials in the blood supply via the sinusoids, which 
travels towards the central vein (Weibel et al, 1969).  
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Figure 1.2.1: Anatomy of the liver.  Lobes, blood supply and other anatomical features are 
highlighted. Adapted from “Textbook of Gastroenterology: Liver: Anatomy, Microscopic Structure, and 
Cell Types”. By Kanel, G.C, 2009.  
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Figure 1.2.2: Schematic representation of a liver lobule. Hepatocytes line the capillaries of the 
lobule in order to absorb material present in the blood.  © IMAIOS 2012.  
 
 
Figure 1.2.3: Schematic representation of a section of liver lobule. Blood floods towards the 
central vein through the portal vein and sinusoids. Adapted from “Liver stem/progenitor cells: their 
characteristics and regulatory mechanisms” by Tanaka, M, Itoh, T, Tanimizu, N and Miyajima, A, 
2011, Journal of Biochemistry: 149(3):231-9.  
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Hepatocytes are the most important cells in the liver for its synthesis and metabolic 
functions and they make up around 80% of its volume (Godoy et al, 2013). The rest 
of the liver is composed of non-parenchymal cells - stellate cells, Kupffer cells and 
sinusoidal endothelial cells (Malik et al, 2002). Sinusoidal endothelial cells are 
involved in transport and filtration of macromolecules within the liver as well as some 
metabolic processes (De Leeuw et al, 1990), Kupffer cells mediate the immune 
response within the liver (e.g. phagocytosis and antigen presentation (Bilzer et al, 
2006), and stellate cells (also known as fat-storing cells) play an essential role in 
regulation and storage of retinoids (Senoo et al, 2004) however when ‘activated’ they 
can contribute to liver fibrosis (Krizhanovsky et al, 2011). Making up most of the 
mass of the liver, hepatocytes are responsible for the majority of the liver’s metabolic 
processes, from the synthesis of macromolecules to the metabolism of xenobiotics 
(Godoy et al, 2013).  
1.3: Xenobiotic metabolism 
 
When material enters the digestive tract, it may be toxic and consequentially a 
method of detoxification has evolved. The liver provides this detoxification method 
and can be seen as the first line of defence against potentially dangerous toxins after 
the digestive tract, consequentially meaning it is the major organ involved in drug 
metabolism (Gonzalez and Lee, 1996), since most drugs are administered orally 
(Mcginnity et al, 2004). It is a rich source of the enzymes involved in drug 
metabolism and various factors can affect the speed and efficacy that substances 
are processed here, such as age (Kinirons and O’Mahony, 2004), diet (Walter-Sack 
and Klotz, 1996) and gender (Tanaka, 1999). The large surface area of the liver 
means it is able to accommodate a higher level of drug metabolising enzymes 
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compared with other organs. The endoplasmic reticulum of hepatocytes provides a 
large surface area for drug metabolising enzymes and consequentially this is where 
such enzymes are accommodated (Stier, 1976). There are two distinct types of drug 
metabolising enzyme – phase I and phase II. Phase I can also be referred to as the 
modification phase and generally results in an active metabolite being produced 
(Omiecinski et al, 2011). Cytochrome P450s (or CYPs) are the major phase I 
metabolism enzyme family (see figure 1.3 for a chart of the major human phase I 
metabolism enzymes). Phase II (or conjugation) involves a diverse group of 
enzymes which generally take an ‘active’ substrate and deactivate it while making it 
water soluble and ready for excretion in urine or bile (Jakoby and Ziegler, 1990).  
 
Figure 1.3: Contribution of phase I enzymes towards human drug metabolism.  ALDH = 
aldehyde dehydrogenase, ADH, alcohol dehydrogenase, NQO1 =  NAD(P)H dehydrogenase, quinone 
1. Adapted from “Pharmacogenomics : Translating Functional Genomics into Rational Therapeutics” 
by Evans, W and Relling, M, 2009, Science: 286: 487 
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1.4: Cytochrome P450s 
 
CYPs were first discovered by Klingenberg (1958) in pig liver microsomes and their 
presence was confirmed by Omura and Sato (1964) when it was noted that they 
showed an unusual absorbance spectrum of 450 nm when bound with carbon 
monoxide, hence the name P450. Like other cytochromes, they are haemproteins, 
containing a haem cofactor in their reaction site, and are involved in electron transfer 
reactions (Gray and Winkler, 1996). They are distinct however in that they are 
primarily involved in detoxification and steroidogenesis, unlike other cytochromes 
which are involved in cellular energy generation (Reedy and Gibney, 2004). They are 
classed as mixed function oxidases, or monooxygenases, due to the fact they act as 
catalysts for the introduction of a single molecular oxygen atom (with a simultaneous 
reduction of the other oxygen atom into H2O) into their substrates (Sono et al, 1996).  
CYPs are present in both eukaryotic and prokaryotic organisms, although it is 
important to note that not all living things contain them – Escherichia coli (E. coli), for 
example, lacks any P450 genes (Werck-reichhart and Feyereisen, 2000). There are 
two distinct classes of P450 – class I and class II, with class I being found 
predominantly in prokaryotes and class II in eukaryotes (Roberts et al, 2002). Class I 
P450s are found in the mitochondria (Omura, 2006). In bacteria, they often have 
roles in the metabolism of antimicrobial compounds while in eukaryotes they have 
thus-far only been attributed to endogenous metabolism, specifically relating to 
adrenal and sex hormones (Omura and Morohashi, 1995). Class II P450s (otherwise 
known as microsomal P450s) are solely a eukaryotic class of P450 and are 
responsible for the vast majority of xenobiotic metabolism in eukaryotes as well as 
metabolism of endogenous compounds (Nebert and Gonzalez, 1986).  
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1.4.1: Mechanism of CYP-based metabolism 
 
As phase I metabolism enzymes, P450s can be seen as the first line of defence 
against potential toxins after digestion. Together with nicotinamide adenine dinucleotide 
(NADPH), cofactors (cytochrome b5 and cytochrome P450 reductase) and oxygen 
they generally create an active metabolite (see figure 1.4.1). It is possible to 
summarise CYP-based metabolism based on the following four main stages 
(Meunier et al, 2004):  
1. Substrate binding: this occurs near the haem cofactor, which is located in 
the active site. The spin-state is altered (low to high) and consequentially 
the spectral properties of the enzyme change, from ~420nm to 390nm 
(Schenkman and Jansson, 2006). 
2. Reduction of the haem: an electron is transferred from NADPH and the 
haem cofactor is reduced to the ferrous state (Fe3+ to Fe2+). 
3. Binding of molecular oxygen: molecular oxygen binds to the ferrous haem 
iron to form a dioxygen complex. 
4. Second reduction and subsequent protonation: the dioxygen complex is 
reduced and becomes negatively charged. This forms a peroxo group 
which is protonated twice and P450 compound I is released (Rittle and 
Green, 2010). 
From here, the metabolites, which are most often active, move onto phase II of the 
metabolism process where they are generally detoxified and excreted.  
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Figure 1.4.1: The P450 cycle. AH represents the substrate and CPR represents cytochrome 
P450 reductase. B5 represents cytochrome b5 and b5R represents cytochrome b5 reductase, 
which are involved in the electron transport cycle for some – but not all – P450s. Adapted from 
“Biodiversity of the P450 catalytic cycle: yeast cytochrome b5/NADH cytochrome b5 reductase 
complex efficiently drives the entire sterol 14-demethylation (CYP51) reaction” by Lamb, D.C., 
Kelly, D.E., Manning, N.J., Kaderbhai, M.A., Kelly, S.L., 1999, FEBS Letters: 462(3):283-8 
 
1.5: Other phase I metabolism enzymes  
 
Although P450s catalyse most of the phase I metabolic processes, there are 
numerous other enzymes, which are not related to them, involved in phase I 
metabolism. Most metabolise endogenous substances however a notable few are 
essential in drug metabolism, although some have the same substrates as CYPs. 
The most significant non-P450 phase I enzymes are flavin monooxygenases, 
monoamine oxidase, alcohol dehydrogenase, aldehyde dehydrogenase, aldehyde 
oxidase and xanthine oxidase (Beedham, 1997).  
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1.5.1: Flavin monoxygenase 
 
Flavin Monoxygenases (FMOs) are found in microsomes along with the more 
abundant P450s and, like P450s, use NADPH as a cofactor (Zeigler, 1993). Many of 
the drug metabolites produced by FMOs are the same as for P450s thus it can be 
difficult to differentiate between them in vivo or in microsomal studies, however some 
substrate specificities are known (Cashman, 2000).They are involved in the 
metabolism of various xenobiotics ranging from pesticides to some drugs such as 
nicotine and tamoxifen (Damani et al, 1988, Parte and Kupfer, 2005). FMOs have 
also been implicated in trimethylaminuria (‘fish odour syndrome’) due to a lack of 
conversion of trimethylamine by FMO3 into the odourless metabolite trimethylamine-
N-oxide (Messenger et al, 2013).   
1.5.2: Alcohol dehydrogenases 
 
Alcohol dehydrogenases are the major enzymes involved in alcohol metabolism in 
naive individuals (Edenberg, 2007), although ethanol is also a substrate of CYP2E1 
(see later section). They are found predominantly in the liver and stomach however 
they are expressed in various other tissues at lower levels (Estonius et al, 1996). 
Alcohol dehydrogenase converts ethanol into acetaldehyde, the compound thought 
to be the major cause of hangovers (Kim et al, 1994). There are seven alcohol 
dehydrogenase genes in human (Jörnvall et al, 2000) and they also metabolise other 
alcohols in addition to ethanol (Pocker et al,1985, Cotton and Goldman, 1988). 
Alcohol dehydrogenases have also been implicated in the metabolism of the 
endogenous alcohol retinol (Hellgren et al, 2007).   
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1.5.3: Aldehyde dehydrogenase 
 
Aldehyde dehydrogenase is the second enzyme involved in ethanol detoxification, 
where it oxidises acetaldehyde into a non-toxic metabolite (Crabb et al, 2004). There 
are 19 known aldehyde dehydrogenase genes in human (Marchitti et al, 2008). 
Variations in the aldehyde dehydrogenase genes have been linked to reduced 
prevalence of alcoholism (Crabb et al, 2004) as well as the alcohol flush 
phenomenon (Thomasson et al, 1991). The major site of aldehyde dehydrogenase 
expression is the liver although it is found in other tissues such as lung, ovary and 
stomach (Alnouti and Klaassen, 2008). Aldehyde dehydrogenases also metabolise 
other aldehydes such as formaldehyde and acrolein, which are found in cigarette 
smoke and car exhaust fumes, and dietary aldehydes such as benzaldehyde, which 
is used as a food flavouring (Vasiliou et al, 2004). 
1.5.4: Monoamine oxidases 
 
Monoamine oxidases are found in the outer membrane of mitochondria and 
metabolise biogenic amines and certain neurotransmitters (Tipton et al, 2004). The 
neurotransmitters they metabolise are monoaminergic neurotransmitters such as 
serotonin, noradrenaline and dopamine (Edmondson et al, 2004) and high/low levels 
of activity have been associated with mental illnesses such as schizophrenia and 
depression (Simpson et al, 1999, Meyer et al, 2006). Monoamine oxidase inhibitors 
are frequently used in psychiatry in order to increase the availability of the 
neurotransmitters they metabolise (Liebowitz et al, 1990). Monoamine oxidases are 
most abundant in certain types of neurons as well as placenta and platelets; 
however they appear to be expressed in most cell types (Chen, 2004). In addition to 
their link with mental illness, they have also been implicated in the development of 
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some neurodegenerative disorders via oxidative damage to mitochondria 
(Hauptmann et al, 1996).  
1.5.5: Xanthine oxidase 
 
Xanthine oxidase has received particular research attention due to its role in the 
development of conditions such as gout as well as its potential involvement in 
cardiovascular disease (Pacher et al, 2006). Its physiological role is not fully 
understood although some studies have suggested it has a bactericidal function 
(Silanikove et al, 2005), and others imply it may have a role in the production of 
antioxidants (Frederiks and Bosch, 1995).  Its most well-studied role relates to its 
involvement in purine and pyramidine metabolism however it is also important in the 
metabolism of some drugs, such as caffeine (Rashidi and Pashaei-asl, 2009).  
1.6: Phase II metabolism (conjugation) 
 
Phase II metabolism is often also termed conjugation due to the fact that in this 
stage of drug metabolism, the (generally) active metabolites from phase I are 
conjugated with compounds which make them less active and ready for excretion 
(Jakoby and Zeigler, 1990). Like with phase I enzymes, phase II enzymes are 
ubiquotous throughout the body, but are most highly expressed in the liver 
(McCarver and Hines, 2002). Phase II reactions have received less research 
attention that phase I enzymes, mostly because drug-drug interactions involving 
them are very rare (but not absent). Adverse drug reactions due to phase II 
metabolism can have substantial clinical significance (Bjornsson et al, 2003). One of 
the most well-known examples involves cats and their relative lack of the phase II 
enzyme UDP-glucuronosyltransferase – low expression levels here means the 
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enzyme is unable to convert in sufficient quantities the toxic metabolite of CYP-
based metabolism into its inactive form, which can result in severe hepatotoxicity 
(Allen, 2003). The main phase II enzymes are UDP-glucoronosyltransferases 
(UGTs), sufotransferases (SULTs), n-acetyltransferases (NATs) and glutathione S-
transferases (GSTs), Jancova et al (2010).  
UGTs catalyse the most abundant conjugation reaction – conjugating the substrate 
with α-D-glucuronic acid (Cashman et al, 1996). UGTs are highly expressed and 
between 40 and 75% of drugs are metabolised by them (Wells et al, 2004) and they 
are located on the luminal side of the endoplasmic reticulum, giving them direct 
access to phase I metabolism products (Tukey and Strassburg, 2000). At least 117 
UGTs have been identified in mammals (Mackenzie et al, 2005).  
SULTs conjugate various compounds but are particularly important in phenol, amine 
and alcohol metabolism (Glatt and Meinl, 2004). There are four families of SULT in 
human (SULT1, SULT2, SULT4 and SULT6) with there being 13 total known 
(Lindsay et al, 2008). NATs are primarily involved in the metabolism of compounds 
such as aromatic amines and hydrazine (Butcher et al, 2002). Two forms of the 
enzyme are found in humans – NAT1 and NAT2 (Hein et al, 2000). GSTs are mostly 
found in the cytosol and are involved in many important xenobiotic reactions as well 
as playing a role in protection from oxidative stress and metabolism of 
prostaglandins and steroids (Sheehan et al, 2006). 
1.7: Evolution of the P450 superfamily 
 
The cytochrome P450 superfamily can be traced back to an ancestral gene which 
arose around 3.5 billion years ago (Nelson et al, 1993). When oxygen levels 
increased on earth as a result of photosynthetic organisms, systems using oxygen 
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were able to develop at a much faster rate with the result that the eukarya expanded 
rapidly (Knoll, 1992). The Devonian period – when land was colonised by plants and 
animals – is when the biggest explosion in P450s took place, and also when the 
largest rise in environmental oxygen occurred (Cloud, 1976). 
When multicellular organisms started to evolve, many more endogenous chemicals 
arose which P450s were able to evolve to cope with (Lewis, 1997). By around 1000 
million years ago sexual reproduction had developed with the consequence of 
steroid hormones requiring biosynthesis (Close et al, 2010). As life forms grew in 
size, they developed more complex and diverse metabolic processes – from here 
P450s branched out to allow for these new substrates to be metabolised efficiently 
(Nebert et al, 1989). This resulted in the arrival of the CYP3 and CYP4 families 
(McArthur, 2003, Nelson, 1998). The CYP1 and CYP2 families diverged next, 
followed by CYP17 and CYP21, with the end result being that separate CYPs had 
evolved to deal with mostly endogenous or mostly exogenous substrates (Lewis and 
Sheridan, 2001).  
During the Devonian period, P450 systems were expanded on - from their origins as 
enzymes purely involved in the metabolism of endogenous substrates, to being used 
to detoxify potentially dangerous plant materials (which had evolved as a method to 
cope with predators), sometimes known as ‘animal-plant warfare’ (Gonzalez and 
Nebert,1990). Likewise, the evolution of plants and insects is also tied together in 
this way. Many insects eat plants that contain compounds toxic to most species, 
such as tobacco hornworm consuming the leaves of tobacco plants which contain 
nicotine (Snyder et al, 1993) and black swallowtail being able to resist the toxicity of 
its host plant (Ma et al, 1994). P450s have developed to cope with this insect-plant 
warfare much like they have with animal-plant warfare (Futuyma and Agrawal, 2009).  
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The most ancient P450, sterol 14-demethylase (P45014DM or CYP51 for the fungal 
form), is thought to be responsible for the viability of eukaryotic cells; playing a vital 
role in the biosynthesis of the sterols that make up an essential component of 
eukaryotic cell membranes (Yoshida et al, 2000) and is the only CYP which is 
spread throughout eukarya as well as being found in some bacteria such as 
Mycobacterium tuberculosis, although no role in steroid metabolism here is apparent 
(Lepesheva and Waterman, 2004). Despite the major role this CYP appears to have 
played in evolution, no conclusive evidence has been drawn to suggest its exact 
origin – suggestions have been made for both a bacterial (Yoshida et al, 1997) and 
plant (Renzen et al, 2004) origin. 
P450s can be found in most, but not all, forms of life. Eubacteria such as E. coli, for 
example, contain no CYP genes, nor do archaea (Kelly and Kelly, 2013). There are 
currently over 21,000 P450 genes known, across all kingdoms of life (Nelson, 2009) 
with the highest number- ~5100 - being in plants (Nelson and Werck-Reichhart, 
2011). In addition to the role CYP51 has played in eukaryotic evolution, numerous 
other P450s have contributed towards the evolution of life as we know it, such as the 
ability of plants to produce pollen (Hamberger and Bak, 2013), the survival of insect 
hatchlings (Qui et al, 2012) and the viability of life moving from the sea to dry land 
(Omura, 2013).  
1.8: P450 structure, function and conservation 
 
CYPs generally range in size from 42KDa to 62KDa and the first crystal structure of 
a CYP was generated in 1987 by Poulos et al (P450cam from Pseudomonas putida). 
From the start of the 21st century, many more crystal structures have become 
available. The first mammalian crystal structure – rabbit CYP2C5 - was deduced by 
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Williams et al (2000). Three years later, the same group elucidated the first human 
CYP crystal structure (CYP2C9), Williams et al (2003). In the 11 years since then, 
the number of structures of P450s available has exploded and there are now 
hundreds of unique structures on the protein data bank (www.rcsb.org, Berman et al 
(2000)).  
Structural determination of P450 enzymes is of particular interest to the 
pharmaceutical industry as this could allow for inexpensive and efficient means to 
screen drug candidates against P450s – determining whether a compound is likely to 
interact with a P450, either as an inhibitor or as a substrate (Lewis and Ito, 2009). 
Although structures now exist for various P450s, there are other approaches to 
estimating drug interactions with a particular CYP. Ligand models and homology 
modelling are two alternative approaches (Lui et al, 2013). Whereas X-ray 
crystallography and NMR spectroscopy can pose a challenge due to difficulties with 
crystallisation, solubility or size (De Groot, 2006), homology modelling in particular 
can be a useful substitute (Vyas et al, 2012). Homology modelling involves taking an 
amino acid sequence of a protein and generating a 3D model of its structure based 
on a related protein – it relies on the general observation that amino acid sequences 
generally correlate with tertiary structural features (Kaczanowski and Zielenkiewicz, 
2010). Homology modelling has been used for various P450s based on those crystal 
structures that are available (Lewis, 1999). Ligand modelling can take the form of 
either pharmacophore or 3D-QSAR modelling (Quantative structure-activity 
relationship, which is a type of modelling that involves defining the mathematical 
relationship between structure and function) and has been used for various P450s 
thus far (De Groot and Ekins, 2002).   
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The general structure of a CYP involves a conserved C-terminal containing the 
haem-binding domain as well as conserved k-helix and PERF domains (Denisov et 
al, 2005). Microsomal CYPs also contain a conserved N-terminal for anchoring to the 
ER membrane (Poulos, 2005).   
The primary structure of CYPs varies significantly across families; however protein 
folding is highly conserved, in both microsomal and mitochondrial enzymes (Graham 
and Peterson, 1999). The most conserved area is the haem-binding region and 
consequentially it provides a method to quickly determine whether a sequence might 
belong to a P450 as the motif FxxGxxxCxG is found in all P450 sequences 
(Ranasinghe and Hobbs, 1998). As far as substrate specificity is concerned, it 
seems there are specific residues within the primary structure that are linked with the 
substrate-binding region (Zharkova et al, 2013). The most thorough map of this was 
compiled by Zawaira et al (2011) as an expansion to the work of Gotoh (1992) where 
residues involved in substrate recognition within the CYP2C family were deduced. 
Zawaira et al used ten different CYP isoforms across multiple mammalian species 
and found 33% of the sequence was involved in substrate recognition. Furthermore, 
numerous studies have been carried out in order to ascertain the specific residues 
involved in recognition of specific substrates. Melet et al (2003) found that the 
residues Phe114, Ser356 and Phe 479 were essential for the binding of two different 
drug substrates (sulfaphenazol and diclofenac). Likewise, a study carried out by Van 
Waterschoot et al in 2006 found that Phe120, Glu216 and Thr309 were involved in 
substrate binding in CYP2D6. Many of the major CYPs have been studied this way, 
including 2E1 (Collom et al, 2006), 2B4 (Sulc et al, 2008), 2A6, 2A13 (Devore et al, 
2011), 2B6 (Shah et al, 2011), 3A4 (Roussel et al, 2000) and 1B1 (Wang et al, 
2011).  
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1.9: P450 nomenclature convention 
 
Originally, P450s were named based on certain phenotypic characteristics such as 
substrate specificity and enzymatic activity however as increasing numbers of CYPs 
were isolated it became apparent that this system was not wholly efficient, largely 
because overlaps of enzymatic activities between different families were possible 
(Nelson, 2004). In 1987, a new system was devised to combat this issue whereby 
CYPs were named based on amino acid sequence identity (Gonzalez, 1990a). This 
system meant that P450 names would all start with ‘CYP’ followed by a number 
denoting their family (determined based on whether sequence similarity is >40%), a 
letter for their subfamily (>55% sequence identity) and a number to denote the 
specific gene - e.g. in CYP3A4, ‘3’ represents the family, ‘A’ is the subfamily and ‘4’ 
refers specifically to the gene itself. A sequence identity variation of >3% is needed 
for a gene to be classified as unique (Nelson et al, 1996). P450 pseudogenes also 
have a nomenclature system, with naming being based on how complete the gene is 
- e.g. the suffix ‘P’ is used if the gene is near full-length and if it is so short that it 
cannot be assigned to a family, the suffix ‘un’ is used (Nelson et al, 2004a). For 
polymorphisms, an asterisk is used after the gene name followed by a number to 
denote the allele, e.g. CYP2C9*3 represents the CYP2C9 polymorphism Leu359 
(Sullivan-Klose et al, 1996). Before a new P450 can be named, it must be submitted 
to a P450 nomenclature committee for approval in order to ensure names are not 
repeted and rules are adhered to (Nelson, 2004). 
1.10: Expression and tissue distribution of P450 enzymes 
 
Cytochrome P450s are expressed to the largest degree in the liver however they are 
present in almost all tissues, ranging from the brain to kidney, lung, spleen, 
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leukocytes, heart and kidneys amongst others, and their expression patterns vary in 
each tissue (Seliskar and Rozman, 2007). Although it is the major source of P450s, 
not all isoforms are expressed in the liver. P450s can play important endogenous 
roles when expressed differentially within specific tissues (Nebert and Dalton, 2006). 
For example, some have been shown to be involved in maintaining vascular 
homeostasis in the cardiovascular system (Flemming, 2001), involved in regulation 
of cerebral blood flow (Harder et al, 1998) and essential for the determination of 
germ cell fate in mice (Bowles et al, 2006). Outside of the liver, the intestines, 
kidneys and lung have relatively high P450 content (Preissner et al, 2013).  
On a subceullar level, eukaryotic P450s are all membrane-bound and are primarily 
found in microsomes, anchored to the endoplasmic reticulum via the N-terminal 
(Sakaguchi et al, 1984). Eukaryotes also possess mitochondrial P450s, which make 
up around 10% of known human CYPs (Nelson et al, 2004a). Mitochondrial P450s 
are involved in the biosynthesis of steroids (Omura and Morohashi, 1995) and 
Vitamin D3 metabolism (Masumoto et al, 1988). There have been some suggestions 
of involvement in xenobiotic metabolism (Honkakoski et al, 1988, Niranjan et al, 
1984) as well as microsomal-type P450s being found in the mitochondria (Shayig 
and Avadhani, 1989). Mitochondrial xenobiotic-metabolising P450s may also play a 
more significant role in pathophysiology than originally thought (Knockaert et al, 
2011), although more research is needed in the area before conclusions can be 
drawn. Outside of microsomes and mitochondria, P450s have been found in the 
nucleus of ovarian cancer patients (Leung et al, 2005), the cytosol in mice with haem 
impairment (Meyer et al, 2005) and on the plasma membrane in patients with 
autoimmune hepatitis (Loeper et al, 1993).  
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CYP expression levels can vary across different people and within an individual can 
be influenced by various factors. The biggest influencing factors on P450 expression 
are sex, age, diet and lifestyle (Kramer and Testa, 2009). Sex differences have had 
adverse clinical consequences particularly for women due to their historical 
underrepresentation in clinical trials (Schmucker and Vesell, 1993). Hormonal 
changes have been attributed to differences in P450 expression in women (Kashuba 
and Nafziger, 1998) and some specific P450 isoforms seem to have variable activity 
according to gender, such as CYP1A2 being more active in men and the metabolism 
of some CYP3A4 substrates being faster in women (Parkinson et al, 2004).  Aging 
has been studied significantly in regards to drug metabolism as it can affect drug 
disposition to a significant extent, particularly since individuals are more likely to be 
receiving treatments with multiple drugs when they get older (Jörgensen et al, 2001). 
Reasons for aging-related changes in drug metabolism are numerous, such as 
decreased gastric motility altering oral bioavailability (Orr and Chen, 2002) and 
changes in body composition (Beaufrère and Morio, 2000) altering the volume of 
distribution of some drugs. However, as far as P450 expression levels are 
concerned, in humans it does not seem expression decreases with age (Parkinson 
et al, 2004) although in rats there are significant differences with age (Vieira-Brock et 
al, 2013). Diet and lifestyle can affect P450 metabolism as many substances 
consumed through the diet have the potential to either inhibit or induce P450 
enzymes (Boullata and Hudson, 2012). Lifestyle factors play a similar role, with 
smoking status (Rasmussen et al, 2002) and alcohol consumption (Girre et al, 1994) 
altering drug metabolism to some extent. Another lifestyle factor that may affect 
P450-based metabolism is exercise, with some evidence suggesting certain P450 
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enzymes are upregulated during exercise (Vistisen et al, 1991, Frenk et al, 1980), 
although this has been disputed (Michaud et al, 1994).  
1.11: Human P450s  
 
P450s have been studied in humans more than in any other species, largely due to 
the fact they hold much importance therapeutically. There are 57 P450 genes in the 
human genome and about 75% of all drugs are metabolised by CYPs in humans 
(Guengerich, 2008), and they have become a central issue in clinical science; 
affecting treatment regimens and drug development to a great extent (Ingelman-
Sundberg, 2004). Drug-drug interactions are a particular concern, since some drugs 
can inhibit or induce P450s (Rendic, 2002). Consequently the major research focus 
has been around characterising potential drug-drug interactions in order to negate 
harmful interactions occurring in patients treated with multiple drugs at once (e.g. 
Overholser and Foster, 2011, and Zhou et al, 2003).  
The major xenobiotic metabolising CYPs in humans are CYP3A4, CYP2D6, 
CYP2C9, CYP2C19 and CYP2E1 (see figure 1.3). Others of important clinical 
importance are CYP2C8, CYP2B6, CYP2A6, CYP1B1, CYP1A1 and CYP1A2 
(Evans and Relling, 1999). Importantly, these CYPs also have significant roles 
outside of drug metabolism (Ding and Kaminsky, 2003). 
1.11.1: The CYP1 family 
 
The CYP1 family includes CYP1A1, CYP1A2 and CYP1B1 and research attention 
around them has had particular focus on their ability to bioactivate polycyclic 
aromatic hydrocarbons (PAHs) and other procarcinogens to generate carcinogenic 
metabolites (Baird et al , 2005). Compared with other CYPs they do not contribute 
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heavily towards drug metabolism due to their largely extrahepatic nature (although 
CYP1A2 metabolises some important drugs) but nevertheless have high clinical 
importance due to their role in carcinogenesis (Cui and Li, 2014), Go et al, 2015).    
1.11.1.1: CYP1A1 
 
There is very little CYP1A1 expression in the adult liver; however it is expressed in 
the foetal liver (Kitada et al, 1991) and evidence suggests it can be induced in adult 
liver by PAHs such as benzo[a]pyrene, 7,12-dimethylbenz[a]anthracene and 
benzo[k]fluoranthene (Galván et al, 2005). It is primarily expressed in the lung 
(Shimada et al, 1992) although can also be found in the placenta (Lucier et al 1987) 
as well as lymphocytes and monocytes (Robie-Suh et al, 1980). When discovered, 
CYP1A1 was named aryl hydrocarbon hydroxylase due to its role in the 3-
hydroxylation of benzo[a]pyrene (Nebert and Gelboin, 1968).   
Induction of CYP1A1 has been studied extensively due to the enzyme’s link to lung 
cancer in smokers as smoking induces lung CYP1A1 expression (McLemore et al, 
1990). Other substances which induce CYP1A1 expression are heterocyclic amines 
and polychlorinated biphenyls (Lucier et al, 1987) as well as the drug omeprazole, 
which acts as an aryl hydrocarbon-like inducer for the CYP1A subfamily (Diaz et al, 
1990).  
1.11.1.2: CYP1A2 
 
Unlike CYP1A1 and CYP1B1, CYP1A2 is largely expressed in the liver rather than 
lung and consequentially is the only 1A P450 involved significantly in drug 
metabolism (Shimada et al, 1996). There is some evidence that CYP1A2 is at least 
present at the mRNA level in the lower digestive tract (Mercurio et al, 1995) although 
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to date no expression in the lung has been documented despite much searching.  
Around 10-15% of total hepatic P450 content is CYP1A2 (Breimer and Schellens, 
1990). CYP1A2 has a large list of drug substrates, with some examples being 
paracetamol (which is also a substrate of CYP2E1 and CYP3A4, Patten et al, 1993), 
caffeine, clozapine, melatonin and bufaralol (Wang and Zhou, 2009). In addition to 
being a substrate, caffeine is also a potent inducer of CYP1A2 (Chen et al, 1996). 
Other inducers are charbroiled food, tobacco smoking, omeprazole, cruciferous 
vegetables and even exercise (Vistisen et al, 1992). CYP1A2 induction can have 
profound effects on treatment regimens involving drugs metabolised by the enzyme 
(Gunes and Dahl, 2008). One of the most well-known examples involves treatment 
using certain antipsychotics in smokers, since drugs such as clozapine, haloperidol 
and olanzapine are metabolised by CYP1A2 and thus smokers require higher 
dosages to achieve adequate effects (de Leon, 2004). Similarly, smokers also 
consume more caffeine on average than non-smokers due to CYP1A2 induction 
(Swanson et al, 1994).  
CYP1A2 has the ability to bioactivate certain carcinogens, especially heterocyclic 
and aromatic amines, although it has other carcinogenic substrates such as 
polycyclic and nitropolycyclic hydrocarbons (Nebert and Dalton, 2006). High 
CYP1A2 activity has been associated with colorectal cancer via food-borne 
heterocyclic amines (Lang et al, 1994). Inhibitors of CYP1A2 include polycyclic 
acetylenes (Shimada et al, 1998), furafylline (Racha et al, 1998) and fluvoxamine 
(Brøsen, 1995).  
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1.11.1.3: CYP1B1 
 
CYP1B1 is most highly expressed in the kidneys and is also expressed in the 
spleen, prostate, thymus, lung, small intestine, ovaries, uterus, large intestine and 
mammary glands (Shimada et al, 1996a). CYP1B1 expression in these tissues has 
particular significance as it has been associated with malignant tumour development 
(Murray et al, 1997). Additionally, CYP1B1 mutations have been associated primary 
congenital glaucoma therefore is thought to play a role in foetal development (Stoilov 
et al, 1998).  
Like with CYP1A1 and CYP1A2, CYP1B1 has the ability to bioactivate 
procarcinogens such as polycyclic hydrocarbons, heterocyclic and aromatic amines 
and nitropolycylic hydrocarbons (Shimada et al, 2001). It has also been implicated in 
oestrogen-related cancers where it produces carcinogenic metabolites from the 
metabolism of 17-beta-estradiol (Hayes et al, 1996) and oestrone (Shimada et al, 
1999).   
Various polycyclic compounds are strong inhibitors for CYP1B1 (Shimada et al, 
1998). There are a number of other known inhibitors, one of the most interesting of 
which is a compound called resveratrol found in red grapes which is known to inhibit 
the development of cancer (Chang et al, 2000). Importantly, it seems the anti-cancer 
effect of this compound is also aided by the fact CYP1B1 metabolises it into 
piceatannol which is known to have anti-cancer properties (Potter et al, 2002). Other 
anticancer compounds also seem to have inhibitory effects on CYP1B1 (Rochat et 
al, 2001). 
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1.11.2: The CYP2 family 
 
The CYP2 enzymes are much more diverse than the CYP1 enzymes, catalysing a 
huge variety of reactions (Rendic, 2002). CYP2 enzymes are responsible for as 
much as 50% of all drug metabolism, the majority of which is carried out by CYP2C9, 
CYP2C19, CYP2D6 and CYP2E1 (Lewis, 1998). P450s of the CYP2 family tend to, 
in comparison to other CYPs, have substrates that are of small to medium molecular 
weight, and despite the variety of substrate specificities amongst members of the 
subfamilies, there is some overlap; particularly between CYP2A and CYP2E (Rendic 
and Di Carlo, 1997). 
1.11.2.1: CYP2A 
 
There are three CYP2A P450s in human – CYP2A6, CYP2A7 and CYP2A13 (Su et 
al, 2000). Although they are not major drug-metabolising enzymes, they have 
received research attention due to CYP2A6 and its role in metabolising nicotine as 
well as the bioactivation of many carcinogens (Fernandez-Salguero and Gonzalez, 
1995, Messina et al, 1997). CYP2A6 accounts for around 1-10% of total hepatic 
P450 content and is also expressed in the respiratory tract (Su et al, 2000).   
CYP2A7 meanwhile appears to be liver-specific and has no documented catalytic 
activity while CYP2A13 has low hepatic expression and is predominantly expressed 
in the respiratory tract (Su et al, 2003). Although little is known about its activity, 
CYP2A13 seems to have some overlap in substrate specificity with CYP2A6, 
metabolising substrates such as nicotine, cotinine and coumarin (Fukami et al, 
2007).  Drugs metabolised by CYP2A6 include the anti-epileptic drug losigamone 
and the anticonvulsant valproic acid (Raunio et al, 2001).  
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1.11.2.2: CYP2C9 
 
CYP2C9 is one of four known human CYP2C enzymes (the others being CYP2C8, 
CYP2C18 and CYP2C19) and is a major drug metabolising enzyme, contributing to 
the metabolism of around 20% of drugs in humans (Breimer et al, 1990). Despite 
sharing high sequence similarity, there is little overlap in substrate specificities 
across the CYP2C enzymes (Goldstein and de Morias, 1994). It is the second most 
highly-expressed P450 in the liver (Shimada et al, 1994) and has also been found in 
the intestine (Obach et al, 2001). One of the first major CYP2C9 substrates 
discovered was the anti-epileptic phenytoin (Shimada et al, 1986) while drugs such 
as warfarin and various non-steroidal anti-inflammatory drugs (NSAIDs) have 
received much research attention due to their clinical significance relating to drug-
drug interactions and CYP2C9 polymorphisms (Rettie and Jones, 2009). The extent 
of polymorphisms in CYP2C9 was first highlighted when two variations (Cys144 and 
Leu359) of the gene were discovered within a Caucasian population (Stubbins et al, 
1996). Subsequent studies have suggested around 35% of Caucasians possess one 
of six CYP2C9 allelic variations, although the rate of polymorphisms is substantially 
lower in other ethnic groups (Lee et al, 2002). Significantly, polymorphisms have 
been associated with various severe adverse drug reactions, such as prolonged 
bleeding times during warfarin therapy (Aithal et al, 1999) and overdose with 
phenytoin (Ninomiya et al, 2000). They have also been associated with reduced 
clearance time of drugs, with some polymorphisms generating as little as half the 
clearance rate of the wildtype for a variety of clinically important drugs (Kirchheiner 
and Brockmöller, 2005).  
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In addition to xenobiotics, CYP2C9 metabolises some endogenous substances such 
as vitamin A (McSorley and Daly, 2000) and linoleic acid (Draper and Hammock, 
2000). It also has various well-characterised inhibitors, including the anti-fungals 
sulfaphenazole (Veronese et al, 1990), miconazole and fluconazole (Iwa et al, 2005), 
and tienilic acid as a mechanism-based inhibitor via s-oxygenation (Dansette et al, 
1992).  
1.11.2.3: CYP2C19 
 
CYP2C19 is mostly expressed in the liver, accounting for around 5% of total hepatic 
P450 content (Breimer and Schellens, 1990), although it has also been detected in 
the intestines (Lapple et al, 2003) and brain (Booth Depaz et al, 2015). CYP2C19 
does not metabolise as many drugs as CYP2C9 although it does have some 
significant clinical importance, particularly relating to a polymorphism that was first 
discovered in mephenytoin metabolism, noting a genetic deficiency of the 
hydroxylation of the drug (Kupfer and Preisig, 1984). In total there are eight 
CYP2C19 polymorphisms that can result in poor metabolism and have been 
estimated to be present within 12-23% of Asian populations, 1-6% of Caucasian 
populations and 1-1.75% of black African populations (Desta et al, 2002). Substrates 
primarily metabolised by CYP2C19 include mephenytoin, omeprazole (Karam et al, 
1996), thalidomide (Ando et al, 2002) and clopidogrel (Hulot et al, 2006). CYP2C19 
has some involvement with steroids such as progesterone and testosterone, playing 
a relatively important role in their oxidation (Yamazaki and Shimada, 1997).  
1.11.2.4: CYP2D6 
 
CYP2D6 is the second most important drug metabolising enzyme, with involvement 
in around 25% of xenobiotic metabolism (Evans and Relling, 1999). Despite this, 
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hepatic expression levels are relatively low, accounting for around 5% of total liver 
P450 content, although this figure can be as low as 1% in some individuals 
(Shimada et al, 1994). CYP2D6 expression has also been detected in lung (Guidice 
et al, 1997), and brain (Siegle et al, 2001) where higher expression levels have been 
associated with alcoholism (Miksys et al, 2002). The first discovered CYP2D6 
substrate was debrisoquine, and this was also the first xeonobiotic found to be 
subject to polymorphic metabolism (Mahgoub et al, 1997). CYP2D6 metabolises a 
range of highly prescribed drugs such as antidepressants, beta-blockers, opioids and 
antiarrhythmics (Ingelman-Sundberg, 2005). Consequentially CYP2D6 
polymorphisms are the most clinically significant of the P450 polymorphisms and can 
cause a range of adverse reactions. Although a few endogenous substrates have 
been found relatively recently (Yu et al,2003, Yu et al, 2003a), it seems CYP2D6 
does not play any major physiological role, since individuals lacking an active gene 
appear to have no major negative consequences, although psychological studies 
have suggested that personality may be affected in CYP2D6 poor metabolisers due 
to lack of metabolism of certain neurotransmitters (Llerena et al, 1993, Roberts et al, 
2004). Additionally, it has been suggested that patients possessing certain 
polymorphisms are more likely to develop schizophrenia (Llerena et al, 2007) 
although this finding conflicted with previous reports of no association (Daniels et al, 
1995). Unlike many other CYPs, CYP2D6 does not appear to be inducible (Zanger et 
al, 2004) although inhibitors include various cardiovascular drugs (Otton et al, 1984), 
bupropion (Kotlyar et al, 2005) and some antidepressants (Ereshefsky et al, 1995).  
There are at least 74 alleles of CYP2D6 (Zhou, 2009), giving phenotypes that can 
either generate no metabolism, poor metabolism, ‘normal’ metabolism or ultra-rapid 
metabolism – and of these 74 alleles, 15 are known to code non-functional proteins 
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(Wolf and Smith, 1999). Understandably, the vast range of phenotypes an individual 
may possess can create many different clinical outcomes, from those that are 
undetected to those that are fatal (Zanger et al, 2004). Examples of some adverse 
drug reactions that can occur due to CYP2D6 polymorphisms are excessive 
morphine concentrations during codeine treatment of ultra-rapid metabolisers (Crews 
et al, 2012), an increased risk of peripheral neuropathy amongst poor metabolisers 
treated with the antianginal drug  perhexiline (Shah et al, 1982), an increased risk of 
central nervous system side effects for poor metabolisers treated with the 
antiarrythmic  propafenone (Siddoway et al, 1987) and a longer duration of 
pulmonary effects in poor metabolisers treated for bronchoconstriction with 
maprotiline (Firkusny and Gleiter, 1994).  
1.11.2.5: CYP2E1 
 
CYP2E1 is not one of the major drug metabolising enzymes however it has received 
most research attention due to its role in ethanol metabolism (Kessova and 
Cederbaum, 2003, Leung and Nieto, 2012). Mixed function oxidase of ethanol was 
discovered almost 50 years ago (Orme-Johnson and Ziegler, 1965). Since then the 
role of CYP2E1 in ethanol metabolism has been debated, with the consensus 
eventually becoming that although alcohol-dehydrogenase is the main enzyme 
responsible for ethanol metabolism, CYP2E1 is inducible by ethanol (Song et al, 
1986) and with prolonged ethanol exposure it appears to play a more important role 
in ethanol metabolism (Lu and Cederbaum, 2008). CYP2E1 ethanol induction is 
associated with increased liver injury due to the reactive metabolites produced by 
this pathway which otherwise would be detoxified via the alcohol 
dehydrogenase/aldehyde dehydrogenase pathway (Lu et al, 2010).  
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CYP2E1 is most highly expressed in the liver, making up ~7% of total hepatic P450 
content, and it appears in infant livers a few hours after birth (Vieira et al, 1996). It is 
also expressed in the lungs (Hukkanen et al, 2002), gastrointestinal tract (Ding and 
Kaminsky, 2003), nasal mucosa (Zhang et al, 2005), pancreas (Foster et al, 1993) 
and the brain (Farin and Omiecinski, 1993). It is important with regard to 
endogenous substances such as acetone (Bondoc et al, 1999) and ketones (O’Shea 
et al, 1994) as well as some xenobiotic compounds of clinical significance 
(Anzenbacher and Anzenbacherová, 2001). Drugs metabolised by CYP2E1 include 
the muscle relaxant chlorzoxazone (Kim and Peter, 1996), paracetamol (Lee et al, 
1996) and some anaesthetics (Spracklin et al, 1997, Kharasch et al, 1999). It has 
significant roles relating to various carcinogenic compounds, such as N-nitrosamines 
(Wrighton et al, 1986), benzene, styrene and various other low molecular weight 
suspected carcinogens (Guengerich et al, 1991). Inhibitors include some that also 
inhibit alcohol dehydrogenase and aldehyde dehydrogenase such as 4-
methylpyrazole (Pernecky et al, 1990) and 3-amino-1,2,4-triazole (Koop, 1990).  
1.11.3: The CYP3 family 
 
In humans, the CYP3 family includes CYP3A4, CYP3A5, CYP3A43 and CYP3A7, 
although only CYP3A4 and CYP3A5 make any significant contribution towards drug 
metabolism (Williams et al, 2002). CYP3A7 is mostly expressed in foetal liver and 
has only occasionally been detected in adult liver while CYP3A43 is most highly 
expressed in the prostate with low expression in adult liver (<5% that of CYP3A4), 
Williams et al (2002). CYP3A enzymes are involved in the metabolism around 50% 
of all drugs (Guengerich, 1999) and as such are considered the most important 
therapeutically, although they also contribute to the metabolism of many endogenous 
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substances (Nakamura et al, 2002). Of the CYP3A enzymes, CYP3A4 has the most 
substrates attributed to it and is the most highly expressed, making it the most 
important of the CYP3A family (Thummel and Wilkinson, 1998).  
1.11.3.1: CYP3A4 
 
CYP3A4 makes up, on average, 25-30% of total liver P450 volume (Shimada et al, 
1994), although its highest relative expression level is in the small intestine – up to 
60% of total P450 volume (Guengerich, 1990). It can also be found expressed in the 
large intestine, stomach (Ding and Kaminsky, 2003) and lung (Kelly et al, 1997).  
The list of CYP3A4 substrates is long (Rendic, 2002) but some important examples 
include statins (Wang et al, 1991), protease inhibitors for HIV treatment (Huang et al, 
2001), various anticancer agents (Harmsen et al, 2007) and calcium channel 
blockers (Yoshida et al, 2008). In addition to xenobiotics, CYP3A metabolises the 
steroid hormones testosterone (Waxman et al, 1988), cortisol (Abel and Back, 1993), 
progesterone (Yamazaki and Shimada, 1997) and estradiol (Kerlan et al, 1992). It 
also seems to play a role in cholesterol metabolism (Lütjohann et al, 2009).  
Inhibitors of CYP3A4 can cause severe clinical consequences and have caused 
some drugs metabolised by the enzyme to be withdrawn, such as the antihistamine 
terfenadine, which was withdrawn after drug interactions were shown to cause 
cardiac arrhythmias (Kivistö et al, 1994). The most well-known inhibitor of CYP3A4 is 
grapefruit juice, which has had such a profound effect on CYP3A4-mediated 
metabolism that many drugs metabolised by this P450 now contain warning labels 
about consumption of grapefruit juice during treatment (Greenblatt et al, 2001). 
Various furanocoumarins are thought to be the main substance responsible for this 
inhibitory effect (Guo et al, 2000), however only orally administered drugs appear to 
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be inhibited by grapefruit juice (Ducharme et al, 1995). As well as being substrates of 
CYP3A4, many protease inhibitors used in HIV treatment are also strong inhibitors, 
which can be particularly problematic for avoiding drug-drug interactions due to HIV 
patients being on variable treatment regimens with multiple protease inhibitors (van 
Heeswijk et al, 2001). Other clinically important examples of inhibitors include oral 
contraceptives, which cause mechanism-based inactivation (Lin et al, 2002), 
macrolide antibiotics (Westphal, 2000) and the antifungal ketoconazole (Lorusso et 
al, 2008).   
As far as inducers are concerned, St John’s wort is a potent inducer and is 
associated with many drug-drug interactions (Zhou et al, 2004). It can cause the 
failure of oral contraceptives, due to overly rapid elimination of 17-alpha-
ethynylestradiol (Schwarz et al, 2003) and it has been associated with organ 
rejection in patients treated with the immunosuppressant cyclosporine (Mai et al, 
2003) as well as lowered efficacy of antidepressants metabolised by CYP3A4 (Johne 
et al, 2002). Similarly, rifampicin is a CYP3A4 inducer and has been associated with 
organ rejection (Capone et al, 1996) as well as potential sub-therapeutic levels of 
protease inhibitor in HIV patients where it is often co-administered (Grub et al, 2001). 
Barbiturates are another clinically important CYP3A4 inducer (Guengerich, 1988). 
1.11.3.2: CYP3A5 
 
Although CYP3A5 does not hold the same level of importance clinically as CYP3A4, 
it does have many important metabolic properties (Emoto and Iwasaki, 2006). 
CYP3A5 expression levels vary significantly across ethnicities (Kuehl et al, 2001) 
and CYP3A5 substrates tend to be the same as those for CYP3A4 (Williams et al, 
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2002). It is the main CYP3A enzyme expressed outside the liver and intestines, in 
tissues such as kidney, lung and leukocytes (Kuehl et al, 2001).  
1.13: CYPs in non-mammals 
 
In non-mammals, P450s have often been studied due to their roles in insecticide and 
drug resistance. For example, roles relating to drug susceptibility have been found 
for CYPs with the pathogenic fungus Aspergillis (Mellado et al, 2011) as well as M. 
tuberculosis, the causative agent of tuberculosis (McLean et al, 2007). Similarly, 
CYPs have been found to have a role in insecticide resistance – which is especially 
important with regards to mosquitos that can transmit malaria (Djouaka et al, 2011). 
Another role for CYPs in infectious agents can be exemplified via the protozoan 
parasite Leishmania donnovani, where CYP5122A1 has been found to be involved in 
the infection process (Verma et al, 2011). 
Plants have more identified P450s than any other organism, with a total of 246 being 
found in Arabidopsis and 356 in rice (Nelson et al, 2004). In fact, some plants 
contain so many P450 genes that they make up as much as 1% of the genome of 
rice, Arabadopsis, grape, papaya, moss and poplar (Nelson et al, 2008).  Fish have 
also received a relatively high amount of research attention and 137 fish CYP genes 
have been identified thus far (Uno et al, 2012). Zebrafish and fugu have been 
studied most and have 81 and 54 CYPs respectively (Nelson, 2003). Fish CYPs also 
have the intriguing use of being used as biomarkers for water pollution (Fent, 2003). 
1.14: CYPs in mammals  
 
Mice and rats, as key model organisms, have had many CYPs identified and studied 
and as such much is known about their activities. 102 CYP genes have been found 
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in the mouse genome (Nelson et al, 2004a) and 89 have been found in the rat 
(compared to the 57 known CYP genes in human (Nelson, 2009).  
Comparative studies between species are common. The advantages of this type of 
research are that it both allows for potential model species to be identified (Sharer et 
al, 1995, Bogaards et al, 2000) and it is useful for highlighting important species 
differences in drug metabolism (Martignoni et al, 2006, Eberhart et al, 1991, 
Yasumori et al, 1993).   
P450s in many animals which are not so easily available for research purposes have 
been studied, such as monkeys, chimps and dogs (Emoto et al, 2013,Williams et al, 
2007, Zhou et al, 2010). Monkeys and chimps are seen as being good models for 
humans (Uno et al, 2001) while dogs are occasionally used as an alternative to 
rodent studies – although their status as companion animals also fuels research into 
the therapeutic role of CYPs (Shou et al, 2003). In the dog, CYPs from many of the 
major families in human have been identified, with nine in total being sequenced and 
seven being recombinantly produced using a bacmid insect cell system and later an 
E. coli expression system (Locuson et al, 2009). Other domestic animals where 
P450s have been studied include cow, pig, chicken and horse (Giantin et al, 2008, 
Anzenbacher et al, 2002, Yang et al, 2014, Scarth et al, 2011).  
1.15: Equine drug metabolism  
 
Horses are important both socially as companion animals throughout history and as 
athletic animals, with particular significance economically especially within the 
horseracing industry. In the UK, the horseracing industry is estimated to be worth 
around £3.9 billion per year (British Horseracing Authority, 2014). When compared 
with that of many species, knowledge of equine P450s is very limited. Despite this, 
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studies into equine P450s hold a high level of importance for numerous reasons. As 
popular companion and athletic animals, horses are frequently administered multiple 
drugs at once with the consequence that drug-drug interactions are possible, many 
examples of which can be found in the literature. Examples of reported adverse drug 
interactions in the horse include increased clearance of barbiturates after repeated 
dosing, faster metabolism of phenylbutazone when prescribed along with rifampin, 
slower clearance of quinidine when dosed along with digoxin and inhibited 
metabolism of xanthines by fluroquinolones (Scarth et al, 2011, Brumbaugh, 2001).   
Considering the central importance drug-drug interactions have in human medicine, 
it is logical that they should also be given this status in equine medicine. Another 
area where equine P450s may have vast importance is within the horseracing 
industry. Doping control is a huge concern in horse racing and many substances, 
such as anabolic steroids, are banned within racehorses due to potential 
performance-enhancing effects (Scarth et al, 2010). Recent years have seen doping 
scandals in the horseracing industry highlighted by the media, such as the scandal 
involving the dosing of an anabolic steroid to horses in the Godolphin stables (Wood, 
2013). Like with human athletes, doping control in racehorses involves searching for 
certain metabolites in the plasma and urine; however unlike the human situation 
much of the data  regarding horse-dosing and potential drug-drug interactions is 
largely based on other species as details of the specific enzymes involved in the 
horse are sparse. Furthermore, many studies involving comparisons of drug 
metabolism between species suggest that it may not be ideal to extrapolate 
metabolism data between species (e.g. Chauret et al, 1997, Martignoni et al, 2006, 
Mössner et al, 2011). Drug metabolism studies in the horse are often much more 
difficult to conduct than in other animals, due to their size; expense; difficulty 
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obtaining large sample numbers and the associated regulations around large 
mammal research (Animals in Science Regulation Unit, 2014). With the elaboration 
of in vitro research techniques the area of equine drug research has expanded in 
recent years. Standards for approval of veterinary drugs are lower than for those 
used in human medicine therefore it is arguably understandable that much less is 
known about drug metabolism in the horse. From a horse racing angle, it is worth 
noting that many more substances are banned than in human sport (BHA Rules of 
Racing, The World Anti-Doping Code 2014) so an expanded knowledge of 
metabolite production is all the more crucial to keep on top of doping control. 
1.15.1: Equine P450s 
 
The first equine CYP to be discovered was found by Komori et al (1993) and was 
named P450-(h-1). Although the full sequence for it was never generated, the 
assumption was that it belonged to the CYP2C family due to the cross-reactivity of 
an antibody generated against it with rat 2C P450s. P450 research in the horse at 
this time was scarce and the next equine P450 study was a comparative one 
between horse, dog, human and cat. This involved the use of microsomes and the 
finding was that troleandomycin, an inhibitor of CYP3A4 in humans, did not affect the 
metabolism of testosterone in the horse although inhibitors of other CYPs did affect 
the metabolism of specific compounds (Chauret et al, 1997).  
Although microsome studies do not necessarily give specific information about P450-
based metabolism they do act as good starting points for hypothesising how P450s 
operate in a species. Other comparative microsome studies include Nebbia et al 
(2003) using probe substrates for CYP1A, 2B, 2E, and 3A,  Mössner et al (2011) 
using inhibitors of CYP3A4, CYP2A6, CYP2C19, CYP2B6 and CYP2C9 to look into 
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ketamine metabolism in the horse and Darwish et al (2010) using an antibody 
against rat CYP1A1 to demonstrate that metabolism of certain compounds was 
CYP1A-dependent. More recently, testosterone metabolism in horse, dog and 
human was compared using known inhibitors against various human P450s 
(Zielinska and Mevissen, 2015), finding small but significant species differences, 
such as CYP2B6 appearing to be involved in testosterone metabolism in horse and 
human but not dog and sulphenazole inhibiting metabolism in horse less than in 
human. 
As far as specific studies in the horse go, Lakritz et al (2000) attempted to determine 
activities of various P450s in horses of different ages. This involved using known 
human substrates of different P450 isoforms. Although this study was again limited 
in that it used microsomes, it did give some interesting insight into drug metabolism 
in the equine; particularly that pulmonary xenobiotic metabolism was significantly 
lower in young than adult horses while hepatic metabolism did not vary significantly. 
A subsequent study by Nebbia et al (2004) further corroborated this finding.  
1.15.2: Equine P450 expression levels 
 
Some research focus has been given to equine P450 expression levels in recent 
years. Schmitz et al (2010) identified seven potential CYP3A genes in the horse and 
subsequent analysis of expression of these P450s has been performed. Members of 
the CYP3A subfamily have been found in the liver, intestine (Tyden et al, 2012) and 
airway (Tyden et al, 2012a). The finding of these studies was that CYP3A93 and 
CYP3A96 were highly expressed in the intestines, CYP3A89, CYP3A94, CYP3A96 
and CYP3A97 were highly expressed in the liver and CYP3A95 was only minimally 
expressed in the liver and lung but not in the intestine. Furthermore, Tyden et al 
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(2014) expanded upon this by examining more P450 isozymes in the horse liver and 
intestines, this time the focus was on CYPs 1A, 2A, 2C, 2D and 2E. CYP1A and 
CYP2C were expressed most highly in the intestines but also had high liver 
expression. CYP2E was expressed moderately in the intestines and liver while 
CYP2D was low in both and CYP2A was almost undetectable. 
1.15.3: In vivo equine studies 
 
The vast majority of data regarding equine drug metabolism has been generated 
through in vivo studies, although this has significant ethical and financial 
implications, since it often involves the sacrifice of the research animals. The most 
detailed method of in vivo study involves injecting a radiolabelled drug and 
monitoring its fate and excretion. This gives the most thorough analysis although it is 
becoming the less-favoured option compared to other in vivo approaches (Scarth et 
al, 2010). As a consequence of doping control and routine drug testing within the 
horseracing industry, the vast majority of equine drug metabolism data comes from 
within this industry. Urine analysis is the most popular method for doing this although 
hair (Dunnet, 2005), saliva (Horner, 1976), blood (Kwok et al, 2010) and faeces 
(Popot et al, 2006) can also be used.  
1.15.4: Recombinant equine P450s 
 
Recombinant enzyme systems have become central to modern molecular biology 
and pharmaceutical research, providing an easy method of generating large scale 
proteins on demand (Schmidt et al, 2004, Assenberg et al, 2013). They offer the 
advantage of allowing the user to generate a protein of interest without necessarily 
knowing anything about its structure or function. There are many types of protein 
expression systems available, from bacterial systems to mammalian cell lines and 
47 
 
the choice of a system depends upon many variables such as the type of organism 
the protein of interest comes from, the amount of protein required and expense/ease 
of use (Sodoyer, 2004, Demain and Vaishnav, 2009). For P450 protein expression, 
insect cell systems are the most well established although with advances in 
technology bacterial systems are becoming more popular (Gonzalez, 1995, 
Guengerich and Martin, 2006, Zelasko et al, 2013).   
It is only relatively recently that recombinant equine P450s have been produced, 
which contrasts heavily with the situation in humans where recombinant CYPs have 
been around for many years and are now an integral part of drug development 
procedures. DiMaio Knych and Stanley (2008) produced the first recombinant horse 
CYP (CYP2D50, an isoform of the human CYP2D6 which was used for comparison) 
using an insect cell expression system. The same authors have since used this 
expression system to study the enzyme kinetics of two other equine P450s – 
CYP2C92 which is the orthologue of human CYP2C9 (DiMaio Knych et al, 2009) and 
CYP3A96 (DiMaio Knych et al, 2010) which is the possible orthologue of human 
CYP3A4. During the 2010 study, two other equine P450s (CYP3A89 and CYP3A97) 
were recombinantly expressed, however the former did not display catalytic activity 
and the latter failed to show up within the characteristic 450 nm spectrum when 
bound with carbon monoxide (although it did appear to be catalytically active). To 
date these are the only recombinant equine P450 studies that directly compare the 
activities of the equine enzymes with those of another species.  
From all three of these studies, the equine enzymes displayed generally lower 
activity than their human orthologues although it is important to note that only a few 
substrates were used for each. For CYP2D50, dextromethorphan and debriquisone 
were used as substrates with the formation of metabolites (o-demethylation for 
48 
 
dextromethorphan and 4-hydroxydebriquisone for debriquisone) being 180 fold and 
50 fold slower than in the human enzymes, respectively (which, interestingly, 
conflicts with Chauret et al who showed higher dextromethorphan metabolism in 
horse than human). For CYP2C92 the probe substrates were diclofenac and 
warfarin. Here, formation of 4-hydroxydiclofenac was 20 fold slower than in the 
human enzyme, although formation of hydroxy (s)-warfarin and hydroxy tolbutamide 
was similar in horse and human. Knych et al (2010) showed testosterone and 
nefedipine metabolism by CYP3A96 to be 20 and 10 fold slower in horse compared 
to human, respectively.  
Using a different expression technique, equine CYP2B6 (Peters et al, 2013) and 
CYP3A94 (Dettwiler et al, 2014) have also been recombinantly expressed. In these 
studies, V79 hamster lung fibroblasts were used along with ketamine as the potential 
substrate for CYP2B6 and, for CYP3A94, 7-benzyloxy-4-trifluoromethylcoumarin (a 
substrate of multiple CYPs which is metabolised to a flourescent product, Donato et 
al, 2004) was used to validate P450 activity. For CYP2B6, the metabolite 
norketamine was detected, as well as metabolites of norketamine itself (such as 5,6-
dehydronorketamine). Additionally, clopidogrel was found to be an inhibitor of the 
metabolism of ketamine to norketamine. No comparison to other species was made 
in this study, however in humans, CYP3A4 is the major metaboliser of ketamine 
while CYP2B6 and CYP2C9 play more minor roles (Hijazi and Boulieu, 2002).   
1.16: Methods used to study hepatic metabolism  
 
As far as in vitro studies are concerned, there are four main ways to study hepatic 
metabolism – taking liver sections, isolating hepatocytes, isolating microsomes and 
producing recombinant drug metabolising enzymes (Brandon et al, 2003) - see figure 
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1.16 for a summary. Liver slices and hepatocyte cultures can give the most holistic 
view of liver processes although systems for hepatocyte culturing and 
cryopreservation are not available for all species. Liver slices are of particular use for 
studying induction of liver enzymes and provide a model that keeps liver architecture 
in place (Edwards et al, 2003). Compared to other methods however, liver slices 
have dropped in popularity since the 1970s (Ekins et al, 2001) due to handling 
difficulties, particularly with regard to maintaining viability (Hashemi et al, 2000). 
Hepatocytes can be fresh, cultured or cryopreserved. Fresh hepatocytes lose 
viability after a few hours (Bayliss et al, 1999). Hepatocytes can be cultured for as 
much as four weeks although some enzyme activities become gradually lower after a 
few days of culture maintenance (George et al, 1997). Cryopreservation is popular 
particularly for human hepatocytes where tissue availability is limited (Hengstler et al, 
2000) and cryopreserved cells seem to retain good enzyme activity (Silva et al, 
1999).  
Microsomes are vesicles formed from the endoplasmic reticulum of cells and are the 
most straightforward and popular method for investigating liver drug metabolism 
function (Asha and Vidyavathi, 2010). Microsomes contain a variety of phase I and 
phase II drug metabolising enzymes, such as P450s and UGTs (Zhang et al, 2012). 
Microsomes are relatively easy to use for drug metabolism studies and have the 
extra advantage of being low cost, particularly since fresh liver is not required to 
produce them (Skaanild and Friis, 2000). The main disadvantage of microsomes is 
that they tend to give a higher rate of metabolism than would be found in vivo 
(Sidelmann et al, 1996).  
Despite the vast usefulness of hepatocytes, liver slices and microsomes, they do not 
give isoform-specific information about drug metabolising enzymes. As such, 
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recombinant enzyme systems are now commercially available for many drug 
metabolising enzymes (Fasuni et al, 2012). Recombinant systems offer a means of 
investigating drug metabolism at the molecular level as well as allowing for the study 
of drug-drug interactions (Yao et al, 2001). This is particularly important for 
cytochrome P450-mediated metabolism, where knowledge of P450 isoform-specific 
metabolism is essential (Lynch and Price, 2007). 
Figure 1.16: In vitro methods used to study hepatic metabolism. Liver slices and hepatocytes can 
be used to study phase I and phase II metabolism together while liver fractions generated from 
ultracentrifugation may be used to study specific types of enzyme. Recombinant enzymes may be 
used to study specific isoforms. © The Hamner Institutes for Health Sciences, 2010.  
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1.17: Rational for current study 
 
Drug metabolism in the horse may be different to that of human for various reasons. 
Horses are herbivores while humans are generally omnivores therefore diet, a 
known factor that can affect drug metabolism to a large extent (Walter-Sack and 
Klotz, 1996, Harris et al, 2003), may vary greatly between the two species. In 
addition to this, there is some evidence to suggest that exercise may affect the 
expression of certain P450 isoforms (Vistisen et al, 1991, Frenk et al, 1980), and, 
therefore, equines used for sport may have particularly divergent metabolism of 
certain substances when compared with other horses or humans. This, in addition to 
the differences illustrated by comparative studies between the two species, 
highlights the crucial need for more horse-specific data to be generated. With the 
equine genome now being available (Wade et al, 2009), it is possible to generate a 
full picture of the genes involved in equine drug metabolism. Once these have been 
elucidated, creation of recombinant enzymes and subsequent screening against 
drugs will provide vast amounts of much needed data about P450 isoform-specific 
drug metabolism, giving novel insight into equine pharmacokinetics.  
1.17.1: Aims of study 
 
To isolate and characterise equine P450s. P450 enzymes will be identified via 
searching the equine genome, isolated from equine liver, cloned and expressed 
before being functionally tested against a range of frequently used equine 
medications. This will allow for identification of novel substrates of CYP P450s in the 
horse.   
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Chapter 2: Materials and methods 
 
2.1: Bioinformatics analysis  
 
2.11: Alignments of known horse and human sequences 
 
Equine sequences were collected using the NCBI database 
(http://www.ncbi.nlm.nih.gov/) using the query ‘P450’ and filtering for Equus caballus. 
Isoforms of human P450s were also collected via this method. ClustalW2 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/) was used for the alignments. Heat maps 
were generated in Microsoft Excel in order to display percentage similarities in a 
graphical format – two for all known equine sequences (protein and nucleotide) and 
one for the equine and their human isoforms (nucleotide).  
2.12: Searching of equine genome 
 
The equine genome was probed by searching the UCSC genome browser 
(http://genome.ucsc.edu/). Two searches were carried out – the first used  various 
P450 sequences from horse and other species, chosen as a cross-species selection 
of P450s involved in drug metabolism  (see table 2.1) while the second used all 
known human P450 sequences on UniProt (http://www.uniprot.org/uniprot/). All 
identified potential equine P450 sequences were analysed using NCBI BLAST 
(http://blast.ncbi.nlm.nih.gov/) in order to quantify sequence similarities with P450s in 
other species. Those with e values greater than zero were removed, as this 
decreased the likelihood that the match occurred by chance (Altschul et al, 1997).  
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Species CYP name NCBI accession number 
Dog CYP2B11 NM_001006652.1 
Horse CYP2C92 NM_001101652.1 
 CYP3A89 NM_001101651.1 
 CYP3A93 NM_001190938.1 
 CYP3A94 NM_001190939.1 
 CYP3A95 NM_001190940.1 
 CYP3A96 FJ755695.1 
 CYP3A97 NM_001146164.1 
Human CYP1A2 NM_000761.3 
 CYP2B6 NM_000767.4 
 CYP2C9 NM_000771.3 
 CYP2C19 NM_000769.1 
 CYP2D6 NM_001025161.1 
 CYP3A4 NM_017460.5 
Mouse CYP3A11 NM_007818.3 
Rat CYP2C11 NM_019184.2 
Table 2.1: Sequences selected for first equine genome search. Sequences were selected as a 
cross-species selection of known drug-metbolising enzymes. 
 
2.13: Searching for automatically annotated equine sequences 
 
Due to the fact the direct equine genome searching generated many sequence 
fragments, the Ensembl ((www.ensembl.org/) and NCBI databases were searched 
for sequences automatically annotated as P450s in the horse. ‘P450’ was used as 
the search term in both databases and this data was aligned with that gathered from 
the direct genome search in order to determine the level of crossover. These 
‘predicted’ sequences had all been named automatically based on their similarity to 
certain P450 isoforms (e.g., ‘CYP2D6-like’) and these were the names used for the 
purpose of the current analyses. A table was generated of the predicted sequences, 
ordered by chromosome number in order to more easily compare gene clusters 
across species.   
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2.14: Generation of phylogenetic trees 
 
Phylogenetic trees were created using ClustalW2 Phylogeny 
(http://www.ebi.ac.uk/Tools/phylogeny/) via the neighbour joining method with 
distance correction turned on (Bruno et al, 2000), and percentage identity matrix and 
excluding gaps turned off. Two trees were produced – one for all predicted equine 
P450s (where separation into the nine vertebrate clans was highlighted) and one for 
all known equine P450s and their human isoforms, in order to look at predicted 
evolutionary divergence.    
2.15: Identification of conserved haem-binding motif 
 
The FxxGxxxCxG haem-binding motif is conserved amongst all P450s (Ranasinghe 
and Hobbs, 1998) therefore for final sequence validation, all predicted sequences 
were analysed for the presence of this domain. Protein sequences were obtained 
using ExPaSy Translate (http://web.expasy.org/translate) and the motif was 
searched manually in each sequence.  
 
2.2: Cloning, sequencing and protein structure predictions 
 
2.21: Isolation of RNA from equine liver  
 
A liver was acquired from a one year old male gelding. Liver was removed 
immediately after death and was in a healthy condition. It was immediately packaged 
onto dry ice and transported to the laboratory where it was cut into 4-5cm3 chunks 
and stored at -80oC in RNAlater (Life Technologies). A Qiagen RNeasy Maxi Kit was 
used following the manufacturer’s protocol to extract total RNA from 1g of liver. Total 
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RNA was then quantified using a nanodrop 8000 spectrophotometer, with 
concentration ranging between 400-600ng/µl and a 260/280 purity value of 1.8-2.   
2.22: Synthesis of cDNA 
 
The SuperScript III First Strand Synthesis System (Life Technologies) was used for 
cDNA synthesis using a random hexamer priming method (reviewed in Rio, 2014). 
500ng-1µg total RNA was used per reaction and cDNA was stored at -20oC. 
2.23: RT-PCR analysis 
 
Primers were used to amplify sequences obtained during the in silico analysis in 
order to verify their expression in liver. Primers were designed manually and 
specificity validated via NCBI Primer-BLAST 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). Additionally, primers for the already 
known CYP3A97 were designed as a positive control (Table 2.1.1). Polymerase 
chain reaction comprised of 10µl of MegaMix-Blue (Microzone), 1µl of cDNA and 2µl 
of each primer (2µM stock). Reactions were carried out with an annealing 
temperature gradient of 50oC to 68oC in 33 cycles with initial denaturation at 95oC for 
30 seconds followed by 33 cycles of denaturation at 95oC for 30 seconds, annealing 
for 1 minute and extension for 1.5 minutes at 68oC with a final extension for 5 
minutes at 68oC. PCR products were run on 1% agarose gels in 1x TBE buffer with 
10µl ethidium bromide/100ml at 100v for 40 minutes. Imaging was carried out using 
an Image Quant 300 (GE Healthcare) in UV mode.   
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Template 
sequence 
name 
Forward primer Reverse primer 
Ecab.P450.1 5’TCGACCCCACCTTTGTCCTT3’  5’AATTACAAGCTCTGCATCAT3’ 
Ecab.P450.4 5’CAGTTGCCTCAGCATTTTGT3’ 5’AGCCTTACCTCATCTGTGCA3’ 
Ecab.P450.5 5’ATGATGTTGTCCCAGCTCAG3’ 5’GCACGGCTACGGTTTTCCAT3’ 
Ecab.P450.17 5’AGCTTCAGTGATGACAACCT3’ 5’TGTCTTTGGCTTCCTGGTGA3’ 
Ecab.P450.18 5’GGAGGTATATCAACTGTGGT3’ 5’TGCTTCAGCGGTTTCACTTG3’ 
P450.Equ.18 5’GCCATTGCCCCCAAGGATGA3’ 5’TGGCTGAACGTGGAGCCGCT3’ 
P450.Equ.23 5’CCTTCTGGGACACCTCCCCT3’ 5’TCGAGTTCCGGCTGGTGCCC3’ 
P450.Equ. 37 5’AGGCATAGCCGCTGTGCTGC3’ 5’GCAAATGGCTTTGGCCCAGG3’ 
CYP1A1-like 5’ATGTTTTCTGTGTTTGGATT3’ 5’AGGATGAAGAAACACGCTGA3’ 
CYP1B1-like 5’ATGGCCACTAGCCTCAGCCT3’ 5’CCGAGGAAGACAGCCAGTGA3’ 
CYP2U1-like 5’TGATCACGTCCTTGAAGGGA3’ 5’CCTGACTGGAAGATACGGTC3’ 
CYP3A97 5’aataagtcgacATGGAGCTGGGAAGA
GCCTT3’ 
5’CCGTGACTGGAGCCTGACaagcttttatt
3’ 
CYP2C26-like 5’aataagtcgacAGAAGAGACAATGGAT
CTGGTTGTG3’ 
5’GCTCTGCTTTATTCCTGTGTGAaagc
ttttatt3’ 
Table 2.1.1: Primer sequences for RT-PCR of P450 sequences. Restriction sites are highlighted in 
yellow. Refer to appendix for regions primers were designed against.  
 
2.24: Commercial clones 
 
Clones were purchased from Genscript in the pUC57 vector (all constructs were 
cloned into vector using Xba I and BamHI). Six of these were obtained – CYP1A1, 
CYP2D50, CYP2E1, CYP3A96, CYP2A13, and CYP2C92. All constructs were 
cloned in the same direction except CYP1A1, which was cloned in the opposite 
direction (BamHI --> XbaI). Clones were selected based on likihood of being involved 
in drug metabolism (CYP2D50, CYP2E1, CYP3A96 and CYP2C92) or because they 
had not previously been recombinantly produced (CYP1A1, CYP2A13).  
2.25: Cloning for pCold expression system 
 
Top 10 E. coli cells (Life Technologies) were transformed with the pUC57 construct 
according to manufacturer guidelines. These were then were grown in 10ml general 
purpose nutrient broth (Oxoid) with ampicillin (100μg/ml) for 24hrs after which 
plasmid DNA was extracted using a Quiagen QuickLyse miniprep kit. DNA 
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concentrations were recorded using a Nanodrop 8000 spectrophotometer. See figure 
2.21 for vector maps and multiple cloning sites. Plasmid DNA was digested using the 
strategies outlined in table 2.21. Restriction enzymes and DNA ligase were 
purchased from Promega and manufacturer’s protocol was followed. DNA obtained 
from PCR reactions (for CYP3A97 and CYP2C26-like) was directly ligated into 
expression vector using the restriction sites in the primers (see table 2.21).  
Figure 2.21: Vector maps and multiple cloning sites. Sequences were first of all cloned into the 
pUC57 vector using Xba I and BamHI and subsequently cloned into the pCold vector for expression 
using the enzymes in table 2.21. Note that CYP1A1 was inserted into the pUC57 vector in the 
opposite direction and so was digested using the cloning strategy of BamHI+ XbaI to correct this. 
Adapted from “Cold Shock Expression System pCold™ DNA manual” by Takara Inc. and “pUC57 
plasmid DNA datasheet” by Genescript.  
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Construct pCold cloning 
strategy 
1A1 BamHI+ XbaI 
2A13 BamHI + HindIII 
3A96 SalI + XbaI 
3A97 SalI + HindIII 
2D50 EcoRI + HindIII 
CYP2E1 BamHI + HindIII 
2C92 BamHI + HindIII 
2C26-like SalI + HindIII 
Table 2.21: Cloning strategies for insertion into pCold vector. Restriction enzyme combinations 
used for each P450 construct are highlighted.  
2.26: Cloning for sf9 expression system 
 
Top 10 cells from Life Technologies were transformed with the pUC57 constructs as 
per manufacturer’s transformation protocol. Plasmid DNA was extracted using a 
Quiagen QuickLyse miniprep kit and plasmid DNA concentration was measured 
using a nanodrop. Restriction digests (1μl of each restriction enzyme, 1μg DNA, 5μl 
of buffer, total reaction volume: 50μl) were performed as outlined in table 2.22 and 
DNA was ligated  into the pFastBac 1 expression vector (Life Technologies) as per 
manufacturer’s protocol. See figure 2.22 for vector map.  
 
pUC57 
construct 
pFastBac-1 
cloning strategy 
1A1 KpnI + SalI 
2A13 SalI  + XbaI 
3A96 SalI  + XbaI 
3A97 SalI + HindIII 
2D50 EcoRI + XbaI 
CYP2E1 BamHI + HindIII 
2C92 Acc65I + HindIII 
 
Table 2.22: Cloning strategies for insertion into pFastBac-1 vector. Restriction enzyme 
combinations used for each P450 construct are highlighted.  
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Figure 2.22: pFastBac 1 expression vector. Vector contains a polyhedron promotor (PPH) for 
production of high quantity of recombinant protein in baculovirus-infected insect cells as well as 
ampicillin and gentamycin resistance markers. Multiple cloning site (MCS) features are highlighted.  
2.27: Sequence verification of cloned constructs 
 
Successfully cloned products were sequence verified via Sanger sequencing 
(Source Bioscience, Nottingham, UK) using primers designed against both ends of 
the pCold cloning vector (forward: ACGCCATATCGCCGAAAGG, reverse: 
GGCAGGGATCTTAGATTCT, hightlighted in figure 2.21). M13 primers were used 
for the pFastBac 1 constructs. Sequencing output chromatograms were analysed 
using BioEdit (Ibis Biosciences).  
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2.28: Protein structure prediction 
 
DNA sequencing results were translated using ExPaSy Translate with standard 
genetic code. Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2) was used in normal mode to 
generate 3D structure predictions of the protein sequences. In the cases where the 
reference sequence varied from the expression construct, predictions were made of 
both sequences for comparison.   
2.3: Protein expression and verification  
 
2.31: BL21 pCold expression 
 
BL21 E. coli competent cells were ordered from New England Bioscience (NEB) and 
were transformed with pCold I constructs from Takara Bio as per NEB protocol. 
Serial dilutions (1 in 10 and 1 in 100) were spread onto 90mm plates containing 
nutrient agar and 100μg/ml ampicillin. After overnight incubation at 37oC, individual 
colonies were inoculated into 10ml nutrient broth with 100μg/ml ampicillin and 
shaking at 200rpm/37oC overnight. Glycerol stocks were established (500μl 
overnight bacterial culture and 500μl of 50% glycerol (Sigma-Aldrich) with 50% 
sterile reverse osmosis (RO) water) for subsequent expression studies. Stocks were 
frozen and stored at -80oC. All cultures used for glycerol stocks were sequence 
verified to ensure no mutations had occurred.   
To induce expression, a 1:100 dilution of overnight culture into fresh nutrient broth + 
ampicillin was incubated with shaking at 37oC until OD600 was between 0.4-0.5. 
Temperature was then brought down to 15oC and cultures were left to stand for at 
least half an hour after which induction using the optimum IPTG (isopropyl-β-d-
thiogalactopyranoside, VWR International) concentration (determined by performing 
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titrations ranging from 0 to 1mM) was initiated and cultures were left shaking 
overnight at 15oC. Cells were pelleted by centrifugation for 10 minutes at 3000rpm 
and lysed using CelLytic B (Sigma-Aldrich) with protease inhibitor and lysozyme 
(Sigma-Aldich) at the concentrations recommended by the manufacturer.  20% 
glycerol was added for protein stability (Gekko and Timasheff, 1981). Total protein 
was measured using a Bradford assay (Sigma-Aldrich) according to manufacturer’s 
protocol and a spectrophotometer with detection at 595nm. Lysate was stored at -
80oC in 1ml aliquots.  
Two further lysis techniques were also used to compare protein integrity – one 
involved using lysozyme (concentration 1mg/ml – incubated at 5oC with rotation 
overnight) for lysis and the other involved sonication (30 seconds on/ 30 seconds off 
for 5 minutes) using a standard lysis buffer (50mM Tris-HCl (Merk Millipore), 100mM 
NaCl, 1mM  dithiothreitol (DTT), 5% glycerol) with protease inhibitor. Lysates were 
centrifuged at 16,000g for ten minutes. 
2.32: Integration of pFastBac-1 constructs into bacmid  
 
Incorporation of DNA into bacmid involved using the Bac-to-Bac expression system 
(Life Technologies), see figure 2.32 for summary. 100μl of DH10Bac cells containing 
the bacmid DNA were incubated on ice with 1ng of pFastBac DNA for 30 minutes 
after which they were heat shocked at 40oC for 45 seconds, chilled on ice for two 
minutes, mixed with 900μl of super optimal broth media and incubated at 
37oC/225rpm for four hours. 10-fold serial dilutions were performed and cells were 
streaked on LB agar plates containing 50μg/ml kanamycin (Sigma-Aldrich), 7μg/ml 
gentamycin (Sigma-Aldrich) and 10μg/ml tetracycline (Sigma-Aldrich) along with 
100μg/ml x-gal (Promega) and 40μg/ml IPTG for blue-white screening. Plates were 
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incubated for 48 hours at 37oC before white colonies were selected and restreaked 
on fresh plates for further verification. Overnight liquid cultures of 10ml were then set 
up using nutrient broth with 50μg/ml kanamycin, 7μg/ml gentamycin and 10μg/ml 
tetracycline. These cultures were used to extract DNA for the next stage using the 
PureLink HiPure Plasmid DNA Miniprep Kit (Life Technologies).  
2.33: Insect cell maintenance, transfection and viral stock amplification 
 
Sf9 insect cells (Life Technologies) were grown and maintained in sf-900 III SFM 
media (Life Technologies) at 28oC with gentamycin at 10μg/ml prior to transfection 
experiments. Daily cell counts were performed to ensure log phase growth (2-
2.5x106 cells/ml) was maintained and viability was monitored using trypan blue (Life 
Technologies) to ensure >95% viability (Richardson, 1995). Subculturing was carried 
out in 75ml flasks with filter caps when cell density reached >2.5x106 cells/ml.  
Prior to transfection, cells were counted, centrifuged at 500rpm for five minutes and 
resuspended in unsupplemented Grace’s Insect Cell media (Life Technologies) to 
generate a cell density of 4x105 cells/ml. 2ml of cell culture was added to each well 
of 6-well plates and cells were left to attach for 15 minutes. 8μl of Cellfectin II reagent 
(Life Technologies) was diluted in 100μl of unsupplemented Grace’s media while 1μl 
of bacmid DNA (~0.5ng/μl) was diluted in 100μl Grace’s media. Both dilutions were 
combined and incubated at room temperature for 15-30 minutes after which the 
mixture was added to each well (209μl mixture per well). Cells were incubated for 
five hours at 27oC and subsequently the transfection mixture was removed by 
centrifugation of cells after which Grace’s media supplemented with 10% FBS (Life 
Technologies) was added. Cells were then placed back into the incubator and were 
monitored for signs of viral infection via microscopic observation from 72hrs post-
63 
 
infection (with late stage infection being shown by cell lysis). When cells reached late 
stage infection, virus was removed by collecting the supernatant after centrifugation 
at 500g for 5 minutes. Viral stocks were stored protected from light at 4oC (aliquots 
were also stored for long term purposes at -80oC).  
P1 viral stock was added to sf9 cells in 6-well plate format (4x106 cells/ml in SFM 
media) at volumes ranging from 10μl-100μl and cells were incubated at 27oC for 48 
hours after which samples were removed and virus isolated – sample times ranged 
from 48 hours to 90 hours to determine optimal incubation time. P2 viral stocks were 
stored along with P1 stocks.   
2.34: Sf9 expression attempts 
 
For protein expression, 6x105 cells were added per well to a 24 well plate and 
bacmid stock was added (volumes ranging between 10μl-100μl). Cells were 
incubated at 27oC and harvested at various time points ranging from 0 to 72hr post-
transfection in order to assess optimal time for protein expression. For analysis, 1ml 
of cells at each time point was centrifuged and lysed in 1x lithium dodecyl sulfate 
(LDS) sample buffer (Life Technologies) and run on coomassie stained gels or 
Western blots. 
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Figure 2.32: Summary of sf9 insect cell expression procedure.  The gene of interest in a donor 
plasmid (pFastBac 1) is used to transform DH10Bac E coli , where the gene of interest is transposed 
into the bacmid present in the DH10Bac cells. Recombinant bacmid DNA is then extracted and used 
to transfect insect cells for recombinant protein expression. Adapted from “Bac-to-Bac Expression 
System User Guide” by Life technologies.  
2.35: Western blotting 
 
Lysates were prepared by mixing them in a 1:1 ratio with diluted 4x NuPage LDS 
sample buffer (Life Technologies) and 100mM DTT added as the reducing agent. 
After heating at 70oC for 10 minutes, 20-30μl of sample was loaded to 4-12% bis-tris 
mini gels (Life Technologies) which were run on an Xcell SureLock electrophoresis 
system (Life Technologies) at 200 volts for 40 minutes. Protein markers were either 
a 175KDa prestained protein (NEB) or MagicMark 220KDa (Life Technologies). 
Transfer of proteins was achieved by sandwiching the gel between filter paper and 
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nitrocellulose membrane with a pore size of 0.45um (Life Technologies). Transfer 
was carried out at 30 volts for 60 minutes in an XCell Blot Module (Life 
Technologies) using NuPage transfer buffer (Life Technologies) prepared as a 1x 
solution as per manufacturer’s guidelines.The membrane sandwich was 
disassembled and the nitrocellulose membrane underwent blocking in 2.5% non-fat 
milk (Marvel) in PBS for half an hour at room temperature with rotation on a roller. All 
primary antibodies (rabbit anti-P450 - Enzo Life Sciences, rabbit anti-CYP2D6 - 
Antibodies-online and rabbit anti-his tag - Novagene) were diluted 1:1000 in PBS 
and incubated with membranes at 4oC overnight with rotation. Secondary (anti-rabbit 
conjugated to horse radish peroxidase, Source Bioscience) antibody (1:1000 dilution 
in PBS) was incubated at room temperature for 1.5 hours with rotation. After blocking 
and primary and secondary antibody incubations, three five-minute wash steps in 
PBS were carried out. ECL Prime (Amersham) was used according to 
manufacturer’s instructions and a Typhoon Trio Variable Mode Imager set to detect 
with the blue laser at 488nm allowed visualisation of the blot.  
2.36: Coomassie staining of cell lysates 
 
Protein samples were prepared as above and run on 10% bis-tris gels for 40 minutes 
at 200v with the 175KDa prestained protein marker. Gels were then washed three 
times for five minutes in distilled water then stained in a tray with rotation for one 
hour at room temperture using 20ml of SimplyBlue Safe Stain (Life Technologies). 
Destaining took place overnight in 100ml distilled water and images of gels were 
taken using an Image Quant 300 (GE Healthcare) in white light mode.  
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2.37: Protein purification  
 
His-Select columns (Sigma-Aldrich) and immunoprecipitation (using an anti-P450 
antibody) were used to purify recombinant proteins from the total protein lysate. His-
Select columns were equilibrated with buffer containing 50mM sodium phosphate 
and 0.3M sodium chloride. The lysate was loaded onto the column with 
centrifugation at 5000rpm. Two washes using buffer containing 50mM sodium 
phosphate, 0.3M sodium chloride (Sigma-Aldrich) and 5mM imidazole (Sigma-
Aldrich) were followed by a final elution with 50mM sodium phosphate (Sigma-
Aldrich), 0.3M sodium chloride and 250mM imidazole. A Dynabeads protein G kit 
(Life Technologies) was used for immunoprecipitation. Anti-P450 antibody (10μg) 
was bound to 3mg of beads in 50μl citrate-phosphate buffer, pH 5, (rotation at room 
temperature for 10 minutes) after which the beads with captured with a magnet and 
the supernatant was removed. 500μl-1ml of cell lysate (variable depending on 
protein concentration – refer to chapter 5) was added and incubated with rotation for 
~20 minutes in order to bind the target antigen to the antibody/bead complex. Beads 
were separated from the supernatant using a magnet after each step and the 
complex was washed three times in 200μl PBS before antigen elution using 20μl 
0.1M citrate.  
2.38: Mass spectrometry protein identification 
 
Purified protein concentration was measured using a Bradford assay as previously 
described and samples were run on a Q-TOF2 mass spectrometer using ESI and 
and a Waters CapLC HPLC system with a C18 column. Positive ion mode was used 
and a capillary voltage of 3000v was selected. Data directed analysis was used to 
switch between MS and MS/MS based upon charge state, intensity and mass and 
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cone voltage varied between 15-55v. ProteinLynxGlobalServer, MASCOT (web 
version), Swissprot and NCBI were used for data analysis and interpretation. Work 
carried out in collaboration with Dr Susan Liddell. 
2.39: P450 quantification 
 
P450 quantification involved using the carbon monoxide difference spectrum as first 
described by Omura and Sato (1964). Protocol followed was as per Guengerich et al 
(2009) whereby CO was bubbled into both samples before reduction by sodium 
dithionite (Sigma-Aldrich) of one sample. A Unicam UV4 spectrophotometer set to 
detect wavelength between 390-510nm was used and absorbance values at 420nm, 
450nm and 490nm were recorded.     
2.4: Enzyme kinetics  
2.41: Recombinant P450 phenotyping 
 
Preliminary drug assays were carried out with each CYP in order to gauge which 
compounds were turned over by the enzyme. Three time points were used – 0, 30 
and 60 minutes. Incubation involved shaking at 500rpm in a 37oC incubator. Test 
compounds were dissolved in DMSO (Sigma-Aldrich) to give a stock concentration 
of 300μM. Each incubation contained 296μl phosphate buffer (pH 7.4), 20μl crude 
pCold lysate, 20μl P450 reductase (45 pmol/ml, Sigma-Aldrich), 20μl b5 (225 
pmol/ml, Sigma-Aldrich), 4μl test drug (3μM, Sigma-Aldrich) and 40μl NADPH 
(11.3mM, Roche). All components of incubation mixture except NADPH were 
preincubated at 37oC for 5 minutes in order to equilibrate. Addition of NADPH 
immediately started the reaction. At each time point, 50μl of the incubation was 
removed and quenched into 100μl of ice cold methanol and immediately stored at -
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20oC in capped tubes for a minimum of four hours before being centrifuged at 
500rpm for ten minutes to remove any unprecipitated material.  
2.42: Enzyme kinetic analysis 
 
When turnover with a specific drug appeared to take place in the preliminary studies, 
attempts were made to determine the kinetic parameters of each drug with 
rCYP2C92 by carrying out incubations at eight different concentrations, ranging from 
1 to 150 μM. Samples were removed and quenched at 0, 2, 4, 8, 12, 16, 30 and 60 
minutes. Internal standards were used at a concentration of 5μM in quenching 
methanol in order to ensure apparent decrease in substrate concentration was not 
due to non-specific processes or analysis error.    
2.43: CYP2C92 inhibition assay 
 
In order to further demonstrate whether the CYP2C92 construct had P450-like 
activities an inhibition assay was carried out using fluconazole (VWR International), a 
potent inhibitor of human CYP2C9 (Kunze et al, 1996). Inhibitor concentration 
ranged from 0 to 125 μM and diclofenac was used as the substrate at 75 μM. 
2.44: Negative control assays 
 
To ensure apparent drug metabolism was caused specifically by the rCYP2C92 
construct two sets of negative control were carried out – one set involving a 
denatured (left at room temperature overnight) CYP2C92 construct and one set 
involving the other, CYP2D50, construct. All four NSAIDs were used with each at a 
concentration of 75 μM. 
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2.45: Microsome assays 
 
To complement the recombinant enzyme drug incubations, equine liver microsomes 
(provided by Mr Khaled Shibany) were also tested against the NSAIDs that had 
apparent turnover in the recombinant system as well as with the presence of 
fluconazole. Microsomal P450 content was determined by the CO absorbance 
spectral shift to be 0.61nmol/mg of protein. NADPH and test drug concentrations 
used were the same as for the recombinant enzyme incubations.  
2.46: Human recombinant supersomes 
 
Commercially produced human recombinant supersomes (CYP2C9*1) were 
purchased from BD Biosciences. P450 concentration in incubations was 10 pmol 
and these were run under the same conditions as the equine incubations. 
2.4.7: Liquid chromatography mass spectrometry (LCMS) method development 
 
Methods for all compounds were developed on a Micromass Quattro Ultima mass 
spectrometer using electrospray positive mode with an Agilent 1100 HPLC. Stock 
compounds were prepared in methanol at a concentration of 10mg/L. Solvent flow 
rate was kept a constant 0.5 ml/min with an upper pressure limit of 400 bar. Solvent 
A was 10% methanol, 90% water and 0.002% formic acid and Solvent B was 100% 
methanol and 0.002% formic acid. See table 2.4.1 for details on methods developed 
for each drug. 
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Time (mins) B% 
0 50 
2 100 
4 100 
5 50 
7.5 50 
Table 2.42: HPLC gradient used for diclofenac and flunixin analysis. The percentage of solvent B 
with time is highlighted.  
 
Time (mins)  B% 
0 50 
1 50 
3 100 
4 50 
5 50 
Table 2.43: HPLC gradient used for phenylbutazone analysis. The percentage of solvent B with 
time is highlighted.  
 
Time (mins) B% 
0 0 
2 100 
5 0 
6 0 
Table 2.44: HPLC gradient used for ketoprofen analysis. The percentage of solvent B with time is 
highlighted.  
 
In addition to substrate depletion, diclofenac and phenylbutazone samples were 
monitored for the appearance of known metabolites, 4-hydroxydiclofenac and 
oxyphenbutazone. These ions were monitored for along with the parent drug ions 
and methods developed ensured retention times for drug and metabolite varied 
enough to distinguish between peaks.  
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2.48: LCMS data analysis 
 
LCMS data was analysed via the Masslynx v4.0 software (Waters). The natural 
logarithm (Ln) of each chromatogram peak area (measured in arbitrary units) was 
calculated using Microsoft Excel. This was plotted against time using GraphPad 
Prism 6 in order to generate linear graphs at each substrate/inhibitor concentration. 
The initial rate (𝒗𝟎) was calculated using the slope of the line (kdep) of each individual 
graph via the following equation where [S]0 is the initial substrate concentration: 
 
𝒗𝟎=𝒌𝒅𝒆𝒑[𝑺]𝟎 
𝒗𝟎 was used to generate a Michaelis-Menten analysis in order to estimate the 
Michaelis constant (Km) and/or the maximum velocity of the reaction (Vmax). 
Michaelis-Menten graphs were created in GraphPad Prism 6. When the substrate or 
metabolite caused inhibition of metabolism, Michaelis-Menten kinetics could not be 
used and so a substrate inhibition curve was fitted to the data in GraphPad Prisim 6.  
In order to generate an intrinsic clearance (CLint), the following equation was used:  
 
In cases where the Vmax and Km could not be estimated (i.e. where substrate 
inhibition had occurred), the initial velocity (the slope of the line where substrate 
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concentration is below Km) of the reaction was used to estimate CLint (see Chapter 
6). 
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Chapter 3: Bioinformatics analysis 
3.1: Introduction 
 
The equine genome was first sequenced in 2009 (Wade et al, 2009) using a single 
Thoroughbred mare (‘Twilight’). Since then, the genome for an American Quarter 
horse has been sequenced (Doan et al, 2012) as well as draft genomes for 
Przewalski’s horse (Equus Przewalski) and a donkey (Equus asinus), Orlando et al 
(2013). The sequencing of the equine genome means new approaches can now be 
taken in equine genomic research, and the in silico applications of this are numerous 
(Hert et al, 2008, Hobert, 2010). The choice of a Thouroughbred for the original 
sequencing was largely due to the high level of homozygosity this breed contains, 
which is a factor that can greatly influence the assembly of a genome, making the 
assembly process substantially easier than for more heterozygous genomes (Kajitani 
et al, 2014). A whole-genome shotgun method was used and the genome was found 
to be ~2.5 Gb in size, which is around the same size as mouse (Mouse Genome 
Sequencing Consortium, 2002), smaller than human (3 Gb, International Human 
Genome Sequencing Consortium, 2001), and cow (3 Gb, Bovine Genome 
Sequencing and Analysis Consortium, 2009) but larger than dog (2.4 Gb, Lindblad-
Toh et al, 2005). During sequencing of the equine genome, a single nucleotide 
polymorphism (SNP) map was created, which has since been expanded, with 54,000 
SNPs being analysed (McCue et al, 2012). See table 3.1 for details of gene numbers 
from the equine genome assembly (Ensembl build 80.2).  
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 Horse Human Mouse Dog Cow 
Genome Size 
(Gb) 
2.5 3 2.5 2.4 3 
Coding 20,449 20,296 22,547 19,856 19,994 
Non-coding 2,142 25,173 12,583 3,774 3,825 
Pseudogenes 4,400 14,424 8,770 950 797 
Table 3.1: Summary of predicted genes for Horse, Human, Mouse, Dog and Cow. Data was 
retreived from Ensembl (http://www.ensembl.org/) build 81.2 (horse), 81.38 (mouse and human), 
81.31 (dog and cow). 
3.1.1: Equine P450 genes 
 
To date, no research has been carried out to ascertain how many CYP genes the 
equine genome may contain, although Schmitz et al (2010) analysed the CYP3A 
gene cluster, finding six potential genes, which contrasts with the four in human 
(Gellner et al, 2001). Two pseudogenes were also found, which matches the number 
of CYP3A pseudogenes in human (Finta and Zaphiropoulos, 2000) and P450 
sequences in both species were highly homologous. The first aim of this study was 
to expand on this knowledge by finding all P450 genes present in the horse. This 
was implemented in two ways – first, the equine genome was searched using all 
known human CYP genes as probes. Secondly, the Ensembl and NCBI databases 
were searched for all equine genes automatically annotated as P450s. Duplicate 
genes were removed and so a full list of potential equine P450 genes was 
generated.  
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3.1.2: P450 clans 
 
In human, there are 57 known P450 genes and 58 pseudogenes, however P450 
numbers vary significantly across species – even within the Mammalia - with 102 
functional genes in the mouse, 89 in the rat, 59 in cattle and pigs, and 62 in the 
chimpanzee (Nelson et al, 2003, Nelson, 2009, Sim and Ingelman-Sundberg, 2010, 
Puccinelli and Gervasi, 2011). P450s are divided into ‘clans’, which are sometimes 
also referred to as gene clusters (Good et al, 2014, Nelson, 1998). Clans/clusters 
are used to organise P450s based on evolution, with P450s being grouped together 
due to common evolutionary ancestors determined via phylogenetic analysis of 
sequence divergence (Kirischian et al, 2011, McArthur et al, 2003). It is possible for 
P450s of different families to be in one clan as they may be closely related 
phylogenetically (Nelson, 1998). In mammals there are nine distinct clans – CYP1, 
CYP2, CYP3, CYP4, CYP19, CYP20, CYP26, CYP51 and the mitochondrial P450 
clan (Nelson, 2003, Omura, 2012) – see table 3.1.2. 
There are currently 14 known equine P450 genes – CYP3A89, CYP3A93, CYP3A94, 
CYP3A95, CYP3A96, CYP3A97 (Schmitz et al, 2010, DiMaio Knych et al, 2010), 
CYP2C92 (DiMaio Knych et al, 2009), CYP2D50 (DiMaio Knych and Stanley, 2008), 
CYP2B6 (Peters et al, 2013), CYP11A1 (Boerboom and Sirois, 2001), CYP27B1, 
CYP2A13, CYP2E1 (based on unpublished data by DiMaio Knych et al) and 
CYP19A1 (Seralini et al, 2003). Genes from the CYP1 CYP4, CYP7, CYP20, CYP26 
and CYP51 clans have yet to be found in the horse (see table 3.1.2).  
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Clan/Cluster Families in Clan/Cluster Equine Genes in 
Clan/Cluster 
CYP1 CYP1 None 
CYP2 CYP2 CYP2A13, CYP2B6, 
CYP2C92, CYP2D50, 
CYP2E1 
CYP3 CYP3, CYP5 CYP3A89, CYP3A93, 
CYP3A94, CYP3A95, 
CYP3A96, CYP3A97 
CYP4 CYP4, CYP5 None 
CYP17 CYP17, CYP21 None 
CYP19 CYP19 CYP19A1 
CYP20 CYP20 None 
CYP26 CYP26 None 
CYP51 CYP51, CYP7, CYP8, 
CYP39 
None 
Mitochondrial  CYP11, CYP27 CYP11A1, CYP27B1  
Table 3.1.2: Organisation of mammalian P450 families into clans along with those known in the 
horse. All mammalian P450 clans/clusters are highlighted along with which families they contain. All 
14 known equine P450 genes are highlighted in order to display which clans they belong to.  
 
3.1.3: Current study 
 
For the current study, attempts were made to find all equine P450s by searching the 
equine genome. Once sequences had been gathered, homology was determined 
through multiple sequence alignments and phylogenetic relationships were inferred 
through the generation of phylogenetic trees, allowing the validation of grouping the 
sequences into clans. Additionally, haem-binding (conserved across all P450s, 
Ranasinghe and Hobbs, 1998) and substrate recognition regions were highlighted in 
order to validate their P450 status and to postulate potential substrate similarities 
with human isoforms.  
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3.2: Results 
3.21: Alignment of known equine P450s shows high homology 
 
A heat map was generated based on the DNA sequence similarities of all known 
equine CYPs (fig 3.1) The mitrochondrial P450s have the lowest overall similarity 
with other CYPs as well as having relatively low similarity to each other. The lowest 
score was between CYP27B1 and the CYP3A subfamily, ranging from a 45.9-
52.63%. The highest degree of similarity was between the 3A P450s (ranging from 
88.23-91.6%). A heat map of an alignment of the protein sequences of these 
enzymes was also generated (fig 3.2). Protein sequence scores had a much larger 
range, from the lowest value of 16.99% for the alignment between CYP2D50 and 
CYP11A1 to the highest for CYP3A89 and CYP3A93 (88.47%), indicating that the 
protein sequences vary more between isoforms. Overall the protein alignment scores 
are much lower than for the DNA alignments. For those of the same subfamily (i.e. 
3A), protein alignment scores are similar to DNA alignment scores, indicating high 
homology within subfamilies.  
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Figure 3.1: Heat map of an alignment between all known equine P450s. All known equine CYPs 
were aligned using ClustalW and a heat map was produced to highlight levels of percentage 
similarity, with the highest in green and the lowest in red (colour changes occur every five percentage 
points, e.g. 95-100 is darkest green etc.).   
 
Figure 3.2: Protein sequence alignment heat map of known equine P450s. All known equine 
CYPs were aligned using ClustalW and a heat map was produced to highlight levels of percentage 
similarity, with the highest in green and the lowest in red.  
 
A third heat map was generated from an alignment of all known equine P450s with 
their human isoforms (fig 3.3). The highest scores were within subfamilies of the 
same species (e.g between the equine CYP3A sequences) and the highest overall 
CYP2A13 CYP2B6 CYP2C92 CYP2D50 CYP2E1 CYP3A89 CYP3A93 CYP3A94 CYP3A95 CYP3A96 CYP3A97 CYP11A1 CYP19A1 CYP27B1
CYP2A13 100
CYP2B6 67.07 100
CYP2C92 64.44 60.94 100
CYP2D50 59.19 57.51 56.75 100
CYP2E1 63.16 62.96 65.17 58.75 100
CYP3A89 59.39 57.71 55.82 53.36 56.36 100
CYP3A93 49.49 53.13 57.41 46.91 54.3 91.6 100
CYP3A94 52.26 54.34 59.39 47.17 55.29 91.73 91.01 100
CYP3A95 53 54.07 56.75 46.17 54.89 89.68 88.89 88.89 100
CYP3A96 53.13 53.67 56.3 47.84 52.78 88.52 88.43 88.82 88.62 100
CYP3A97 57.78 58.25 52.65 52.3 53.79 87.98 89.68 89.62 88.23 87.53 100
CYP11A1 52.93 53.54 52.53 53.43 52.91 54.7 52.12 50.33 50.07 50.07 51.12 100
CYP19A1 64.11 65.52 60.11 62.48 62.37 56.78 63.23 63.76 63.23 61.6 62.26 63.34 100
CYP27B1 53.94 54.61 49.68 55.89 51.61 52.63 45.97 49.07 45.9 49.26 51.61 53.28 60.93 100
CYP2A13 CYP2B6 CYP2C92 CYP2D50 CYP2E1 CYP3A89 CYP3A93 CYP3A94 CYP3A95 CYP3A96 CYP3A97 CYP11A1 CYP19A1 CYP27B1
CYP21A13 100
CYP2B6 53.77 100
CYP2C92 51.63 51.53 100
CYP2D50 37.8 41.1 41.19 100
CYP2E1 48.58 47.55 55.21 36.12 100
CYP3A89 24.57 24.78 26.3 24.15 24.14 100
CYP3A93 25.22 25.65 26.74 24.15 23.92 88.47 100
CYP3A94 25 25.86 25.43 24.36 23.92 88.07 86.48 100
CYP3A95 24.57 25.65 25.22 23.5 22.84 85.09 83.3 84.29 100
CYP3A96 20.69 22.41 22.17 21.15 21.12 78.93 76.74 78.33 77.53 100
CYP3A97 24.78 25.22 25.87 22.86 23.71 85.29 84.1 84.69 81.31 76.34 100
CYP11A1 18.5 18.72 19.73 16.99 18.76 23.97 23.33 22.46 23.97 19.44 23.54 100
CYP19A1 20.52 19.56 20.26 17.67 21.23 21.27 22.85 22.17 20.36 18.33 22.62 17.08 100
CYP27B1 21.4 22.2 22.47 20.91 22.81 24.68 24.68 22.73 24.24 21 24.03 31.25 18.69 100
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score was between human CYP3A7 and CYP3A4 (94.18). The highest interspecies 
score was between human CYP3A4 and equine CYP3A93 (85.19%). The 19, 11 and 
27 subfamilies had consistently low (<45%) scores with other P450s and between 
each other, however lowest score overall was between human CYP3A43 and equine 
CYP2A13 (29.22%).  
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3.22: Equine genome and annotated sequence search, 59 potential sequences 
 
Two approaches were taken to identify novel equine P450 sequences – searching 
the UCSC genome browser via BLAT and searching the Ensembl and NCBI 
databases for automatically annotated sequences. 
From the BLAT search 59 potential sequences were extracted, although most 
appeared to be partial sequences due to being less than 1kb in length. Using NCBI 
BLAST, the sequences were compared against the full NCBI database and those 
that matched non-P450 genes at this stage were removed. For the second method, 
the Ensembl and NCBI sequence databases were searched for equine sequences 
automatically annotated with ‘P450’ by searching within the Equus Caballus build for 
this term. These sequences were aligned with the sequences from the equine 
genome BLAT search in order to detect overlaps and duplicates. All sequences from 
the equine genome BLAT search are displayed in table 3.2, highlighting which P450s 
they match and whether they are an exact match for an annotated sequence. 
Sequence lengths are illustrated as one parameter to differentiate full from partial 
sequences, since most P450s are around 1.5kb in length.  
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Given Name Chromosome Strongest BLAT 
Match 
Clustal % 
Horse 
Clustal 
% 
Human 
Length 
(bp) 
Ecab.P450.1 chr1 CYP2E1 100%   1179 
Ecab.P450.2 chr1 CYP2C26 100% predicted   675 
Ecab.P450.3 chr1 CYP2C26  100% predicted   645 
Ecab.P450.4 chr1 CYP2R1  90%  681 
Ecab.P450.5 Chr1 CYP1A2 100% predicted   1545 
Ecab.P450.6 chr1 CYP1A1 100% predicted   1524 
Ecab.P450.7 chr10 CYP2B6 97%   648 
Ecab.P450.9 chr13 CYP2W1   86%  615 
Ecab.P450.10 chr13 CYP3A97 100%   1509 
Ecab.P450.11 chr13  CYP3A12 100% predicted   1506 
Ecab.P450.12 chr13 CYP2G1 91% predicted    
717 
Ecab.P450.13 chr15 CYP1B1  100% predicted   1311 
Ecab.P450.14 chr2 CYP2J2 100% predicted   624 
Ecab.P450.15 chr2 CYP2U1 100% predicted   780 
Ecab.P450.17 chr28 CYP2D14 99% predicted   639 
Ecab.P450.18 chr7 CYP2R1. 100% predicted 
E. przewalskii  
 1197 
Ecab.P450.19 unmapped CYP2D14 100% predicted   897 
P450.Equ.1 Chr1 CYP1A1 100% predicted   519 
P450.Equ.2 Chr10 CYP2B6 99%   666 
P450.Equ.6 Chr13 CYP2G1 92% predicted   480 
P450.Equ.12 Chr15 CYP1B1 100% predicted   1311 
P450.Equ.16 Chr18 CYP20A 1 100% predicted   1119 
P450.Equ.17 Chr2 CYP2U1 100% predicted   636 
P450.Equ.18 Chr21 CYP4F22  100% predicted   1212 
P450.Equ.19 Chr21 CYP4F3 100% predicted   1557 
P450.Equ.23 Chr24 CYP46A1  100% predicted   1395 
P450.Equ.30 Chr28 CYP2D14 97% predicted   507 
P450.Equ.37 Chr6 CYP27B1  100%   837 
 
Table 3.2: Sequences generated from equine genome search.  The UCSC genome browser was 
searched using probe sequences from other species. Those highlighted in bold match previously 
known equine P450s while those in italics match sequences predicted as P450s on the NCBI 
database. The strongest match for each sequence is shown and % similarity (horse or human, 
depending on strongest match) is displayed.  
 
The annotated P450 sequences are listed in table 3.3, ordered by chromosome 
number. All major P450 families (1A, 2B, 2C, 2D, 2E, 3A) are represented and in 
total there were 46 full-length sequences, verified by BLAST database searches 
against P450s in other species.  
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Chromosome P450 genes  
1 CYP2E1,  CYP17A1-like, CYP2C21-like, CYP2C92, 
CYP2C19-like, CYP2C18-like, CYP26A1-like,  
CYP26C1-like , CYP1A2-like, CYP1A1  
CYP11A1-like, CYP19A1 
2 CYP2J2-like, CYP4X1-like, CYP4B1-like, CYP4A11-
like, CYP4A7-like, CYP2U1-like 
6 CYP27B1 
9 CYP11B1-like 
10 CYP2F5-like, CYP2A13, CYP2B6, CYP2G1-like, 
CYP2B4-like, CYP2S1-like 
13 CYP3A93, CYP3A89, CYP3A94, CYP3A95, 
CYP3A96, CYP3A97, CYP3A12-like 
15 CYP26B1-like, CYP1B1-like 
18 CYP27C1-like, CYP20A1-like 
21 CYP4F22-like, CYP4F6-like, CYP4F3-like 
24 CYP46A1-like 
27 CYP4V2-like 
28 CYP2D14-like, CYP2D50 
Table 3.3: Summary of predicted and known equine sequences on each chromosome. 
Sequences were sorted by chromosome and order within chromosome. In total there are 46 
sequences (14 known and 32 novel).  
 
Only three sequences (E.cab.P450.4, Ecab.P450.9 and Ecab.P450.18) of the 59 
from the original UCSC genome search using human probe sequences were not 
matches with the 46 annotated (known and predicted) equine sequences – and of 
these none appear to be full length sequences, although at 1197bp Ecab.P450.18 is 
near the expected length for a P450 gene. E.cab.P450.4 does not possess the 
FxxGxxxCxG haem-binding motif (which is conserved across all P450s) however 
Ecab.P450.18 and Ecab.P450.9 do, meaning they appear to at least be partial P450 
sequences.  
All other sequences were identical to NCBI/Ensembl annotated equine sequences. 
Ecab.P450.18 was aligned with its closest protein BLAST match in order to 
demonstrate the level of sequence conservation and to point out the haem-binding 
region (fig 3.4). The haem-binding region is also highlighted for Ecab.P450.9 (fig 
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3.5). Additionally, the protein sequences of all annotated sequences were analysed 
for the presence of haem-binding motif (refer to appendix for sequences). CYP3A12-
like, CYP2S1-like and CYP20A1-like all lack this motif while the rest were confirmed 
to possess it. Additionally, some sequences (CYP2C, CYP3A, CYP2D, CYP2E1 and 
CYP1A2) which are most likely involved in drug metabolism (due to being matches 
with human isoforms involved in drug metabolism) were aligned with their human 
isoforms with substrate recognition sites highlighted in order to demonstrate whether 
substrate specificities may be the same (figures 3.6-3.10). For downstream studies 
(chapter 4), sequences were selected based on their likihood of being involved in 
drug metabolism (Ecab.P450.1, Ecab.P450.5, P450.Equ.30, CYP3A97, CYP2C26-
like) or because expression levels/substrate specificities in other species are not well 
characterised (Ecab.P450.5, Ecab.P450.18, P450.Equ.18, P450.Equ.23, 
P450.Equ.37, CYP2U1-like). Additionally, CYP1B1-like and CYP1A1-like were 
selected as P450s not expected to be significantly expressed in liver.   
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Figure 3.4: Clustal Omega alignment of sequence (Ecab.P450.18) from equine genome with 
CYP2R1 from Equus przewalskii. Protein sequences were aligned with 100% identity and haem 
binding region is highlighted (red box).  
 
Figure 3.5: Protein sequence of Ecab.P450.9 with haem-binding region highlighted. 
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Figure 3.6: Annotated protein alignment of human CYP2D6 and equine CYP2D50 (% identity 
77.26). Alignment was carried out with Clustal Omega. Substrate recognition regions (SRSs) as 
proposed by Ito et al (2008) are highlighted on the human isoform in order to observe similarity with 
the horse isoform. The residues determined to be critical for substrate recognition are highlighted in 
yellow (Ito et al, 2008).  
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Figure 3.7: Annotated protein alignment of human CYP2C9 with all predicted equine CYP2C 
isoforms. Alignment was carried out with Clustal Omega. Substrate recognition regions (SRSs) as 
proposed by Zawaira et al (2011) and Lewis and Ito (2009) are highlighted on the human isoform in 
order to observe similarity with the horse isoforms. The residues determined to be critical for substrate 
recognition are highlighted in yellow.  
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Figure 3.8: Annotated protein alignment of human CYP3A4 with all known equine CYP3A 
isoforms. Alignment was carried out with Clustal Omega. Substrate recognition regions (SRSs) are 
highlighted on the human isoform (Lewis and Ito, 2009) in order to observe similarity with the horse 
isoforms. The residues determined to be critical for substrate recognition are highlighted in yellow.   
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Figure 3.9: Annotated protein alignment of human CYP31A2 with the predicted equine CYP1A2 
(‘CYP1A2-like’), % identity 83.53. Alignment was carried out with Clustal Omega. Substrate 
recognition regions (SRSs) are highlighted on the human isoform (Lewis and Ito, 2009) in order to 
observe similarity with the horse isoforms. The residues determined to be critical for substrate 
recognition are highlighted in yellow.   
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Figure 3.10: Annotated protein alignment of human CYP2E1 with equine CYP2E1 (% identity 
83.53 (% identity 79.3). Alignment was carried out with Clustal Omega. Substrate recognition regions 
(SRSs) are highlighted on the human isoform (Lewis and Ito, 2009) in order to observe similarity with 
the horse isoforms. The residues determined to be critical for substrate recognition are highlighted in 
yellow.  
 
3.23: Phylogenetic analysis 
Once equine P450 sequences had been gathered phylogenetic trees were 
generated using ClustalW2 Phylogeny. Firstly, only the predicted equine sequences 
were used (figure 3.7) and then the previously known equine and their corresponding 
human orthologs (figure 3.8).  Distance values (the number of nucleotide changes 
divided by the length of the sequence) are presented next to the gene names and 
aid in comparison of divergence between similar isoforms. From these phylogenetic 
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trees, a clear separation into clans (shown in bold in figure) is evident. All clans are 
represented in these predictions. The only equine P450 that could not be grouped 
into a clan is CYP46A1. 
 
Figure 3.7: Phylogenetic tree of all known and predicted Equus caballus sequences. Tree was 
created using the neighbour joining method (Saitou and Nei, 1987) in Clustal Omega. Distance values 
are given next to the gene names and signify the predicted evolutionary divergence ((calculated as 
the number of nucleotide changes divided by the length of the sequence (Kimura, 1980)) All clans are 
highlighted. CYP46A1, which does not fit into any current clan, is outlined in red. 
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Figure 3.8: Phylogenetic tree of known horse P450s and their human orthologs. Genes with 
suffix ‘-HS’ are the human isoforms and those with suffix ‘-EC’ are the equine isoforms. Method used 
to create tree was the same as for figure 3.4.   
 
Along with the construction of phylogenetic trees, the equine predicted P450s were 
analysed for synteny with all 57 human P450s. Figure 3.9 shows the result of this 
analysis, with regions of conserved order highlighted. The most conserved 
chromosome was chromosome 1, which showed synteny with two human 
chromosomes (10 and 15).  
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Figure 3.9: synteny between equine and human P450 genes. NCBI Map Viewer 
(http://www.ncbi.nlm.nih.gov/mapview/) was used to determine the order of P450 genes in each 
chromosome of human and horse. When order was conserved, genes names were highlighted via 
colour coding while lines were used to illustrate homologues.  
 
3.3: Discussion 
 
The data presented in this chapter are the first attempts to fully ascertain the number 
of cytochrome P450 genes present in the equine genome. The first approach taken 
was to probe the equine genome using P450 sequences from other species - this 
generated 59 sequences however most were only fragments. The second approach 
involved searching the NCBI RefSeq and Ensembl databases for sequences that 
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had been automatically predicted as being P450s using their computational genome 
annotation software (Pruitt et al, 2002, Curwen et al, 2004). A list of predicted equine 
P450s was compiled and compared with those manually obtained from the equine 
genome. As expected, there was a large degree of overlap between the two 
datasets, with almost all manually-obtained sequences matching a predicted 
sequence 100%. Only three manually-obtained sequences did not match a predicted 
sequence; however none were the ~1.5kb expected for P450s (Nelson et al, 1996). 
Two (Ecab.P450.4 and Ecab.P450.18) matched CYP2R1 genes in Homo sapiens 
and Equus przewalskii, respectively, while one (Ecab.P450.9) matched human 
CYP2W1. Ecab.P450.18 and Ecab.P450.9 possess the characteristic FxxGxxxCxG 
motif of the P450 haem-binding region (see figures 3.4 and 3.5) while Ecab.P450.4 
does not. These may be gene fragments or pseudogenes as full length sequences 
could not be obtained in either the UCSC genome browser or via annotated genome 
searching. 
The aim of these two approaches was to assemble a list of equine P450s across all 
nine vertebrate clans. A phylogenetic tree was created using ClustalW2 Phylogeny 
to group sequences into clans; this served as further validation of the predicted P450 
sequences, showing that they did indeed cluster together. All sequences clustered 
on the tree as expected (figure 3.8). CYP40A1 was the only sequence that could not 
be grouped into a clan, which is as expected when compared to phylogenetic 
analysis of other species, where it also did not cluster with other sequences (Nelson, 
2003, Kawashima and Satta, 2014). The known horse CYP450s and their human 
isoforms were also used to generate a ClustalW2 phylogenetic tree, which is useful 
for observing how closely-related the enzymes are in the two species. The CYP2 
enzymes appear to be the most diverged, particularly CYP2A13, CYP2B6 and 
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CYP2C92/CYP2C9. The CYP19A1 and CYP11A1 isoforms are the least diverged. 
For the CYP3As, equine CYP3A89 appears to be most similar to human CYP3A5 
while equine CYP3A96 and CYP3A97 are most similar to CYP3A7. In human, 
CYP3A5 is not majorly expressed in the liver in most people and only contributes a 
minor role towards drug metabolism (Westlind et al, 2001). CYP3A7 is only highly 
expressed in faetal liver and therefore does not seem to play any significant role in 
drug metabolism (Leeder et al, 2005). CYP3A93 was the closest match to the major 
human drug-metabolising P450, CYP3A4, which is responsible for around 50% of 
drug metabolism (Evans and Relling, 2009). As an additional analysis of evolutionary 
divergence, synety between equine and human P450s was analysed. Although 
chromosome 1 showed a high conservation of gene order, others (e.g. chromosome 
10) did not. Not all equine P450s identified during this research have homologues in 
human, however since some subfamilies appear to be more expanded in human and 
horse (e.g. CYP4F and CYP11), this may suggest either evolutionary divergence or 
that not all equine sequences were identified during this research.    
When contrasted with some other mammalian species, the number of P450s in the 
horse appears to be relatively small (for example, there are 57 P450 genes in 
human, 59 in cattle and 89 in rat (Nelson et al, 2003, Nelson, 2009, Sim and 
Ingelman-Sundberg, 2010). There may therefore be some that have not been found 
within this study, however it is important to point out that P450 numbers vary 
substantially across species, even within vertebrates – from 41 in chicken to 102 in 
the mouse (Nelson et al, 2013, Hrycay and Bandiera, 2009).  
The only previous study looking at P450 gene clusters in the horse was by Schmitz 
et al (2010) whereby the CYP3A gene cluster was characterised. The present study 
agrees with this data, since the ‘CYP3A12-like’ enzyme in the current study appears 
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to be a pseudogene, due to the fact it lacks the haem-binding motif and therefore 
cannot be an active P450. Two other sequences also lack the haem-binding motif – 
CYP2S1-like and CYP20A1-like. Lacking this motif is by no means the only signifier 
of a P450 pseudogene (Wen et al, 2001) but it does mean a functional P450 protein 
cannot be produced, since the haem-binding region is required for P450 function 
(Guengerich, 2007, Ranasinghe and Hobbs, 1998). As another method of predicting 
function, some sequences were aligned with their human isoforms in order to 
compare substrate recognition regions (SRSs). The CYPs looked at here were 
CYP2D and CYP2C. Both had some key differences between the human and equine 
isoforms. A lab-based approach will be required to validate functionality further. 
Taken together, this data gives an insight into the number of P450 genes in the 
horse; however expression of each P450 sequence and functional analyses are 
needed before conclusions can be drawn about its significance. Using equine liver 
samples to look for gene expression will provide evidence that these genes exist in 
vivo, and once completed this will be followed by isolation, expression and functional 
testing of each gene.  
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Chapter 4: Cloning and sequence verification 
 
4.1: Introduction 
 
4.1.1:  cDNA synthesis and RT-PCR  
 
Generation of complementary DNA (cDNA) has allowed for the development of 
recombinant DNA technology while also enabling the user to gain an insight into 
which messenger RNAs (mRNA) are expressed within a tissue (Okayama, 2012). 
Reverse transcription polymerase chain reaction (RT-PCR) is a highly sensitive 
technique used to study gene expression and is often the method of choice for this 
type of analysis (however for high throughput studies, DNA microarrays and RNA 
sequencing are more efficient techniques), Costa et al (2013).  
RT-PCR has been widely used to study expression of P450 genes within various 
species such as mouse, human and zebrafish (Sarikaya et al, 2007, Goldstone et al, 
2014, Graves et al, 2013). In the horse, RT-PCR has been used to detect P450 
expression in the liver, digestive tract and airway (Schmitz et al, 2010, Tyden et al, 
2012, Larrson et al, 2012). Six CYP3A isoforms have been detected in equine liver 
(CYP3A89, CYP3A93, CYP3A94, CYP3A95, CYP3A96 and CYP3A96, Schmitz et 
al, 2010). Additionally, equine liver expression of CYP1A, CYP2A, CYP2C, CYP2D 
and CYP2E1 have been detected (Tyden et al, 2014, DiMaio Knych et al, 2009, 
DiMaio Knych et al, 2009, Peters et al, 2013). For cloning and subsquent functional 
protein expression (in sf9 insect cells and V79 hamster fibroblasts), RT-PCR 
amplification of CYP3A96, CYP2D50, CYP2C92, CYP2B6 and CYP3A94 from 
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equine liver has been carried out (DiMaio Knych et al, 2008, DiMaio Knych et al, 
2009, DiMaio Knych et al, 2010, Peters et al, 2013, Dettwiler et al, 2014).  
4.1.2: DNA sequencing 
 
Despite the advancement of next generation sequencing (NGS), Sanger sequencing 
is still a widely used sequencing technology (Lee et al, 2013). NGS is ideal for large 
sequencing studies due to the ability to run thousands to millions of reactions in 
parallel (Van Dijk et al, 2014).  For smaller studies (< ~ 1400 bp), Sanger sequencing 
is often preferred due to having a lower error rate than NGS (Lee et al, 2013). 
Automated Sanger sequencing allows all four fluorescently tagged- 
dideoxynucleotides (ddNTPs) to be mixed in one reaction tube and run together for 
subsequent capillary electrophoresis and laser detection at different wavelengths. 
This results in an output chromatogram with peaks of different colours for each base 
(Kircher and Kelso, 2010). Automatic Sanger sequencing can produce quality reads 
up to around 700-900 bp, thereby meaning sequencing in the forward and reverse 
direction is required for longer sequences (Kircher and Kelso, 2010).   
4.1.3: Molecular cloning methods   
 
Most cloning vectors utilise E. coli as a host although other organisms can be used, 
such as yeast and mammalian cells (Joska et al, 2014, Okayama, 2012). For protein 
expression, plasmids must contain a strong promotor before the multiple cloning site 
(MCS). The lac promoter is the most widely used however bacteriophage promoters 
such as T7 and sp6 often give much stronger expression (Rosano and Ceccarelli, 
2014). Promoters for specialist applications are also available, for example cold-
induction of the cspA promoter at 15oC (Hayashi and Kojima, 2008). The pCold I 
vector employs the cspA promotor in order to allow for protein expression at lower 
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temperatures while it also contains a 6x polyhistadine-tag (his-tag) between the 
promoter and the MCS for protein purification using antibodies or affinity 
chromatography (Terpe, 2006). This vector system has been successfully employed 
for the recombinant expression of many eukaryotic proteins that have been hard to 
express via conventional bacterial methods (Sugiki et al, 2014).  
Baculovirus has also been used extensively for expressing eukaryotic proteins that 
are difficult to express in bacterial systems (Van Oers et al, 2014). The Autographa 
californica multiple nuclear polyhedrosis virus (AcMNPV) is a baculovirus used for 
recombinant protein expression in Spodoptera frugiperda (sf9 or sf21) cells 
(Carinhas et al, 2011). The Bac-to-Bac expression system (Life Technologies) allows 
for an efficient method of cloning a gene of interest and recombining it into a bacmid 
(baculovirus) shuttle vector for subsequent transfection of insect cells. The pFastBac 
series of vectors are used as donor plasmids for initial cloning in E. coli and contain 
a baculovirus promotor and a Tn7 transposable element which is used for site-
specific recombination into the bacmid. DH10Bac cells containing bacmid DNA are 
used for recombination, allowing for production of sufficient recombinant baculovirus 
with an overnight incubation (Sung et al, 2014).   
4.1.4: CYP P450 protein structure prediction  
 
The way in which a protein folds is crucial to its function, and therefore any means of 
determining protein folding can be an effective tool for predicting its functional traits 
(Dorn et al, 2014). Xray crystallography and NMR spectroscopy have proved 
invaluable for analysing how structure affects function however it is also possible to 
analyse protein structure through in silico methods (Pavlopoulou and Michalopoulos, 
2011). Homology modelling is based on the observation that proteins with a high 
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degree of primary structure similarity are likely to have similar tertiary structure 
(Watson et al, 2005). It uses a ‘template’ of a protein with a known (experimentally-
determined) structure and predicts the structure of the query protein based on an 
alignment of this template with the query sequence (Kelley and Sternberg, 2009). 
There are many homology modelling tools available (see Dorn et al, 2014), one of 
the most widely used of which is the Phyre2 server (Kelley et al, 2015). This software 
involves comparison of the query with a database of protein sequences in order to 
find similarity, after which an alignment between the query and a protein with a 
known structure is carried out such that a homology model can be compiled. 
Homology modelling is particularly beneficial for the study of enzymes and has been 
used extensively for P450s (Ito and Lewis, 2009). Analysis of the active site of P450s 
enables the user to compare active site structure between similar isoforms to predict 
drug metabolising properties (Zhang et al, 2012). Using this approach, it becomes 
possible to make assumptions about the functional integrity of an enzyme therefore 
meaning a more targeted approach can be taken to in vitro functional screening (Ito 
and Lews, 2009).  
4.1.5: Current study 
 
For the current study, RT-PCR was used to detect P450 expression in equine liver. 
Amplified P450 sequences were isolated and cloned along with six commercially-
produced clones into two expression vectors – a cold-induction vector (pCold) for E. 
coli protein expression and an insect cell vector (pFastBac 1) for sf9 protein 
expression via integration into a bacmid shuttle vector. All clones were sequence 
verified using Sanger sequencing and 3D structural predictions carried out using 
Phyre2 (http://www.sbg.bio.ic.ac.uk/phyre2).     
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4.2: Results 
4.2.1: Amplification and sequencing of P450 sequences from equine liver 
 
One full-length novel sequence was successfully amplified from equine liver cDNA – 
‘CYP2C26-like’. Additionally, one previously known P450, CYP3A97, was amplified. 
(table 4.2.1). After amplification, gel bands containing PCR products were excised 
(figure 4.2.1) and cloned into expression vectors using the restriction sites in the 
primers (see table 2.1, chapter 2). Following this, all clones were sequence verified 
(sections 4.2.2 and 4.2.3). The majority of P450 sequences that primers were 
designed for did not fully amplify however some gene fragments were successfully 
amplified and subsequently sequence verified (table 4.2.1). E.cab.P450.4, 
E.cab.P450.17, P450.Equ.30, Ecab.P450.13 and CYP1B1-like were all partially 
amplified.    
Sequence Name Liver 
Expression 
Detected? 
Expected 
size (bp) 
PCR product size 
(bp) 
Ecab.P450.1 (CYP2E1) No 973 N/A 
Ecab.P450.4 (CYP2R1-like) Yes 681 571 
Ecab.P450.5 (CYP1A2-like) No 1545 N/A 
Ecab.P450.13 (CYP1B1-like) Yes 1311 483 
Ecab.P450.17 (CYP2D14-like) Yes 592 571 
Ecab.P450.18 (CYP2R1-like) No 1170 N/A 
P450.Equ.18 (CYP4F22-like) No 1211 N/A 
P450.Equ.23 (CYP46A1-like) No 1270 N/A 
P450.Equ.30 (CYP2D14-like) Yes 507 475 
P450.Equ. 37 (CYP27B1) No 827 N/A 
CYP1A1-like No 1563 N/A 
CYP1B1-like Yes 1632  1084 
CYP2U1-like No 1167 N/A 
CYP3A97 Yes 1535 1535 
CYP2C26-like Yes 1319 1319 
Table 4.2.1: Summary of amplification of sequences via RT-PCR.  Size in base pairs (bp) is given 
for the full length sequences as well as for what was obtained after sequencing of PCR products.  
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Figure 4.2.1: RT-PCR products using primers for CYP3A97 (left) and CYP2C26 (right). Negative 
controls (Neg) were run without template DNA. Band sizes of the 1 kilobase (Kb) DNA marker are 
highlighted.   
 
 
Figure 4.2.2: Gene fragment RT-PCR products. A: 1B1-like, B: Ecab.P450.17, C: Ecab.P450.4 (1), 
P450.Equ.30 (2) and Ecab.P450.13 (3). Neg = negative control (reaction mixture without template 
DNA). Arrows highlight sequenced products and Band sizes of the 1 kilobase (Kb) DNA marker are 
also highlighted.   
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4.2.2: Cloning into pCold expression vector and sequence verification 
 
P450s cloned into the pCold expression vector were sequence verified to ensure no 
base changes had occurred. Six sequences were incorporated into the expression 
vector (table 4.2.3). CYP2D50, CYP1A1 and CYP3A96 were full matches for the 
reference sequence, with changes having occurred in the sequences of all other 
constructs. CYP3A97 was not cloned into the correct reading frame due to the 
deletion of an adenine in the TEE region of the vector (figure 4.2.3), therefore it could 
not be carried through to the next stage (see table 4.2.2 for a summary of this data). 
CYP2D50, CYP3A96 and CYP1A1 were all 100% matches with their reference 
sequences while mutations occurred in CYP2A13 (3 changes – G 735> A, T929>C, 
A969 >T) and CYP2C92 (7 changes- G4>C, G1191>A, T1361>A, T1438>C, 
T1460>C, C1466>T, C1479>A), highlighted on figures 4.2.4 and 4.2.5 respectively. 
Despite various attempts, CYP2C26 and CYP2E1 were not cloned into the pCold 
vector.  
 
pCold construct RefSeq accession no. % match 
CYP1A1 XM_005602921.1 100% 
CYP2A13 NM_001111337.1 99.88% (see figure 
4.2.3) 
CYP2C92 NM_001101652.1 99.53% (see figure 
4.2.4) 
CYP2D50 NM_001111306.1 100% 
CYP3A96 NM_001146163.2 100% 
CYP3A97 NM_001146164.2 Not in frame – see figure 
4.2.1 
Table 4.2.2: Comparison of pCold constructs with NCBI reference (RefSeq) DNA sequences. 
Acession numbers of reference sequences are highlighted along with the percentage match between 
cloned and reference sequences.   
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Once the DNA sequences had been analysed, they were translated into protein 
sequences using ExPASy Translate (http://web.expasy.org/translate/) to observe any 
amino acid differences caused by the nucleotide changes. For CYP2A13, there was 
one amino acid change – L310>P (figure 4.2.2). For CYP2C92, there were two 
amino acid changes, S478>F and Y486>C), figure 4.2.3.    
 
 
Figure 4.2.3: Translated protein sequence for CYP3A97 cloned into the pCold vector. 
Nucleotide sequences were translated using ExPASy translate (http://web.expasy.org/translate) and 
open reading frames are highlighted in pink. Figure shows A: alignment of vector sequences, B: The 
reading frame construct was cloned into and C: The reading frame with the his-tag present.   
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Figure 4.2.4: Summary of Clustal Omega alignment between NCBI reference sequence 
(NM_001111337.1) and the cloned CYP2A13 pCold construct. DNA sequence regions with a 
100% match are illustrated with a dashed line while base variations are highlighted along with their 
position in the sequence. The one change in the amino acid sequence, highlighted in red (L310>P). 6-
his tag is highlighted in blue and haem-binding region is highlighted in yellow.  
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Figure 4.2.5: Summary of Clustal Omega alignment between NCBI reference (NM_001101652.1) 
sequence and the cloned CYP2C92 pCold construct. DNA sequence regions with a 100% match 
are illustrated with a dashed line while base variations are highlighted along with their position in the 
sequence.  The two changes in the amino acid sequence, highlighted in red (S478>F and Y486>C). 
Also highlighted are substrate recognition regions (grey, Zawaira et al , 2011) and the haem-binding 
region (yellow). 
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4.2.3: Cloning into pFastBac 1 expression vector and sequence verification 
 
The seven sequences cloned into the pCold expression vector were also cloned into 
the pFastBac 1 expression vector for expression in sf9 insect cells. CYP2C26 was 
the only sequence not cloned into pFastBac 1. Table 4.2.3 displays a summary of 
sequencing data for the six clones along with percentage matches with reference 
sequences.  
pFastBac 1 construct RefSeq accession no. % match 
CYP1A1 XM_005602921.1 98.82% (figures 4.2.5 
and 4.2.6). 
CYP2A13 NM_001111337.1 99.87% (figure 4.2.7) 
CYP2C92 NM_001101652.1 99.46% (figure 4.28) 
CYP2D50 NM_001111306.1 100% 
CYP2E1 NM_001111303.2 100% 
CYP3A96 NM_001146163.2 100% 
CYP3A97 NM_001146164.2 96.33% 
Table 4.2.3: comparison of pFastBac 1 constructs with NCBI reference (RefSeq) DNA 
sequences. DNA sequences. Acession numbers of reference sequences are highlighted along with 
the percentage match between cloned and reference sequences.   
 
Figures 4.2.6-4.2.9 display the nucleotide and amino acid changes that occurred 
during the cloning process. Three constructs were 100% matches for their reference 
sequence (CYP2D50, CYP2E1 and CYP3A96) while the other constructs ranged 
from 96.33% (CYP3A97) similarity to 99.87% (CYP2A13) similarity.  
The CYP1A1 DNA sequence was truncated at the beginning and end compared to 
the reference sequence although the translated protein sequence had two extra 
residues on the end (threonine and arginine), as well as having an entirely different 
sequence from 513-526 (figure 4.2.6).  
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 CYP1A1_pFast       ------------------------------------------------------------ 0 
CYP1A1_RefSeq      ATGTAACCAGCCCTCAGATCAAGAGACAGAATGTTACCAGCATCCTAGAACCTCCTTGTG 60 
CYP1A1_pFast       --------------------------------------                   22 
CYP1A1_RefSeq      CTCCTTCCCCCAGCCACCTTGAGATCCCTACGCGGATC                   120 
CYP1A1_pFast       CTGCAGTTTGCAGTAAACACAGAGGATGAAGAAACACGCTG--                   1580 
CYP1A1_RefSeq      GTGCGCCCTCAGGGGACTGAAAGCCCTGCAGCCTAGACTCTGT                   1680 
 
CYP1A1_pFast       -AATTGGATCTAG---------------------------------------          1592 
CYP1A1_RefSeq      CTACCTGACCTGCTTGGGCAGCCAGGCCAGGGTGCTGGCCTGGGGGGTCTAG          1732 
 
CYP1A1_RefSeq      ATACAGTGCCTGGGGGGATTGCCTCCCTCTGCC                             2193 
Figure 4.2.6: Sequence alignment between the CYP1A1 pFastBac 1 construct and the CYP1A1 
reference sequence (XM_005602921.1). Differences between sequences occurred at both ends of 
the alignment while the middle portion was a 100% match. For the protein sequence, Residues that 
vary between the sequences are highlighted in red. Highlighted in grey are the potential substrate 
recognition regions (Chinta et al, 2005) and highlighted in yellow is the haem-binding region. 
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The CYP2A13 DNA sequence had a 17 AA insert (figure 4.2.7) which caused the 
reading frame after this to be disrupted, meaning the sequence had low similarity 
after this insertion (highlighted in red).  
 
Figure 4.2.7: Sequence alignments between the CYP2A13 pFastBac 1 construct and the NCBI 
reference sequence (NM_001111337.1 ). DNA sequence regions with a 100% match are illustrated 
with a dashed line while base variations are highlighted along with their position in the sequence. 
Inserted region is highlighted in red. 
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When sequenced, CYP2C92 pFastBac construct had 7 nucleotide changes (G4>C, 
G1243>A, T1360>A, T1437>C, T1460>C, A1462>A, C1466>T) and three protein 
residue changes (F478>S, Y484>C and a deletion of V490) – two of which (F478>S 
AND Y484>C) were the same as for the pCold construct (figure 4.2.8). 
 
Figure 4.2.8: Sequence alignments between the CYP2C92 pFastBac 1 construct and the NCBI 
reference sequence (NM_001101652.1). DNA sequence regions with a 100% match are illustrated 
with a dashed line while base variations are highlighted along with their position in the sequence.  The 
three changes in the amino acid sequence, are highlighted in red (S>F (478), Y>C (486) and no 
valine at position 490). Also highlighted are substrate recognition regions (grey) and the haem-binding 
region (yellow).  
 
112 
 
CYP3A97 had seven mutations in the DNA sequence (figure 4.2.9) which translated 
to three amino acid differences inside the protein sequence and truncated end 
(missing the last four residues). One mutation (T119>I) was within a theoretical 
substrate recognition region.  
 
Figure 4.2.9: Sequence alignments between the CYP3A97 pFastBac 1 construct and the NCBI 
reference sequence (NM_001146164.2 ). DNA sequence regions with a 100% match are illustrated 
with a dashed line while base variations are highlighted along with their position in the sequence. The 
four changes in the amino acid sequence are highlighted in red (E10 > G, T119 > I, D336 > G and an 
end terminal truncated by four amino acids (VTGA)). Also highlighted are substrate recognition 
regions (grey) and the haem-binding region (yellow). 
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4.2.4: Protein structure predictions   
 
There have not been any equine P450 structures published to date. Homology 
modelling was used on those sequences that had been successfully cloned into the 
pCold construct during the current study to infer if functional changes may have 
occurred along with the sequence changes.  
CYP2D50 and CYP1A1 were compared to the human isoforms since the pCold 
constructs were a 100% match for their reference sequence. The 3D structure is 
highly similar between the two isoforms although there are a number of small, yet 
potentially significant, differences (figure 4.2.10 and figure 4.2.11). Substrate 
recognition regions vary between both enzymes, with the residues in the horse 
isoforms being highly dissimilar from those in the SRSs for the human isoforms. SRS 
regions are highlighted on both figures.  
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Figure 4.2.10: Phyre2 prediction for CYP2D50 compared with CYP2D6. Highlighted is the haem-
binding region (yellow box and arrow), and potential substrate binding regions (grey boxes and 
arrows), based on the known SRSs for CYP2D6. Colouring is based on a rainbow from the N to C 
terminal (blue to red). Alpha helices, beta sheets and coils are shown.  
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Figure 4.2.11: Phyre2 prediction for horse CYP1A1 compared with that for human CYP1A1. 
Highlighted is the haem-binding region (yellow box and arrow), and potential substrate binding 
regions (grey boxes and arrows), based on the known SRSs for CYP1A1. Colouring is based on a 
rainbow from the N to C terminal (blue to red). Alpha helices, beta sheets and coils are shown.  
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The protein sequence for the CYP2C92 pCold construct varied from the reference 
sequence by two residues (S>F (position 540) and Y>C (position 548)). The S > F 
mutation occurs within an SRS and there is a small structural difference apparent 
(figure 4.2.12, horizontal arrow). The second mutation (Y > C) also has resulted in a 
small structural change.  
CYP2A13 had one amino acid change from the reference sequence (residue 310, 
L>P) however the 3D structure prediction suggests that this has not caused any 
conformational changes (figure 4.2.13).  
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Figure 4.2.12: Phyre2 prediction for CYP2C92. The CYP2C92 pCold construct and the CYP2C92 
reference sequence are compared. Residues that are different between the two sequences are 
highlighted (red boxes and arrows). Also highlighted are the haem-binding region (yellow box and 
arrow), and potential substrate binding regions (grey). Colouring is based on a rainbow from the N to 
C terminal (blue to red). Alpha helices, beta sheets and coils are shown.  
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Figure 4.2.13: Phyre2 prediction for CYP2A13.  The one residue variation between the pCold 
construct and the NCBI reference sequence is highlighted with a red arrow (Phe310). Also highlighted 
is the haem-binding region (yellow). Colouring is based on a rainbow from the N to C terminal (blue to 
red). Alpha helices, beta sheets and coils are shown.  
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4.3: Discussion 
4.3.1: Amplification of cDNA from equine liver 
 
This chapter describes efforts to produce and clone equine P450 cDNAs for 
recombinant protein expression and functional studies. Two full sequences were 
obtained using RT-PCR while all other sequences either did not amplify at all or full 
length sequences were not amplified (tables 4.2.1 and 2.2.2).  Quality of cDNA is 
one possibility that could explain some of the problems in sequence amplification, 
although great care was taken to ensure that degradation was kept to a minimum 
(immediately aliquoting samples to avoid frost/defrost cycles, use of RNase free 
water). cDNA was synthesised using random hexamer primers, which may explain 
some of the difficulty obtaining full length sequences, as this method  can result in 
only partial sequences being amplified (Harbers, 2008). Of those sequences that 
were partially amplified, Ecab.P450.13 and CYP1B1-like had the biggest difference 
between the expected actual PCR product sizes, suggesting the full length cDNA 
may not have been present within the reaction mixture. For future work, gene 
specific primers should be used for cDNA synthesis in order to validate whether the 
full length transcripts are present. Additionally, equine liver samples should be added 
to a storage reagent such as RNAlater immediately after excision to ensure RNA 
degradation is kept to a minimum. 
The isoforms not detected in equine liver were CYP2U1, CYP1A1, CYP4F22, 
CYP46A1, CYP27B7, CYP1A2 and CYP2E1. Some of these isoforms are not 
expressed in the liver of other species therefore this result was as expected. 
CYP2U1, CYP4F22, CYP27B1 and CYP46A1 are only expressed to any significant 
extent in extrahepatic tissues in other species (Devos et al, 2010, (Ohno et al, 2015, 
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Milagre et al, 2010, Adams and Hewison, 2012) while CYP1A1 is only expressed in 
the liver of other species when induced (Galván et al, 2005). CYP2E1 and CYP1A2 
are highly expressed in the liver of other species and were not detected, which also 
conflicts with previous reports of high expression of these enzymes in equine liver 
(Tyden et al, 2014).  
Five isoforms were detected in equine liver - CYP2R1, CYP2D14, CYP2C26, 
CYP1B1 and CYP3A97. CYP2R1 is expressed in human and mouse liver (Zhu et al, 
2013) while CYP2C26 is also expressed in the liver of other species (Sakuma et al, 
1994). Despite the fact CYP1B1 was detected in equine liver within the current 
study, it does not have significant hepatic expression in other species (Palenski et al, 
2013). For CYP2D14, little research has been carried out on this isoform however it 
has been reported to be expressed in cow liver (Tsuneoka et al, 1992). CYP3A97 
was used as a positive control, since it has previously been isolated from equine liver 
(DiMaio Knych et al, 2010), and was detected and fully amplified within the current 
study.    
4.3.2: Cloning and sequence verification 
 
Two separate expression systems were chosen for P450 expression. The sf9 cell 
system was selected due to its establishment as the ‘gold standard’ for recombinant 
P450 production and the bacterial system was selected as an alternative should 
insect cell protein expression fail or produce too low yields (Qing et al, 2004, Van 
Oers et al, 2014). Constructs cloned into each vector were sequence verified on both 
strands and compared with their reference sequences. Some had mutations in their 
sequences, however CYP1A1, CYP2D50 and CYP3A96 had no mutations when 
cloned in the bacterial pCold vector and CYP2D50, CYP3A96 and CYP2E1 had no 
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mutations in the pFastBac 1 vector system. All other constructs had over 95% 
sequence similarity; with the pFastBac CYP3A97 having the lowest score (96.33%). 
For pCold, one construct (pCold CYP3A97) was cloned into the wrong frame due to 
a nucleotide deletion (figure 4.2.1) For the pFastBac 1 vector CYP2A13 had a 
frameshift mutation (a 17 AA insert, figure 4.2.5) and CYP1A1 was truncated at the 
beginning and end of the sequence, with the translated protein sequence having 
additional residues on the end but otherwise was unchanged (figure 4.2.4). These 
mutations may have been introduced due to decreased viability of the E. coli cultures 
as a consequence of repeted use of glycerol stocks, or alternatively inadequate 
viability of the batch of cells used for transformations (Sivashanmugam et al, 2009). 
Other reasons for mutations during E. coli cloning include plasmid instability and 
toxicity of the protein of interest to the host (Rosano and Ceccarelli, 2014).    
4.3.3: Protein structure predictions 
 
Protein homology modelling was carried out on four CYP sequences, two of which 
had changes compared with the reference sequences (section 4.2.3). Models were 
constructed via the Phyre2 homology modelling server (Kelley and Sternberg (2009), 
http://www.sbg.bio.ic.ac.uk/phyre2/).  Using this software CYP2C92 was predicted as 
having various conformational changes and since one amino acid change was in a 
known SRS (figure 4.2.3) it is possible its substrate specificity could be altered as a 
result. Despite having a difference at the primary structure level, the CYP2A13 pCold 
construct was predicted to be identical to the reference sequence. CYP2D50 and 
CYP1A1 were compared with their human orthologs in order to observe 
conformational differences at the potential substrate recognition sites. Both isoforms 
had various changes at these sites. Future work comparing substrate specificities 
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between horse and human will be required to determine if these conformational 
differences are important for function. Ligand modelling could also be used as an 
alternative to in vitro methods, as it is a technique that has been employed within the 
pharmaceutical industry in particular to predict P450 metabolism of specific 
substrates (Raunio et al, 2015).  
Taken together, these results give an insight into the expression of equine liver 
cytochrome P450s while also suggesting there may be functional variations between 
the equine and human isoforms.  
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Chapter 5: Protein expression and verification 
 
5.1: Introduction 
 
Recombinant protein production has been a crucial step in advancing the fields of 
molecular biology and biotechnology, allowing specific proteins to be produced in 
large quantities that were not previously possible (Rosano and Ceccarelli, 2014). E. 
coli systems are by far the most well-characterised and thus most popular choice for 
protein expression (Terpe, 2006). Gram positive bacteria such as Bacillus and 
Lactococcus are also a popular choice, due to their high levels of protein secretion 
into the extracellular media (Vavrová et al, 2010, Morello et al, 2007). The gram 
negative bacterium Caulobacter crescentus is also used for its secretory ability (due 
to exploitation of the RsaA secretion signal), although it is limited with regard to the 
size of proteins that can be produced (Amat et al, 2010). Other bacteria that have 
been used for protein expression include Streptomyces (Binda et al, 2013) and 
Pseudomonas (Retallack et al, 2012).   
Bacterial expression systems are attractive for their ease of use, fast growth and 
high protein production, however eukaryotic expression systems may sometimes be 
necessary if certain post-translational modifications are required or if the protein of 
interest is insoluble in bacterial systems (Rosano and Ceccarelli, 2014). These 
include yeast (Mattanovich et al, 2012) plants such as Arabidopsis, rice and tobacco 
(Rigano and Walmsley, 2005, Borghi, 2010), baculovirus (Van Oers et al, 2014), and 
various mammalian cell lines – some of the most frequently used of which are 
Chinese hamster ovary (Omasa et al, 2010), human embryotic kidney (Lin et al, 
2015) and baby hamster kidney (Conner et al, 2005). Yeast is a popular choice due 
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to ease of use, affordability and their ability to produce high protein yields, although 
variations in glycosylation patterns may pose a problem for some proteins 
(Mattanovich et al, 2012). Mammalian cell lines offer the advantage of having the full 
array of post-translational modifications required for functional expression, however 
they are often costly, time-consuming and have significantly lower protein expression 
levels compared with bacterial and yeast systems (Khan, 2013).  
Baculovirus-infected Insect cells are a popular alternative to mammalian systems 
and offer higher protein titres and relative ease of use. For these reasons, they are 
one of the most popular expression systems for mammalian proteins (Van Oers et al, 
2014). Baculovirus expression systems work by incorporating the gene of interest 
into a bacmid virus particle, which is then used to infect the insect cells of choice 
(generally sf9, sf21 or High FiveTM cells), Van Oers et al, 2014. Baculovirus was first 
used as an expression vector due to its ability to produce high levels of occlusion 
bodies (polyhedra), under the control of the polyhedron promoter, in the nucleus of 
infected cells (Jarvis, 2009). Exploitation of this polyhedron promoter allowed for the 
polyhedral gene to be replaced with a gene of interest, and therefore production of 
high quantities of recombinant protein (Jarvis, 2009).   
5.1.1: Recombinant P450 production 
 
Recombinant proteins are highly useful for studying P450 activity and have been 
used extensively in the area of human P450 research, as well as for research into 
P450s in many other species (Stringer et al, 2009, Gonzalez and Korzekwa,1995). 
Recombinant CYPs for human and some other organisms are commercially 
available and recombinant protein expression has become an important part of the 
drug development process (Zhang et al, 2012). Microsomes and hepatocytes are 
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useful for giving a more holistic approach to in vitro methods of drug development 
than recombinant enzymes since they provide a pool of drug-metabolising enzymes 
(Fasinu et al, 2012), although there are some questions as to the applicability of 
microsome data to in vivo systems due to underestimation of clearance rates (Chiba 
et al, 2009). The advantage of recombinant P450s is that they offer a specific insight 
into the metabolism of a drug – allowing one isoform to be studied in detail without 
the presence of other P450s.  
For recombinant P450 expression, bacterial systems are able to generate the 
highest protein yield although the ways in which they vary from eukaryotic cells can 
be problematic, especially with regards to post-translational modifications such as 
glycosylation and phosphorylation (Khow and Suntrarachun, 2012). Successful 
production of proteins can be a significant problem in bacterial expression of 
eukaryotic DNAs (Rosano and Ceccarelli, 2014). Insect cell systems have been 
particularly popular in P450 research as they are relatively easy to maintain and 
generate higher protein yields than mammalian cells (Stringer et al, 2009). Insect 
cells provide one of the most popular and well-established systems for P450 
expression and have been used for P450s in numerous species such as mosquitos 
(Duangkaew et al, 2011) pigs (Yao et al, 2011), dogs (Zhou et al, 2010, zebrafish 
(Wang-Buhler et al, 2005) and many more (Ohnishi et al, 2012, Sakamoto et al, 
2012, Niu et al, 2011). Insect cells have the advantage over many other eukaryotic 
expression systems in that they do not have endogenous P450 expression (Stringer 
et al, 2009). 
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5.1.2: P450 carbon monoxide binding assay 
 
Since the discovery of P450s, confirmation and quantification of an enzyme’s status 
as a P450 has often relied on use of the carbon monoxide binding assay 
(Guengerich et al, 2009). This method involves binding of carbon monoxide to the 
ferrous (reduced) form of the enzyme in order to observe its absorbance – if a 
reading of 450 nm is made then the enzyme can be classed as a functional P450 
enzyme (Guengerich et al, 2009). It can also be used to quantify the level of P450s 
within a sample by determining the difference in absorbance between 450 nm and 
490 nm. Mass spectrometry and immunoblot analysis have also been used to 
quantify P450s however these do not allow for differentiation between inactive and 
active forms of the enzyme, therefore the carbon mononxide binding is ideal when 
this differentiation is required (Gröer et al, 2014).  
5.1.3: Recombinant equine P450s 
 
To date, equine P450s have been produced via recombination in insect cells (DiMaio 
Knych and Stanley, 2008) and hamster lung fibroblasts (Schmitz et al, 2014). 
Hamster lung fibroblasts, like insect cells, have no endogenous P450 expression 
(Schmitz et al, 2014).  
During the current study, two different expression techniques were used – one using 
an insect cell system and the other using a cold-induction E. coli system. The cold-
induction system (using the pCold I expression vector) was designed to express high 
protein levels at 15oC due to induction of the cspA (cold shock) promoter with 
addition of IPTG after temperature reduction. Cell growth and production of 
endogenous bacterial proteins are halted upon this temperature change (Qing et al, 
2004). Cold-induction expression is useful for when higher temperatures may result 
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in incorrect folding or the formation of inclusion bodies; a common problem in E. coli 
expression of eukaryotic proteins (Rosano and Ceccarelli, 2014). Cold-induction 
bacteria have been successfully used to produce many proteins which were difficult 
to express at higher temperatures (Qing et al, 2004, Hayashi and Kojima, 2008).  
 The aim of this chapter was to produce functional P450 proteins for subsequent 
functional analysis. Sf9 insect cells were used due to being the most highly 
established technique for recombinant P450 production while E. coli was used for its 
higher protein production capacity. Expression was confirmed via Western blotting, 
mass spectrometry and the carbon-monoxide binding assay. 
5.2: Results 
 
5.2.1: Sf9 insect cell expression  
 
Cells infected with baculovirus constructs were harvested at time points ranging from 
0 to 72hrs in order to ascertain time for optimal protein production by observing band 
size. Figure 5.2.1 displays expression attempts which show clear bands at 
approximately the desired size for the P450 constructs. From this, 24 hours post-
infection seems to be the optimal time for maximal protein production. Western blots 
using anti-P450 antibody were carried out to validate protein production however 
these generated negative results (no bands were present). Immunoprecipitation (IP) 
for CYP2D50 baculovirus cells appeared to be successful, with a final elute band 
appearing at ~52KDa. Despite apparent successful IP, Western blot analysis was 
negative.  
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Figure 5.2.1: Sf9 coomassie-stained gels of baculovirus-infected cells. A: CYP2E1, B: CYP2D50 
- samples at each time point were run along with a negative control (cells without baculovirus, on the 
left of each sample set). C: immunoprecipication using anti-P450 antibody with CYP2D50 cells - 
eluate from wash steps of immunoprecipication (1-3) was run along with the final elute (4). 
 
5.2.2: Bacterial pCold expression 
 
In order to validate that expression of the desired P450 proteins had occurred, 
Western blots were carried out on the lysate of each construct. All clones underwent 
multiple expression attempts, and four constructs were validated to have produced 
P450 proteins – CYP2A13, CYP1A1, CYP2D50 and CYP2C92. IPTG titrations 
ranging from 0mM-1mM were carried out in order to determine optimal IPTG 
concentration to induce protein expression for each construct – Western blots using 
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an anti-P450 antibody are displayed in figure 5.2.3. Table 5.2.1 summarises 
concentrations used for subsequent expression studies.  
Figure 5.2.3: Western blots of IPTG titrations for all expressed P450s. A: CYP2C92, B: 
CYP2D50, C: CYP1A1, D:CYP2A13. A cytochrome P450 polyclonal antibody was used and 30μl 
protein was loaded per well. 
 
P450 construct Optimum IPTG concentration 
CYP2C92 0.2mM 
CYP2D50 0.6mM 
CYP1A1 1mM 
CYP2A13 0.8mM 
Table 5.2.1: Optimum ITPG concentrations for each P450 pCold construct as determined by 
Western blot analysis. IPTG concentrations ranged from 0mM to 1mM.  
 
Figures 5.2.4-5.2.7 show Western blots of samples taken at five different stages 
post-induction using optimal IPTG concentrations and clearly show the 
corresponding protein band (~55-58KDa) increasing. Two different antibodies (anti-
P450 and anti-his tag) were used for each construct – one against cytochrome P450 
and one against the his-tag, which was present in the pCold vector (section 4.1.3). 
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Once expression was confirmed, large-scale (1 litre culture) batches of protein were 
produced for functional assays (to ensure uniformity across all assays) and protein 
content was measured – the result of which is displayed in table 5.2.2. Purified 
protein was stored at -80oC in 1ml aliquots.  
 CYP1A1 CYP2A13 CYP2C92 CYP2D50 
Batch 1 9mg/ml 5mg/ml 6mg/ml 7mg/ml 
Batch 2 2.4mg/ml 7.5mg/ml 5.5mg/ml 8mg/ml 
Batch 3 6mg/ml -------------- 5mg/ml 6.5mg/ml 
Batch 4 -------------- -------------- -------------- 8.5mg/ml 
Table 5.2.2: Protein content (mg/ml) for large batches produced for each pCold construct. 
Protein concentration was measured via Bradford assay (Sigma-Aldrich) according to manufacturer’s 
protocol and a spectrophotometer with detection at 595nm. 
 
 
Figure 5.2.4: Coomassie-stained gel (A) and Western blots of CYP2D50 in the pCold vector. 
Samples were taken at different time points during expression ranging from 0 hours to 24 hours post-
induction and were probed  with B: an anti-his tag antibody and C: an anti-P450 antibody. Band size 
for both is around 55-58KDa.  
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Figure 5.2.5: Coomassie-stained gel (A) and Western blots of CYP2C92 expressed in the pCold 
vector. Samples were taken at different time points during expression ranging from 0 hours to 24 
hours post-induction and were probed with A: an anti-his tag antibody and B: an anti-P450 antibody.  
Band size for both is around 55-58KDa.  
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Figure 5.2.6: Coomassie-stained gel (A) and Western blots of CYP2A13 expressed in the pCold 
vector. Samples were taken at different time points during expression ranging from 0 hours to 24 
hours post-induction and were probed with A: an anti-his tag antibody and B: an anti-P450 antibody.  
Band size for both is around 55-58KDa.   
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Figure 5.2.7: Coomassie-stained gel (A) and Western blots of CYP1A1 expressed in the pCold 
vector. Samples were taken at different time points during expression ranging from 0 hours to 24 
hours post-induction and were probed with A: an anti-his tag antibody and B: an anti-P450 antibody.  
Band size for both is around 55-58KDa. 
 
5.2.2.1: His-Tag Purification 
 
To purify the P450 proteins, the his-tag integrated into the pCold cloning vector was 
used by adding the samples to his columns. Figure 5.2.8 displays a stained protein 
gel of this, with a band of expected size in the final eluate. The products from the 
purification were stored at -80oC for use in functional assays (see chapters 6-10). 
Due to the low yield of this method (protein concentrations of eluted protein were 
around 0.06ml/ml-0.125mg/ml with only 100μl being produced at a time), purified 
protein was not used for most of the functional assays.   
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Figure 5.2.8: His-Select Purification of all four expressed pCold constructs. Supernantants (1-3) 
from wash steps were run alongside the elution product (4) where a band of the expected ~55KDa 
size was present.  
 
5.2.3: Carbon monoxide binding spectrum 
 
The P450 carbon monoxide binding assay is used for determining if an enzyme is a 
P450, via measuring the absorbance pre- and post-addition of carbon monoxide at 
420nm and 450nm (Guengerich et al, 2009). All four pCold P450 constructs 
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(CYP2D50, CYP2C92, CYP2A13 and CYP1A1) were tested in this way, and lysate 
using three different lysis techniques (lysis in Cellytic B buffer, lysis with lysozyme 
and lysis with sonication) was used in case denaturation occurred due to one 
particular method (section 2.31) Lysate in the lysozyme and the sonicated buffer did 
not show peaks (at 420nm, 450nm or 490nm) and so only those in Cellytic B were 
able to be measured (table 5.2.3).  
Microsome samples were used as positive controls – one suspended in PBS and the 
other in Cellytic B buffer. In PBS, the microsomal system displayed a classic peak at 
450nm however in Cellytic B a large peak at 420nm was generated. The 
recombinant P450s had smaller 420nm readings however all had much larger 
420nm than 450nm aborbance values. Figure 5.2.9 displays the readings generated 
for microsomes in Cellytic B and CYP2C92 in Cellytic B, both of which have peaks at 
420nm.  
 Microsomes 
in PBS 
Micorosmes 
in Cellytic B 
CYP2C92 
in Cellytic 
B 
CYP2A13 
in Cellytic 
B 
CYP2D50 
in Cellytic 
B 
CYP1A1 
in 
Cellytic 
B 
420 nm 
(abs) 
0.028 0.103 0.015 0.045 0.046 0.012 
450 nm 
(abs) 
0.087 0.008 0.005 0.071 0.022 0.003 
 
Table 5.2.3: Summary of peaks detected in samples bound to carbon monoxide. Absorbance 
readings were taken at 420nm and 450nm for all samples after being zeroed using samples without 
carbon monoxide.  
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Figure 5.2.9: Carbon monoxide binding spectra for CYP2C92 in Cellytic B (top) and positive 
control microsomes in Cellytic B (bottom). Both samples show a peak at 420nm with no peak at 
450nm.  
 
5.2.4: Mass spectrometry analysis of recombinant proteins 
 
To provide a final validation step, purified bacterial lysate was analysed via liquid 
chromatography mass spectroscopy in collaboration with Dr Susan Liddell in order to 
validate that the specific P450 was present. Data were searched using the MASCOT 
database with default settings and one P450 generated a match - CYP2C92. 
CYP2A13 and CYP1A1 were also analysed however only matches for bacterial 
proteins were obtained – implying protein content may have been too low for 
detection. For CYP2C92, four peptide sequences were matched with the published 
CYP2C92 sequence (table 5.2.4). In addition to CYP2C92 peptides, matches with 
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the E. coli proteins elongation factor Tu, 30S ribosomal protein S10 and fructose-
bisphosphate aldolase were made (table 5.2.5).  
Peptide  Position in 
Sequence 
MASCOT Score 
RFSLMTLRN 125-133 29 
RGRFPVTERV 97-106 32 
RYIDLLPTNVPHAVTRD 356-373 61 
KSHMPYTDAVVHEIQRY 341-357 80 
 
Table 5.2.4: P450 peptide Mass spectrometry matches for CYP2C92. Peptides analysed are 
highlighted along with their position within the CYP2C92 sequence and their MASCOT scores, with a 
total score for all four peptides of 202 (scores above 61 are classed as highly significant, i.e. unlikely 
to be occurring due to chance). 
 
Protein Peptide MASCOT Score 
Elongation factor Tu 
(708) 
RAGENVGVLLRG 68 
 KVGEEVEIVGIKE 61 
 KALEGDAEWEAKI 43 
 KTTLTAAITTVLAKT 58 
 KFESEVYILSKDEGGRH 12 
 KMVVTLIHPIAMDDGLRF 74 
 RTKPHVNVGTIGHVDHGKT 59 
 RGITINTSHVEYDTPTRH 82 
 KILELAGFLDSYIPEPERA 86 
 RELLSQYDFPGDDTPIVRG 84 
 RAIDKPFLLPIEDVFSISGRG 41 
 RQVGVPYIIVFLNKC 40 
30S ribosomal 
protein S10 (104) 
RLVDIVEPTEKT 57 
 RLIDQATAEIVETAKRT 47 
fructose-
bisphosphate 
aldolase (81) 
SKIFDFVKPGVITGDDVQKV 51 
 RFTIAASFGNVHGVYKPGNVVLTPTILRD 21 
 KVKAPVIVQFSNGGASFIAGKG 9 
Table 5.2.3: Summary of non-P450 MASCOT matches for CYP2C92. Overall MASCOT scores are 
given in brackets. 
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5.3: Discussion 
 
The purpose of this chapter was to express recombinant P450 enzymes in E. coli 
and sf9 insect cells. P450 expression was unable to be confirmed for the insect cell 
system, with Western blotting analysis generating negative results despite bands 
appearing around the correct size on coomassie-stained gels (figure 5.2.1). 
Immunoprecipitation appeared to be successful for the CYP2D50 construct however 
subsequent Western blotting of this product using an anti-CYP2D6 antibody 
produced negative results. This may have been due to a lack of reactivity, since this 
antibody was only confirmed to be active against the human, rat and mouse forms of 
the enzyme however no other antibodies were available as alternatives.  
Four constructs were expressed in E. coli – CYP2D50, CYP2C92, CYP1A1 and 
CYP2A13. Western blotting analysis of lysates confirmed P450 expression. Mass 
spectrometry was used as an additional means for conforming expression of the 
desired proteins and for CYP2C92 matches were made with equine CYP2C92 
peptides. With this analysis, various matches were also made with bacterial proteins, 
although his-column purification was carried out before mass spectrometry (section 
5.2.2.1) to minimise bacterial contaminants. Native E. coli proteins are known to 
often co-elute with the target protein using this method, due to possessing high 
affinity for the nickel ions used for his-tag purification (Robichon et al, 2011). 
A third method was used to validate P450 expression – the carbon monoxide binding 
assay, which is often seen as the ‘gold standard’ for P450 verification and 
quantification (Guengerich et al, 2009). A 450 nm peak was not detected for any 
lysate when bound with carbon monoxide therefore suggesting expressed enzymes 
may not be functional P450s. Instead, a P420 peak was detected in multiple enzyme 
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batches. P420 enzymes are generally regarded as denatured forms of P450s 
(Panicco et al, 2008). P420s vary from P450s in the haem-binding region via 
alteration of the haem-thiolate bond which generally becomes weaker when a P420 
species is produced (Omura and Sato, 1964a). Evidence suggests this weakening 
happens due to the thiolate becoming protonated to form a thiol (Sun et al, 2013). 
There is no literature describing catalytically active P420 enzymes, although it has 
been reported that converting the inactive P420s to P450s is possible (Dunford et al, 
2007). Three different lysis techniques were used with this assay in case the ‘main’ 
Cellytic B buffer was responsible for the absorbance change however the two other 
lysis techniques resulted in no change in absorbance upon binding with CO, 
suggesting the enzyme was denatured such that no carbon monoxide binding was 
able to occur.   
Due to the lack of eukaryotic post-translational modifications and potential incorrect 
folding in bacterial expression systems, it is possible that the proteins produced were 
not functional P450s. The cold-induction system was used to minimize this issue, 
since lowering the temperature can reduce incorrect folding and inclusion body 
formation (Hayashi and Kojima, 2008). Often, removal of the amino-terminal section 
of the P450 enzyme that anchors it to the endoplasmic reticulum has been required 
to produce a functional enzyme (Yun et al, 2006). However, E. coli systems have 
been used successfully during some studies without modification of the P450 
sequences (Park et al, 2014, Locuson et al, 2009), although variables such as 
rotations per minute of cultures, culture conditions and additives to cultures may play 
a significant role in the production of functional protein (Faiq et al, 2014). Further 
work will be required on the clones produced within the current study in order to 
determine whether varying these factors alters the spectral properties of the 
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recombinant proteins. Additionally, removal of the N-terminal of the P450 sequences 
should be attempted to ascertain whether this is required to produce enzymes that 
can be functionally classed as P450s.    
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Chapter 6: Recombinant CYPP450 enzyme kinetic analysis 
 
6.1: Introduction 
 
In humans, the majority of pharmacokinetic data is derived from the pharmaceutical 
industry, however in the horse this data largely comes from the horseracing industry 
and relates to doping control (Scarth et al, 2010). As with humans, adverse drug 
interactions can occur in the horse when multi-drug treatments are prescribed 
(Brumbaugh et al, 2001). Various classes of drug are frequently used in the horse, 
including (but not limited to) non-steroidal anti-inflammatory drugs (Lees and 
Higgins, 1985), corticosteroids (Harkins et al, 1993), anticholinergics (Rumpler et al, 
2013) and antihistamines (Benoit et al, 2008, Petersen and Schott, 2009).  
 
As covered in chapter 1 (section 1.15), little is known about CYP-specific metabolism 
in the horse. NSAIDs are frequently prescribed during equine veterinary treatment 
and are one of the most commonly used veterinary medications (National Office for 
Animal Health, 2014), particularly phenylbutazone (Tobin et al, 1986). Other 
commonly used NSAIDs include ketoprofen and flunixin (Goorich and Nixon, 2006). 
6.1.1: Analysis of drug metabolism 
 
Quantitative analysis of equine drug metabolism studies is generally carried out via 
gas chromatography mass spectrometry (GC-MS) or liquid chromatography mass 
spectrometry (LC-MS), which is the technique of choice in most analytical 
laboratories today (McKinney, 2009). GC-MS is still used for some compounds (such 
as testosterone and other steroids) which are poorly ionized by LC-MS (Teale and 
Houghton, 2010). Although the vast majority of equine drug metabolism research 
relies on in vivo data, in vitro studies are becoming more commonplace (e.g. Scarth 
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et al, 2010a, Ho et al, 2007, Ho et al, 2007a). Data relating to recombinant enzyme 
systems in the horse is much more limited, with only two laboratories thus far having 
published studies using recombinant equine enzymes (DiMaio Knych and Stanley, 
2008, DiMaio Knych et al, 2009, DiMaio Knych et al, 2010, Peters et al, 2013, 
Dettwiler et al, 2014). In vitro studies are routinely carried out in human drug 
research and the data generated is often extrapolated in order to predict the in vivo 
effects of drugs (Venkatakrishnan et al, 2001, Mcginnity and Riley, 2001).  
6.1.2: Enzyme kinetic analysis 
 
 
The aim of enzyme kinetic analyses is to work out the velocity of metabolism of a 
substrate by an enzyme (i.e. how fast the reaction occurs), and there are various 
methods a user may choose to do this, the most popular of which is by using 
Michaelis-Menten kinetics (Johnson, 2013). The velocity of metabolism is measured 
by either monitoring disappearance of a substrate or appearance of a product over 
time (Johnson, 2013). When it was discovered that enzymes could be saturated, a 
new way of looking at enzyme kinetics was formed (Brown, 1902). The following 
equation can be used to illustrate an enzymatic reaction: 
 
 
Equation 1 
 
Here, an enzyme-substrate complex is formed (ES) before product formation (P). K1 
and K-1 are the forward and reverse reaction rate constants for the ES complex and 
K2 is the rate constant for product formation. The preferred means of measuring the 
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velocity rate is from measuring product formation. The initial rate (0) for product 
formation is obtained from the initial linear slope of the product concentration versus 
time graph.  
 
6.1.3: Michaelis-Menten kinetics 
 
After Brown’s discovery that enzyme activity could be saturated, Michaelis-Menten 
kinetics was developed (Michaelis and Menten, 1913). This involves looking at the 
initial rate of a reaction across various substrate concentrations. It is one of the most 
widely used kinetic analysis tools and allows for the relationship between the initial 
rate, maximal velocity (Vmax) and Michaelis-Menten constant (Km – defined as the 
drug concentration at half the Vmax) to be defined (Chen et al, 2010).  
 
 
Figure 6.1: Graph displaying the rate of an enzymatic reaction. The initial rate (0) is plotted 
against substrate (drug) concentration. Vmax (maximal velocity) and Km (substrate concentration at half 
of Vmax) are highlighted.  
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Michaelis-Menten kinetics can be defined via the following equation: 
 
 
Equation 2 
 
 
Where the initial rate (0) is equal to the product of Vmax and the substrate 
concentration divided by the sum of Km and the substrate concentration. Micheaelis-
Menten kinetics can be used on its own to study enzyme saturation or the data can 
be extrapolated in order to estimate the intrinsic clearance of a drug (Houston, 
1994).   
 
Although it is ideal to use product formation to determine reaction rate, this is not 
always possible as the product might not be known, or the commercially produced 
product may be unavailable/too expensive. In this case, it is possible to apply 
Michaelis-Menten kinetics to substrate (drug) depletion, and similar values can be 
obtained as for product formation (with the assumption that only one product is 
formed). The following equation represents the disappearance of a substrate over 
time: 
 
Equation 3 
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Where [S] represents the substrate concentration and t = time. Kdep is the depletion 
rate constant, which is calculated by the slope of the line resulting from the natural 
logarithm (Ln) transformed substrate response data versus time. An advantage of 
the substrate depletion approach is that it is not necessary to know the concentration 
of the substrate and only substrate response data is required (e.g. mass 
spectrometry response).The initial rate (0) for product formation approximates to 
 
Equation 4 
 
Where the initial rate of the reaction is equal to Kdep multiplied by the initial substrate 
concentration (t = 0).  
 
6.1.4: Intrinsic Clearance  
 
Data gathered in vitro can be used to estimate the intrinsic clearance (CLint) of a 
drug, which is the ability of the enzymes to metabolise a drug, not taking into account 
factors such as blood flow and protein binding (Houston, 1994). Intrinsic clearance is 
estimated using Michaelis-Menten kinetics via the following equation assuming the 
substrate concentration is less than the Km: 
 
 
Equation 5 
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6.1.5: Substrate Inhibition 
 
There are various types of inhibition that can occur with an enzyme, one of the most 
common of which is substrate auto-inhibition (for a comprehensive review of all types 
of inhibition see Lu and Li, 2010). Substrate auto-inhibition can happen at high 
substrate concentrations due to the substrate blocking the enzyme’s activity, or 
alternatively the product (metabolite) produced by the enzyme inhibiting the 
enzyme’s activity. For either mechanism of substrate inhibition, a typical Michaelis-
Menten analysis may not be possible for the data. The inhibition constant (Ki) can be 
used to determine the reaction velocity rate via the equation:  
 
 
Equation 6 
 
 
At very low concentrations ([S] <<Km and Ki), the equation can be simplified, and the 
reaction velocity rate can be expressed as:  
 
 
Equation 7 
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Therefore, the intrinsic clearance (Clint) can be obtained when the initial velocity is 
plotted against the substrate concentration for the initial linear slope of the graph, 
which is equal to Vmax/Km thus CLint. 
 
6.1.5: Rational for current study 
 
For the current study, drugs of multiple therapeutic classes were screened against 
two recombinant equine P450 enzymes – CYP2D50 and CYP2C92 (isolated in this 
research, see chapter 5). Non-steroidal anti-inflammatory drugs (NSAIDs) were the 
focus of the research due to their importance in equine medicine however other 
drugs studied included fluphenazine, a typical antipsychotic banned by the 
Association of Racing Commissioners International (Association of Racing 
Commissioners International, 2015), the synthetic corticosteroid triamcinolone, used 
frequently to treat joint pain, a common problem in performance horses (Frisbie et al, 
1996) and dextromethorphan, not frequently used in the horse but tested 
experimentally to treat cribbing (Rendon et al, 2001) and used as a positive control 
for CYP2D activity for the purpose of the current study. Likewise, diclofenac, only 
occasionally used as a topical treatment in the horse was used as a positive control 
for CYP2C activity, since it has been used previously for the equine CYP2C92 
isoform (DiMaio Knych et al, 2009). See table 6.21.1 for a list of those drugs used 
along with their human P450 specificities. Once these screens of activity had been 
carried out, those drugs that appeared to be metabolised by the recombinant P450s 
were further analysed (sections 6.3-6.10). 
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6.2: Results 
 
6.2.1: LCMS method development 
 
Ten different drugs were screened against recombinant equine CYP2C92 and 
CYP2D50, most of which are frequently used in the horse (table 6.2.1).  Methods to 
detect the ten different drugs were developed using high performance liquid 
chromatography mass spectrometry (table 6.2.2). In addition, for two drugs 
(phenylbutazone and diclofenac) methods were also developed to monitor for the 
hydroxylated metabolites, 4-hydroxydiclofenac and oxyphenlbutazone, with the 
detected ions being of mass 312.06 and 325.24. Metabolite detection was run 
alongside parent drug detection for subsequent detailed analysis (chapters 7-10) – 
only parent drugs were analysed for initial screens.  Figures 6.2.1 -6.2.10 show the 
full scan spectra obtained for each drug.    
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Table 6.2.1: Drugs used for screening assays. Drug therapeutic classes are highlighted along with 
their known P450 specificity in human.  
 
 
 
 
 
 
 
 
 
 
Drug class Drug P450 metabolism in 
human 
Antitussive Dextromethorphan CYP2D6/CYP3A4 (Yu and 
Haining, 2001). 
   
NSAID Diclofenac CYP2C9 (Miners and 
Birkett, 1998). 
   
NSAID Flunixin Unknown 
   
NSAID Ketoprofen CYP2C (Glówka et al, 
2011). 
   
NSAID Phenylbutazone CYP2C9 (Takanohashi et 
al, 2007). 
   
First generation 
antihistamine 
Pyralamine Unknown (predicted 
substrate of CYP2B6, 
CYP2D6 and CYP3A4 by 
SuperCYP – Preissner et 
al, 2009. 
   
First generation 
antihistamine 
Hydroxyzine CYP2D6 (Hamelin et al, 
1998). 
   
Synthetic corticosteroid Triamcinolone CYP3A4 (Hagan et al, 
2010). 
   
Typical antipsychotic Fluphenazine CYP2D6 (Shin et al, 
1999). 
   
Muscarinic 
anticholinergic 
Glycopyrrolate Unknown 
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6.22: Preliminary assays 
 
In order to determine whether the recombinant enzymes metabolised any of the 
selected drugs, preliminary screening assays were carried out using initial drug 
concentrations of 1μM and samples taken at 0 minutes, 30 minutes and 60 minutes 
after the addition of NADPH. Tables 6.2.3 and 6.2.3 display this data as a 
percentage of the mass spectrometry response at 0 minutes. For CYP2C92, 
diclofenac, flunixin, phenylbutazone and ketoprofen all showed decay at 30 and 60 
minutes. For CYP2D50, the only drug that displayed this trend was 
dextromethorphan, which is a CYP2D6 substrate in human.   
 
Drug Drug % remaining after 
30 mins 
Drug % remaining after 
60 mins 
Dextromethorphan N/A N/A 
Diclofenac 72 88 
Flunixin 91 90 
Ketoprofen 61 43 
Phenylbutazone 27 27 
Pyralamine 110 120 
Hydroxyzine 47 69 
Triamcinolone N/A N/A 
Fluphenazine 80 98 
Glycopyrrolate 78 85 
Table 6.2.3: Results obtained from preliminary screening of all ten drugs with rCYP2C92. 
Samples were analysed at 0, 30 and 60 mins after the start of the reaction. Data was obtained in 
arbitrary units and converted to the percentage remaining after 30 and 60 minutes. N/A signifies that 
data was not obtained.   
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Drug 
Drug % remaining after 
30 mins 
Drug % remaining after 
60 mins 
Dextromethorphan 91 85.3 
Diclofenac 120 180 
Flunixin 99 98 
Ketoprofen 61 110 
Phenylbutazone 55 120 
Pyralamine 120 110 
Hydroxyzine 160 73 
Triamcinolone 59 95 
Fluphenazine 100 100 
Glycopyrrolate 110 130 
Table 6.2.3: Results obtained from preliminary screening of all ten drugs with rCYP2D50. 
Samples were analysed at 0, 30 and 60mins after the start of the reaction. Data was obtained in 
arbitrary units and converted to the percentage remaining after 30 and 60 minutes.  
 
6.3: Diclofenac metabolism 
 
6.3.1: Introduction 
 
Diclofenac is one of the most frequently used NSAIDs in human and is effectively 
used for pain relief for various inflammatory disorders. It was introduced in 1979 and, 
like most NSAIDs, works via inhibition of the cyclooxygenase 1 and 2 enzymes (Gan, 
2010). In horse, diclofenac has generally only received research attention in topical 
formulations (Ferrante et al, 2010, Schleining et al, 2008, Andreeta et al, 2011) and 
has only been approved for use in practice as a topical treatment (Reeder et al, 
2009). Because of this, data relating to oral dosing is scarce although not absent. In 
a 2013 study, Azevedo et al compared oral doses of diclofenac with topical, finding 
good bioavailability with both routes of administration. Additionally, recombinant 
enzymes have been used to study diclofenac metabolism in the horse. DiMaio et al 
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(2009) looked at diclofenac activity with recombinant CYP2C92 by monitoring the 
concentration of 4-hydroxydiclofenac, which is a known metabolite of diclofenac in 
human (Gan, 2010), see figure 6.3. In this study, 4-hydroxydiclofenac was detected 
using both the recombinant system and when using equine liver microsomes, 
although metabolite formation was significantly slower (~20 fold) for both these 
systems compared to the human recombinant CYP2C9 system.  
 
 
Figure 6.3: Metabolism of diclofenac by CYP2C9. Diclofenac is metabolised by CYP2C9 (in 
human) to form 4-hydroxydiclofenac via the addition of an hydroxyl group. Adapted from “Interaction 
of diclofenac and quinidine in monkeys: stimulation of diclofenac metabolism” by Tang, W, Stearns, 
R.A, Kwei, G.Y, Iliff, S.A, Miller, R.R, Egan, M.A,Yu, N.X, Dean, D.C, Kumar, S, Shou, M, Lin, J.H, 
Baillie, T.A, 2009, The Journal of Pharmacology and Experimental Therapeutics: 291(3), 1068–1074. 
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6.3.2: Inhibition of diclofenac metabolism by fluconazole 
 
Fluconazole is an antifungal medication frequently used in both veterinary and 
human medicine (Latimer et al, 2001, Kunze et al, 1996). In human medicine, it is 
known to be a potent inhibitor of CYP2C9 (as well as CYP2C19 and CYP3A4), 
therefore care is needed if drugs metabolised by these enzyme are prescribed at the 
same time (Miners and Birkett, 1998). Significant drug interactions have been 
reported between fluconazole and a wide variety of CYP2C9 substrates including 
warfarin, some selective serotonin reuptake inhibitors (SSRIs), naproxen and 
diclofenac (Ogu and Maxa, 2000). Fluconazole has been shown to be a potent 
inhibitor of diclofenac metabolism in human, with a Ki (the concentration of inhibitor 
needed to decrease the maximal rate of reaction (Vmax) by 50%) of 17 μM 
(Hargreaves et al, 1994). In the horse, interactions between the general anaesthetics 
ketamine and midazolam and fluconazole have been reported, with co-administration 
causing increased recovery time from sedation (Krein et al, 2014). In this study, only 
clinical signs were analysed thus the mechanism of inhibition was not investigated.  
 
For the current study, diclofenac was used as a probe substrate to investigate its 
metabolism by recombinant equine CYP2C92 and compared to equine liver 
microsomes and recombinant human CYP2C9. Additionally, fluconazole was 
incubated with diclofenac in order to determine whether it acts as an inhibitor of this 
isoform in the horse.  
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6.4: Results 
 
6.4.1: LCMS analysis of diclofenac and 4-hydroxydiclofenac 
 
Diclofenac and 4-hydroxydiclofenac were monitored in order to detect enzyme 
activity. The ion of mass 296.19 at a retention time of 4.55 mins was used for 
diclofenac and the ion of mass 312.05 at a retention time of 4.12 mins was used to 
monitor apparent 4-hydroxydiclofenac activity (figure 6.4.1). Because of a lack of a 
authentic 4-hydroxydiclofenac stock, this ion was detected by monitoring incubation 
samples for an ion 16 daltons (oxygen insertion) larger than that for diclofenac.  
 
 
6.4.2: Diclofenac metabolism by equine rCYP2C92 
 
Figure 6.4.2 displays an example of the mass spectrometry response for diclofenac 
with rCYP2C92 at three time points (0, 30 and 60 minutes). Metabolism of diclofenac 
by CYP2C92 was evident across all concentrations (figure 6.4.3). Substrate enzyme 
inhibition appeared to be taking place from 100µM onwards and so two higher 
concentration assays were carried out at 200 µM and 250 µM. 
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Figure 6.4.2: Chromatograms showing depletion of diclofenac by rCYP2C92 with time (A: 0 
mins, B: 30 mins, C: 60 mins). Renention time is displayed on the Y axis of each chromatogram and 
the mass spectrometry response was calculated as the area under the curve. The retention time was 
4.55 (mins).   
 
168 
 
 
Figure 6.4.3: Data gathered using various diclofenac concentrations with rCYP2C92. Data was 
plotted as the natural logarithm (Ln) of substrate concentration against time. Kdep is represented by 
the slope of the line (refer to table 6.4.1). Data was generated from one experiment.  
 
A Michaelis-Menten substrate inhibition curve was fitted to the data according to 
equation 2 in section 6.1.3 (figure 6.4.4), however Vmax and Km could not be 
deconvoluted with any certainty and therefore the initial slope of the Michaelis-
Menten curve was used to estimate a CLint value of 3 µl/min/mg of protein (table 
6.4.4). 
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Substrate concentration 
(µM) 
Kdep 
(/min) 
𝒗𝟎 (µM/min) % drug remaining 
after 60 mins 
1 0.0073 0.0073 79 
5 0.014 0.071 47 
10 0.021 0.21 47 
20 0.022 0.43 30 
50 0.027 1.33 47 
75 0.048 3.6 5.8 
100 0.027 2.7 37 
150 0.021 3.0 33 
200 0.0051 1.0 72 
250 0.0048 1.2 72 
 
Table 6.4.1: Kdep and initial rate values for rCYP2C92 with diclofenac. Substrate concentrations 
ranged from 1-250 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also highlighted is 
the percentage of drug remaining at the end of the assay (60 minutes).  
 
 
 
Figure 6.4.4: Michaelis-Menten Substrate inhibition curve for rCYP2C92 with diclofenac. Initial 
rate is plotted against substrate concentration.  
 
For metabolite appearance, 4-hydroxydiclofenac activity was measured by 
monitoring for an ion of mass 312.05, however no significant production of this 
metabolite could be detected at any substrate concentration. 
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6.4.3: Diclofenac metabolism by equine liver microsomes 
 
Metabolism was evident for equine liver microsomes with diclofenac across all 
concentrations, except at 1µM (figure 6.4.5).  
 
 
 
Figure 6.4.5: Data gathered using various diclofenac concentrations with equine microsomes. 
Data was plotted as the natural logarithm (Ln) of substrate concentration against time. Kdep is 
represented by the slope of the line (refer to table 6.4.2). Data was generated from one experiment.  
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Substrate 
concentration (µM) 
Kdep (/min) 𝒗𝟎 (µM/min) % drug 
remaining after 
60 mins 
1 -0.0028 0.0028 95 
5 0.0073 0.037 97 
10 0.0094 0.094 68 
20 0.014 0.27 65 
50 0.0073 0.37 77 
75 0.0064 0.48 80 
100 0.0069 0.69 75 
150 0.0053 0.80 78 
 
Table 6.4.2: Kdep and initial rate values for equine liver microsomes with diclofenac. Substrate 
concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also 
highlighted is the percentage of drug remaining at the end of the assay (60 minutes). 
 
A partial Michealis-Menten curve was successfully fitted to the depletion data (figure 
6.4.6). Km was estimated at 145 µM and Vmax at 1.57 µM/min. CLint was calculated as 
17.75 µl/min/pmol p450 (table 6.4.4). 
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Figure 6.4.6: Michealis-Menten curve for equine liver microsomes with diclofenac. Initial rate 
(μM/min) is plotted against substrate concentration. 
 
In addition to monitoring diclofenac depletion, the apparent production of 4-
hydroxydiclofenac was monitored (figure 6.4.7). Due to absence of an authentic 
stock solution for 4-hydroxydiclofenac, the concentration of the metabolite could not 
be determined. The mass spectrometry response for the metabolite (obtained in 
arbitrary units, and calculated based on the area under the chromatographic peak) 
was plotted against time (figure 6.4.7) to generate the initial rate in arbitrary units and 
successfully fitted to a Michaelis-Menten curve (figure 6.4.8). Km was estimated at 53 
µM with a standard error (SE) of 28.  
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Figure 6.4.7: Production of 4-hydroxydiclofenac with equine liver microsomes at various 
diclofenac concentrations. MS response (in arbitrary units) is plotted against time.  
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Figure 6.4.8: Michaelis-Menten graph using 4-hydroxydiclofenac production with equine liver 
microsomes. Substrate concentration is plotted against the mass spectrometry response (in arbitrary 
units).  
 
 
6.4.4: Diclofenac metabolism by human rCYP2C9  
 
Since kinetic parameters for diclofenac with human CYP2C9 are already known 
(Bort et al, 1999), fewer concentrations were used (figure 6.4.9) and data was 
successfully fitted using a Michaelis-Menten curve (figure 6.4.10). Km and Vmax 
estimations were 12.24 µM and 0.23 µM/min respectively, with a CLint of 1.88 
µl/min/pmol P450. 
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Figure 6.4.9: Data gathered using various diclofenac concentrations with rCYP2C9. Data was 
plotted as the natural logarithm (Ln) of substrate concentration against time. Kdep is represented by 
the slope of the line (refer to table 6.4.3). Data was generated from one experiment.  
 
 
Substrate 
concentration (µM) 
Kdep (/min) 𝒗𝟎 (µM/min) % drug 
remaining after 
60 mins 
1 0.0050 0.0050 70 
5 0.011 0.054 28 
10 0.011 0.11 57 
20 0.0078 0.16 69 
30 0.0049 0.15 85 
 
Table 6.4.3: Kdep and initial rate values for rCYP2C9 with diclofenac. Substrate concentrations 
ranged from 1-30 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also highlighted is the 
percentage of drug remaining at the end of the assay (60 minutes). 
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Figure 6.4.10: Michaelis-Menten curve for human recombinant CYP2C9 with diclofenac. Initial 
rate (in μM/min) is plotted against substrate concentration.  
 
For metabolite production, apparent 4-hydroxydiclofenac production was monitored 
and mass spectrometry (MS) response vs time was plotted in order to determine the 
initial rate (figure 6.4.11). A Michaelis-Menten curve was successfully fitted to this 
data (figure 6.4.12) with Km estimated at 9.023 µM with a standard error of 9.623.   
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Figure 6.4.11: Production of 4-hydroxydiclofenac with human rCYP2C9 at various diclofenac 
concentrations. MS response is plotted against time.  
 
 
 
 
 
Figure 6.4.12: Michaelis-Menten graph of 4-hydroxydiclofenac production with human 
rCYP2C9 supersomes. Substrate concentration is plotted against the mass spectrometry response 
(in arbitrary units).  
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6.4.5: Summary 
 
Table 6.4.4 summarises the depletion data gathered from all three enzyme systems 
with diclofenac. For apparent 4-hydroxydiclofenac appearance, a Km of 53.45 μM 
was obtained for equine liver microsomes and a Km of 9.023 μM for human 
rCYP2C9. rCYP2C92 showed substrate auto-inhibition therefore only CLint was 
obtained.  
 
Enzyme 
system 
Km 
1 Km SE
1 Vmax 
2 Vmax SE 
2 CLint 
3 
rCYP2C92 N/A N/A N/A N/A 3.00 
      
rCYP2C9 12.24 6.28 0.23 0.02 1.88 
      
Equine 
Microsomes 
145.5 56.17 1.57 0.36 17.75 
 
 
Table 6.4.4: Summary Km, Vmax and Intrinsic clearance (CLint) values for all three enzyme 
systems with diclofenac. Units =  
1
 μM, 
2
  μM/min, 
3
 μl/min/pmol P450 (μl/min/mg protein for 
CYP2C92). N/A signifies the value could not be obtained. SE = standard error. 
 
6.4.6: Diclofenac inhibition 
 
Equine rCYP2C92 and equine microsomes were tested against fluconazole, a potent 
inhibitor of human CYP2C, with diclofenac as the substrate. Fluconazone 
concentrations ranged from 0-75 µM. Figures 6.4.13 and 6.4.14 display the natural 
logarithm transformed graphs of this data, with clear substrate depletion evident 
across all fluconazole concentrations.  
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Figure 6.4.13: Data gathered using various fluconazole concentrations with rCYP2C92 and 
diclofenac as the substrate. Data was plotted as the natural logarithm (Ln) of substrate 
concentration against time. Kdep is represented by the slope of the line.  Data was generated from one 
experiment. 
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Figure 6.4.14: Data gathered using various fluconazole concentrations with equine 
microsomes and diclofenac as the substrate. Data was plotted as the natural logarithm (Ln) of 
substrate concentration against time. Kdep is represented by the slope of the line.  Data was generated 
from one experiment. 
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Percentage inhibition was calculated and graphs were plotted (figure 6.4.15). No 
inhibition trend was evident therefore Ki could be calculated.  
 
 
Figure 6.4.15: Percentage inhibition for CYP2C92 (A) and equine microsomes (B) using 
fluconazole and diclofenac. Fluconazole concentrations were logged (base 10) and plotted against 
percentage inhibition (normalised using the 0 µM concentration).  
 
6.5: Ketoprofen metabolism 
 
6.5.1: Introduction 
 
Ketoprofen, like other NSAIDs, works via the inhibition of COX-1 and COX-2 (Grubb 
et al, 1999). It is widely used in human and veterinary medicine for a variety of 
musculoskeletal disorders and is generally used in the racemate form (Scarth et al, 
2011). Unlike most NSAIDs however, ketoprofen is not majorly metabolised by 
P450s in human, although it does have a P450 pathway, which converts it into 
hydroxyketoprofen and hydroxybenzolketoprofen (Alkatheeri et al, 1999, Skordi et al, 
2004). Its major pathway in human (accounting for 80% of metabolism) is phase II 
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metabolism (Grubb et al, 1999). In mice and rats, ketoprofen is metabolised to a 
much greater extent by P450s (Yamasaki et al, 2010). When metabolised by P450s, 
CYP2C9 is the P450 isoform involved (Zhou et al, 2009a).  
6.5.2: Ketoprofen in equine medicine 
 
Compared with other NSAIDs, ketoprofen has a higher safety margin and lower 
toxicity in the horse (Rehman et al, 2012). Differences in the rate of elimination of the 
S(+) and R(-) isomers have been found in horse (which are combined to create the 
racemate formulation), with the R(-) form being eliminated substantially faster (Verde 
et al, 2001).  
 
As far as phase I metabolism is concerned, hydroxybenzolketoprofen has been 
detected in equine urine (Benoit et al, 1992) as has hydroxyketoprofen (Brink et al, 
1998). No attempts to characterise the enzyme isoforms involved in phase I 
metabolism of ketoprofen in the horse have been made to date. Analysis of 
ketoprofen metabolism generally involves looking for the parent drug itself rather 
than for the hydroxylated metabolite (Baeyens et al, 1999). During the current study, 
phase I metabolism of ketoprofen was investigated by using recombinant equine 
CYP2C92 and compared to equine liver microsomes and recombinant human 
CYP2C9. 
6.6: Results 
6.6.1: LCMS analysis of ketoprofen 
 
To monitor for ketoprofen metabolism, the ion of mass 336.63 was used, coming out 
at a retention time of 4.56 minutes (figure 6.6.1). No authentic metabolite of 
ketoprofen was available so only the parent drug was monitored.  
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Figure 6.6.1: Single ion chromatogram for ketoprofen. The ion of mass 332.63 (Ketoprofen + 
formic acid + methanol) was used to monitor ketoprofen depletion. Retention time was 4.56 minutes. 
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6.6.2: Ketoprofen Metabolism by Equine CYP2C92 
 
There appeared to be metabolism of ketoprofen at the lower substrate 
concentrations, with substrate levels being noticeably depleted at 1 μM and 5 μM. By 
10 μM metabolism becomes negligible (figure 6.6.2) with no evident depletion trend 
thereafter.   
 
 
Figure 6.6.2: Metabolism of ketoprofen by rCYP2C92. Data was plotted as the natural logarithm 
(Ln) of substrate concentration against time. Kdep is represented by the slope of the line (refer to table 
6.6.1). Data was generated from one experiment. 
 
A Michealis-Menten curve could not be fitted to the data therefore Km, Vmax and CLint 
could not be obtained.  
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Ketoprofen 
Concentration (μM) 
Kdep (/min) 𝒗𝟎 (μM/min) % drug 
remaining 
after 60 mins 
1 0.011 0.011 60 
5 0.0055 0.028 70 
10 0.00040 0.0040 130 
20 0.00040 0.0080 120 
50 0.0097 0.49 82 
75 0.0056 0.42 79 
100 -0.0043 0.43 200 
150 0.0050 0.75 70 
 
Table 6.6.1: Initial rate and depletion constant values for equine rCYP2C92 with ketoprofen. 
Substrate concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 
6.1.3. Also highlighted is the percentage of drug remaining at the end of the assay (60 minutes). 
 
6.6.3: Ketoprofen metabolism by equine liver microsomes 
 
At 1μm there appeared to be metabolism of ketoprofen by equine microsomes 
(figure 6.6.4) however with increasing concentration no detectable metabolism was 
noted.  
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Figure 6.6.4: Metabolism of ketoprofen by equine liver microsomes. Data was plotted as the 
natural logarithm (Ln) of substrate concentration against time. Kdep is represented by the slope of the 
line (refer to table 6.6.2). Data was generated from one experiment. 
 
Due to a lack of apparent metabolism of ketoprofen across most concentrations by 
equine liver microsomes, a Michaelis-Menten analysis was not carried out.  
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Ketoprofen 
Concentration (μM) 
Kdep (/min) 𝒗𝟎 (uM/min) % drug 
remaining after 
60 mins 
1 0.0014 0.0014 79 
5 -0.0017 0.0085 110 
10 -0.0070 0.070 160 
20 -0.0056 0.11 130 
50 -0.0022 0.11 130 
75 0.0026 0.19 77 
100 0.0028 0.28 66 
150 0.022 3.35 27 
Table 6.6.2: Initial rate and depletion constant values for equine liver microsomes with 
ketoprofen. Substrate concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 
in section 6.1.3. Also highlighted is the percentage of drug remaining at the end of the assay (60 
minutes).  
 
6.6.4: Metabolism of ketoprofen by human rCYP2C9 
 
No substrate depletion was evident for the human CYP2C9 isoform with ketoprofen 
(figure 6.6.6) therefore Km, Vmax and CLint could not be calculated.  
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Figure 6.6.6: Metabolism of ketoprofen by human CYP2C9. Data was plotted as the natural 
logarithm (Ln) of substrate concentration against time. Kdep is represented by the slope of the line 
(refer to table 6.6.3). Data was generated from one experiment. 
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Ketoprofen 
Concentration (μM) 
Kdep (/min) 𝒗𝟎 (uM/min) % drug 
remaining after 
60 mins 
1 -0.0064 0.0064 230 
5 N/A N/A 73 
10 0.00030 0.0030 100 
20 -0.00020 0.0040 140 
50 0.00080 0.040 81 
75 0.037 2.8 90 
100 -0.0038 0.38 100 
150 0.0021 0.32 67 
Table 6.6.3: Initial rate values for human rCYP2C9 with ketoprofen. Substrate concentrations 
ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also highlighted is 
the percentage of drug remaining at the end of the assay (60 minutes).  
 
6.7: Flunixin metabolism 
 
6.7.1: Introduction 
 
Flunixin is one of the most frequently prescribed veterinary NSAIDs and is one of the 
most potent used in the horse (Beretta et al, 2005). It has been well-characterised in 
the horse and is used for, in addition to muscoskeletal disorders, prevention of 
endotoxic shock and to alleviate symptoms of colic (Carrick et al, 1989). It can be 
administered orally, intramuscularly or intravenously (Pellegrini-Masini et al, 2004). 
Flunixin is hydroxylated by P450s (figure 6.7), with the resulting metabolite having 
been detected in horse plasma and urine (Jaussaud et al, 1987), however the 
majority of pharmacokinetic studies on flunixin involve looking for flunixin itself rather 
than 5-hydroxyflunixin (Luo et al, 2004).  It is not used in human; however it is 
permitted for use in cattle and pigs in addition to horses (Pairis-Garcia et al, 2013). 
Due to its limited use, no data is available about P450-specific metabolism of 
flunixin.  
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In the current study, P450-specifc metabolism was assessed by using recombinant 
equine and human P450s as well as equine liver microsomes in order to determine 
whether CYP2C isozymes are responsible for flunixin metabolism.  
 
 
Figure 6.7: Metabolism of flunixin to 5’hydroxyflunixin. Adapted from “Determination and 
confirmation of 5-hydroxyflunixin in raw bovine milk using liquid chromatography tandem mass 
spectrometry” by Boner, P.L, Liu, D.D.W, Feely, W.F, Wisocky, M.J, Wu, J, 2003, Journal of 
Agricultural and Food Chemistry: 51, 3753–3759. 
 
6.8: Results 
 
6.8.1: LCMS analysis of flunixin 
 
The ion of mass 297.26 was used to monitor for flunixin depletion (figure 6.8.1). The 
retention time was 4.6 mins (refer to chapter 2 for full details of HPLC conditions).  
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6.8.2: Flunixin metabolism by rCYP2C92 
 
For the recombinant CYP2C92, there appeared to be significant turnover of flunixin 
(figure 6.8.2); metabolism was evident at all concentrations. A Michealis-Menten 
curve was successfully fitted to the data (figure 6.8.3), with the data closely fitting the 
curve. Km was estimated at 43.89 μM and Vmax at 1.96 μM/min (table 9.2.4). The 
subsquent CLint value was 297.7 μL/min/mg of protein.  
 
 
Figure 6.8.2: Metabolism of flunixin by equine rCYP2C92. Data was plotted as the natural 
logarithm (Ln) of substrate concentration against time. Kdep is represented by the slope of the line 
(refer to table 6.8.1). Data was generated from one experiment. 
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Flunixin Concentration (μM) Kdep (/min) 𝒗𝟎 (uM/min) % drug 
remaining 
after 60 mins 
1 0.028 0.028 40 
5 0.023 0.12 48 
10 0.035 0.35 33 
20 0.033 0.67 35 
50 0.018 0.91 48 
75 0.018 1.34 50 
100 0.015 1.5 51 
150 0.0093 1.4 73 
Table 6.8.1: Initial rate and Kdep values for rCYP2C92 with flunixin. Substrate concentrations 
ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also highlighted is 
the percentage of drug remaining at the end of the assay (60 minutes).  
 
 
Figure 6.8.3: Michaelis-Menten curve for rCYP2C92 with flunixin. Initial rate is plotted against 
substrate concentration.  
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6.8.2: Flunixin metabolism by equine liver microsomes 
 
Metabolism of flunixin was observed with equine microsomes (figure 6.8.4). With 
increasing substrate concentration, the initial rate firstly increased followed by a 
decline, therefore the data was fitted to a substrate inhibition curve as in equation 6 
in section 6.1.5 (figure 6.8.5). The Km and Vmax values could not be deconvoluted so 
equation 2 in section 6.1.3 was used to estimate a CLint value of 20 μL/min/pmol 
P450.  
 
 
Figure 6.8.4: Metabolism of flunixin by equine liver microsomes. Data was plotted as the natural 
logarithm (Ln) of substrate concentration against time. Kdep is represented by the slope of the line 
(refer to table 6.8.2). Data was generated from one experiment. 
 
 
195 
 
Flunixin Concentration (μM) Kdep (/min) 𝒗𝟎 (uM/min) % drug 
remaining after 
60 mins 
1 0.0052 0.0052 74 
5 0.0059 0.030 73 
10 0.0057 0.057 73 
20 0.0034 0.068 84 
50 0.0012 0.060 95 
75 0.00070 0.053 100 
100 0.0012 0.12 92 
150 0.00070 0.11 95 
Table 6.8.2: Initial rate and Kdep values for equine liver microsomes with flunixin. Substrate 
concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also 
highlighted is the percentage of drug remaining at the end of the assay (60 minutes). 
 
 
 
Figure 6.8.5: Substrate inhibition curve for equine liver microsomes incubated with flunixin. 
Initial rate is plotted against substrate concentration.  
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6.8.3: Metabolism of flunixin by human rCYP2C9 
 
No metabolism of flunixin was observed by human CYP2C9 (figure 6.8.6).   
 
 
 
Figure 6.8.6:  Metabolism of flunixin by human rCYP2C9. Data was plotted as the natural 
logarithm (Ln) of substrate concentration against time. Kdep is represented by the slope of the line 
(refer to table 6.8.3). Data was generated from one experiment. 
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Flunixin Concentration 
(μM) 
Kdep (/min) 𝒗𝟎 (uM/min) % drug 
remaining 
after 60 mins 
1 0.0064 0.0064 250 
5 -0.0010 0.0050 140 
10 -5.000050 0.00050 96 
20 0.000060 0.0012 100 
50 0.00080 0.040 94 
75 0.0011 0.083 9.6 
100 0.0020 0.20 90 
150 -0.0021 0.32 119 
Table 6.8.3: Initial rate and Kdep values for human rCYP2C9 with flunixin. Substrate 
concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also 
highlighted is the percentage of drug remaining at the end of the assay (60 minutes).  
 
6.8.4: Summary 
 
Table 6.8.4 summarises the data gathered for all three enzyme systems with flunixin. 
Parameters could not be determined for human recombinant CYP2C9 due to 
absence of apparent metabolism in this system. Only CLint could be determined for 
equine liver microsomes due to the presence of substrate inhibition.  
 
 
 
 
 
 
 
 
 
198 
 
Enzyme 
system 
Km 
1 Km SE 
1 Vmax 
2 Vmax SE 
2 CLint 
3 
rCYP2C92 43.89 12.99 1.96 0.22 297.7 
      
rCYP2C9 N/A N/A N/A N/A N/A 
      
Equine 
Microsomes 
N/A N/A N/A N/A 20 
 
Table 6.8.4: Km, Vmax and Intrinsic clearance (CLint) values for all three enzyme systems with 
flunixin. Units =  
1
 μM, 
2
  μM/min, 
3
 μL/min/pmol P450 (μL/min/mg protein for CYP2C92). N/A 
signifies the value could not be obtained due to no metabolism (CYP2C9) or data being fit to a 
substrate inhibition curve (equine microsomes). For the microsomal system, the inhibition constant 
was used to calculate the CLint. SE = standard error. 
6.9: Phenylbutazone metabolism 
 
 
6.9.1: Introduction 
 
Phenylbutazone is one of the most well studied equine medications and is the most 
frequently prescribed equine NSAID (Soma et al, 2012). Consequentially, much is 
known about its pharmacokinetics. It can be administered orally or intravenously, 
with both routes having been extensively characterised (Scarth et al, 2011). For 
routine drug testing, the metabolite oxyphenylbutazone is generally used to monitor 
metabolism, although gamma-hydroxyphenylbutazone is another major metabolite of 
phenylbutazone, produced in addition to the minor metabolites shown in figure 6.9 
(Lees and Toutain, 2013). 
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Figure 6.9: Phase I metabolism of phenylbutazone in the horse. The major metabolites are 
oxyphenbutazone and gamma-hydroxyphenybutazone while the minor metabolites are omega-
hydroxyphenybutazone, gamma-hydroxyphenbutazone and gamma-ketophenybutazone.  Adapted 
from “Drug metabolism in the horse” by Scarth, J.P, Teale, P, Kuuranne, T, 2011, Drug Testing and 
Analysis: 3(1):19-53.  
 
Controversy has surrounded the use of phenylbutazone within the horseracing 
industry, due to its particularly high levels of use within this species (Soma et al, 
2012). Adequate screening procedures for phenylbutazone have therefore become 
essential for effective medication control. Despite the levels of use and research on 
phenylbutazone in the horse, there is no data to date about the specific P450 
isoforms responsible for its metabolism. In human, phenylbutazone is an inhibitor 
and substrate of CYP2C9 (Rendic, 2002). For the current study, recombinant equine 
CYP2C92 was used to determine whether this isoform is responsible for 
phenylbutazone metabolism in the horse. Activity was monitored by looking for both 
substrate depletion and metabolite appearance, which is the most frequently used 
method in equine phenylbutazone monitoring (Peck et al, 1996).  
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6.10: Results 
 
6.10.1: Phenylbutazone LCMS analysis 
 
The ion of mass 309.19 was used to monitor phenylbutazone depletion and the ion 
of mass 325.25 was used to monitor the appearance of its metabolite, 
oxyphenbutazone (figure 6.10.1).  
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6.10.2: Phenylbutazone metabolism by equine recombinant CYP2C92. 
 
Figure 6.10.2 shows the mass spectrometry response for phenylbutazone with 
rCYP2C92. Figure 6.10.3 displays the data for phenylbutazone depletion by 
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rCYP2C92. From 50 to 150 μM substrate auto inhibition appeared to be occurring 
with increasing concentration of substrate, due to slope of the line decreasing. A 
substrate inhibition curve was fitted to the data (figure 6.10.4) and consequentially 
Vmax and Km approximations could not be deconvoluted with any certainty and 
therefore the initial slope of the Michaelis-Menten curve was used to estimate a CLint 
value of 6 μl/min/mg protein.  
 
 
Figure 6.10.2: Chromatograms showing depletion of phenylbutazone by rCYP2C92 with time 
(A: 0 mins, B: 30 mins, C: 60 mins). Renention time is displayed on the Y axis of each 
chromatogram and the mass spectrometry response was calculated as the area under the curve. The 
retention time was 5.59 (mins).   
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Figure 6.10.3: Data gathered using various phenulbutazone concentrations with equine 
rCYP2C92. Data was plotted as the natural logarithm (Ln) of substrate concentration against time. 
Kdep is represented by the slope of the line (refer to table 6.10.1). Data was generated from one 
experiment. 
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Phenylbutazone 
Concentration (μM) 
Kdep (/min) 𝒗𝟎  (µM/min) % drug 
remaining 
after 60 mins 
1 N/A N/A N/A 
5 0.0087 0.044 41 
10 0.0096 0.096 37 
20 0.011 0.22 32 
50 0.0021 0.11 70 
75 -0.0017 0.13 99 
100 -0.00090 0.09 91 
150 0.000070 0.011 90 
Table 6.10.1: Initial rate and Kdep values for rCYP2C92 with phenylbutazone. Substrate 
concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also 
highlighted is the percentage of drug remaining at the end of the assay (60 minutes). 
 
 
Figure 6.10.4: Substrate inhibition curve for rCYP2C92 and phenylbutazone. Initial rate (μM/min) 
is plotted against substrate concentration (μM).  
 
In addition to substrate depletion, the major metabolite of phenylbutazone, 
oxyphenbutazone, was monitored for however results were inconclusive – no distinct 
chromatographic peaks were visible. 
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6.10.3: Phenylbutazone metabolism by equine liver microsomes 
 
Metabolism of phenylbutazone by equine liver microsomes was evident across all 
concentrations (figure 6.10.5). A Michaelis-Menten curve was successfully fitted to 
the data (figure 6.10.6) with Km and Vmax values estimated at 15.45 μM and 1.09 
μM/min respectively. This was used to generate a Clint value of 0.16 μl/min/pmol 
p450. 
 
 
Figure 6.10.5: Data gathered using various phenulbutazone concentrations with equine 
microsomes. Data was plotted as the natural logarithm (Ln) of substrate concentration against time. 
Kdep is represented by the slope of the line (refer to table 6.10.2). Data was generated from one 
experiment. 
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Phenylbutazone 
Concentration (μM) 
Kdep (/min) 𝒗𝟎  (µM/min) % drug remaining 
after 60 mins 
1 0.0038 0.0038 94 
5 0.026 0.13 34 
10 0.026 0.26 16 
20 0.025 0.50 37 
50 0.015 0.74 57 
75 0.014 1.1 73 
100 0.0068 0.68 81 
150 0.0071 1.1 84 
 
Table 6.10.2: Initial rate and Kdep values for equine liver microsomes with phenylbutazone.  
Substrate concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 
6.1.3. Also highlighted is the percentage of drug remaining at the end of the assay (60 minutes).  
 
 
Figure 6.10.6: Michaelis-Menten curve for equine microsomes and phenylbutazone. Initial rate 
(μM/min) is plotted against substrate concentration (μM).  
 
In addition to substrate depletion, the appearance of the metabolite, 
oxyphenbutazone, was monitored (figure 6.10.7). At concentrations 1 to 10 μM no 
detectable metabolite was produced however from 20-150 μM significant 
oxyphenbutazone production was detected (figure 6.10.8). Vmax was determined to 
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be 0.7 μM/min while Km could not be deconvoluted due to lack of data for lower 
concentrations.  
 
 
Figure 6.10.7: Data for oxyphenbutazone production with equine liver microsomes. Data was 
plooted as the concentration (in μM) against time.  
 
Figure 6.10.8: Oxyphenbutazone production by equine liver microsomes. Concentration was 
determined using a stock solution of oxyphenbutazone of known concentration to covert mass 
spectrometry response into μM.   
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6.10.4: Phenylbutazone metabolism by human recombinant CYP2C9 
 
Substrate depletion was evident with human rCYP2C9 up until a substrate 
concentration of 150μM (figure 6.10.9). A Michaelis-Menten curve was successfully 
fitted to the data (figure 6.10.10). The estimated Km and Vmax were 18.79μM and 0.94 
μM/min, respectively. CLint was calculated as 5.002 μl/min/pmol P450. 
 
 
 
Figure 6.10.9: Data gathered using various phenulbutazone concentrations with human 
rCYP2C9. Data was plotted as the natural logarithm (Ln) of substrate concentration against time. Kdep 
is represented by the slope of the line (refer to table 6.10.3). 
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Figure 6.10.10: Michaelis-Menten curve for rCYP2C9 and phenylbutazone. Initial rate (μM/min) is 
plotted against substrate concentration (μM).  
 
Phenylbutazone 
Concentration (μM) 
Kdep (/min) 𝒗𝟎  (µM/min) % drug 
remaining after 
60 mins 
1 0.03 0.03 47 
5 0.05 0.24 59 
10 0.03 0.29 81 
20 0.02 0.44 86 
50 0.01 0.66 79 
75 0.01 0.89 86 
100 0.0085 0.85 91 
150 0.0047 0.71 150 
 
Table 6.10.3: Initial rate and Kdep values for human rCYP2C9 with phenylbutazone. Substrate 
concentrations ranged from 1-150 μM and 𝒗𝟎 was calculated as per equation 4 in section 6.1.3. Also 
highlighted is the percentage of drug remaining at the end of the assay (60 minutes). 
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6.10.5: Summary 
 
Table 6.10.4 summarises the data generated for all three enzyme systems with 
phenylbutazone. Only CLint could be determined for rCYP2C92 due to presence of 
substrate auto-inhibition.  
 
Enzyme system Km 
1 Km SE 
1 Vmax 
2 Vmax SE 
2 CLint 
3 
rCYP2C92 N/A N/A N/A N/A 6.0 
      
rCYP2C9 18.79 6.6 0.94 0.09 5.0 
      
Equine 
Microsomes 
15.45 11.4 1.09 0.21 0.16 
 
Table 6.10.4: Summary of Km, Vmax and Intrinsic clearance (CLint) values for all three enzyme 
systems. Units =  
1
 μM, 
2
  μM/min, 
3
 μL/min/pmol P450 (μL/min/mg protein for CYP2C92). N/A 
signifies the value could not be obtained (do to data being fit with a substrate inhibition curve). SE = 
standard error. 
 
6.11: Discussion 
 
 
The primary aim of this research was to characterise equine recombinant P450s by 
using a range of probe substrates frequently used in equine medication.  
 
Initially, drugs of various classes were investigated with rCYP2C92 and rCYP2D50. 
For rCYP2C92, the only drugs that displayed apparent metabolism were the 
NSAIDs. In other species, the vast majority of NSAID metabolism involves CYP2C 
isozymes, particularly CYP2C9 (Miners and Birkett, 1998, Leemann et al, 1993) so 
this result was as expected. The only substrate that rCYP2D50 showed activity with 
was dextromethorphan, which was as expected as this is a known CYP2D6 
substrate in human (Yu and Haining, 2001). Many of the drugs used did not appear 
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to be substrates for either isoform.  Hydroxyzine and fluphenazine are substrates of 
CYP2D6 in human; however equine CYP2D50 showed no activity towards either 
drug. P450 activity towards pyrilamine and glycopyrrolate is currently unknown in 
any species and neither drug appeared to be a substrate for CYP2D50 and 
CYP2C92. Overall, the only unexpected result was for the lack of metabolism by 
CYP2D50 of hydroxyzine and fluphenazine. This may imply CYP2D50 does not 
metabolise these drugs in the horse, however it may also be due to a lack of fully 
functional activity of CYP2D50 used in this research due to impaired post-
translational modifications within the bacterial expression system. In future work, 
rCYP2D50 screening against other known CYP2D substrates will allow for a more 
comprehensive analysis of the activity of this expression method and further insight 
into differences between the equine and human forms. After initial screening, 
rCYP2C92 activity with the NSAIDs diclofenac, ketoprofen, flunixin and 
phenylbutazone was focused on, with attempts being made to determine full kinetic 
parameters along with comparisons to equine liver microsomes and human 
rCYP2C9.  
 
For diclofenac, metabolism of this substrate on its own was analysed as well as 
metabolism in the presence of the potential inhibitor fluconazole. Disappearance of 
diclofenac was monitored along with apparent appearance of the known metabolite 
4-hydroxydiclofenac. For rCYP2C92, a significant decrease in diclofenac 
concentration over time was observed, however substrate auto inhibition was noted 
in this system and not in the microsomal system, which could be due to the 
contribution of other P450 enzymes within the microsomal system, thereby masking 
any CYP2C92-specific inhibition. However, the apparent hydroxylated metabolite 4-
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hydroxydiclofenac could not be conclusively detected with the recombinant system, 
which may imply the metabolic pathway of diclofenac with this recombinant enzyme 
may be altered. 4-hydroxydiclofenac was produced in both the recombinant human 
and equine microsomal systems and has previously been shown to be produced by 
equine CYP2C92 (DiMaio Knych et al, 2009). For the inhibition assay with 
fluconazole, rCYP2C92 and equine liver microsomes were used. This inhibition 
assay was carried out for two reasons – firstly to further study the activity of the 
recombinant enzyme, and secondly to investigate whether fluconazole is an inhibitor 
of CYP2C92 in the horse. Both the recombinant enzyme and microsomal systems 
showed no inhibition trend – data could not be fitted to a standard inhibition curve, 
implying that no significant inhibition was present. In human, the Ki of fluconazole 
when used with diclofenac is 17μM, much lower than the highest concentration used 
within this study (Hargreaves et al, 1994). Since inhibition was not seen in either 
equine system, it may be the case that fluconazole is not an inhibitor of diclofenac 
activity in the horse.  
 
To date, there have been no published reports on which specific isoforms of P450 
may be involved in ketoprofen metabolism in the horse. In human, P450s only play a 
minor role in the metabolism of ketoprofen while in mice and rats they hold a much 
more central importance (Yamasaki et al, 2010). From the results presented in the 
current study, CYP2C92 appears to have some activity towards ketoprofen, with the 
lower concentrations of drug (1 and 5 μM) showing a notable decrease over time. As 
substrate concentration increases however, the enzyme appears to have little to no 
effect on overall drug levels here. Likewise, equine liver microsomes showed a slight 
decrease in substrate concentration at 1μM and no change at higher concentrations. 
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This data implies P450s (CYP2C92 or other isoforms) only play a minor role in 
equine P450 metabolism of ketoprofen, although it should be noted that for the 
microsomal 1 μM assay (fig 6.6.4) the data was a poor fit to the graph,  therefore 
repetition of this assay would be required before substrate depletion can be 
conclusively confirmed. 
 
. Contrasting the equine data with the human data, there appears to be somewhat 
more activity towards the drug in the equine systems – no metabolism, even at 1μM, 
was detectable with human CYP2C9. CYP2C9 is known to have activity towards 
ketoprofen (Zhou et al, 2009a) however direct comparison between isoforms within 
the context of the current study is not possible due to the recombinant equine 
CYP2C92 being unable to be quantified via the carbon monoxide spectral assay 
(chapter 5). Further work will be required to fully ascertain whether the equine and 
human isoforms have different activities towards ketoprofen.   
 
The first use of flunixin with recombinant equine CYP2C92 has been presented in 
the current research, and it provides an insight into isoform-specific P450 
metabolism in the horse. As expected, both the recombinant enzyme system and 
equine liver microsomes showed turnover of flunixin. As a veterinary-only 
medication, flunixin is not permitted for use in humans and therefore data relating to 
its metabolism by human P450 enzymes is unavailable. Surprisingly, equine 
CYP2C92 and human CYP2C9 did not display similar activities with flunixin – no 
metabolism by the human isoform was detected. This was unexpected as CYP2C9 
is the main P450 involved in the majority of NSAID metabolism (Rettie and Jones, 
2005). Another difference between the systems was that equine microsomes 
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showed much more substrate inhibition than CYP2C92. This could be due to other 
P450 isoforms contributing towards metabolism in the microsomal system and thus 
producing metabolites that cause inhibition of flunixin depletion, or it could be due to 
a conformational difference in the recombinant enzyme – since there is an amino 
acid change in SRS6 (see chapter 4) which may affect the activity of the enzyme. 
Further work will be required to determine the reason for these differences – higher 
substrate concentrations will determine if the recombinant enzyme can be inhibited 
in the same way as the microsomal system. Since the P450 content of the 
recombinant system could not be quantified (chapter 5), the difference between the 
microsomal and recombinant systems may be a higher P450 content in the latter, 
thereby reducing the effect of inhibition at higher substrate concentrations. An 
important next step will be identifying the hydroxylated metabolite of flunixin during 
LCMS analysis. Nevertheless, these results give the first indication that CYP2C92 is 
responsible for flunixin metabolism in the horse.  
 
The last drug studied was phenylbutazone, which is the most highly-prescribed 
NSAID in the horse (Soma et al, 2012). Phenylbutazone depletion and 
oxyphenbutazone appearance were both monitored, since oxyphenbutazone is a 
known metabolite in the horse (Lees and Toutain, 2013). For the microsomal system, 
both approaches produced results however for the recombinant system no 
significant metabolite formation was evident. This could imply that another metabolite 
is the major product of CYP2C92 metabolism of phenylbutazone, however it is also 
possible that the recombinant enzyme has conformational changes that have altered 
its metabolic potential – which may also be the case for the lack of the major 
metabolite of diclofenac metabolism, 4-hydroxydiclofenac. Additionally, substrate 
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auto-inhibition was evident with rCYP2C92 but not in the microsomal system, which 
as with diclofenac may be caused by other enzymes present in microsomes 
contributing towards clearance of phenylbutazone. Further studies will be required to 
determine if other P450s are involved in phenylbutazone metabolism while, for 
rCYP2C92, monitoring the full mass spectra of samples will be required to determine 
what metabolites are produced by this recombinant enzyme.  
 
Intrinsic clearance values obtained in vitro can be scaled up to predict hepatic 
clearance and eventually used to predict the full pharmacokinetics of a drug in vivo. 
(Chiba et al, 2009). However, since rCYP2C92 could not be quantified within the 
current study this type of scaling up was not possible. Once recombinant P450s are 
quantified in future work, the CLint values can be used to estimate hepatic clearance 
of each drug by determining the concentration of the P450 isoform present in the 
liver and then scaling up to take into account hepatic blood flow and the total weight 
of the liver (Chiba et al, 2009). Extrapolation of in vitro data is commonplace in the 
human pharmaceutical industry where concentration of a drug with multiple doses 
can be predicted in order to estimate potential drug-drug interactions (Fasinu et al, 
2012). In the horse, in vivo drug metabolism studies are much more well-established 
than in vitro techniques however with increasing research in this area; accurate 
pharmacokinetic models can be developed and refined such that drug clearance and 
drug-drug interactions can be predicted in the laboratory. 
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Chapter 7: General discussion and concluding remarks 
 
The aim of this thesis was to characterise equine P450s by identifying them via 
bioinformatics, detecting them in equine liver and by expressing and functionally 
testing them against probe substrates. Firstly, searching of the UCSC genome 
browser (https://genome.ucsc.edu/ and NCBI database 
(http://www.ncbi.nlm.nih.gov/) was carried out to identity potential P450 sequences, 
which were then analysed for phylogeny and grouped into clans (sequences with 
shared evolutionary divergence, Kirischian et al, 2011). Once in silico data had been 
compiled, RT-PCR was used to detect some of these P450s in equine liver which 
were then cloned using two systems – an insect cell system (well-established in 
P450 research and has previously been used to express equine P450s, DiMaio 
Knych et al, 2010) and a bacterial cold-induction system, selected due to its ability to 
produce eukaryotic proteins that are hard to express in E coli systems Sugiki et al, 
2014. Once recombinant proteins were produced, their P450 status was assessed 
using the carbon monoxide spectral assay (Guengerich et al, 2009) and functional 
tests were carried out using various drugs as probe substrates. After this, the activity 
of rCYP2C92 against four NSAIDs (flunixin, phenylbutazone, diclofenac and 
ketoprofen) was focused on.   
Analysis of the equine genome generated some novel results – in total 46 full length 
sequences were identified, and these spanned across all mammalian P450 clans. 
This is the first insight into how many P450s are present in the equine genome and 
sets the scope for future research to characterise equine P450s.  
Once sequences had been identified, equine liver tissue was used to perform RT-
PCR analysis, in order to detect which P450s are expressed in equine liver. Some 
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interesting results emerged from this analysis, with two isoforms that have high 
hepatic expression in other species being undetected (CYP1A2 and CYP2E1, which 
metabolise many important xenobiotics in human). Similarly, P450 isoforms which 
are not expressed in the liver of other species were detected in equine liver - 
CYP2R1 and CYP1B1. CYP2D14 and CYP2C26 were also detected via RT-PCR 
and are not well characterised in any species however both have been documented 
to have hepatic expression (Tsuneoka et al, 1992, Sakuma et al, 1994). CYP3A97 
was used as a positive control for cDNA integrity (due to having previously been 
detected in equine liver, (DiMaio Knych et al, 2010, Tyden et al, 2012) and was also 
detected within the current study.  
Two protein expression techniques were used to produce P450s in this research – 
sf9 insect cells and cold-induction bacteria. SF9 insect cells are the most well-
established P450 expression system (Gonzalez, 1995) however protein expression 
here was minimal, with Western blot analysis of lysate generating consistently 
negative results. Conversely, the cold-induction bacterial system generated strong 
results – significant protein expression was detected for four isoforms – CYP2D50, 
CYP2C92, CYP1A1 and CYP2A13. Furthermore, for CYP2D50 and CYP2C92 
(which are the most likely drug-metabolising P450s out of these four) showed activity 
towards some drug substrates, despite carbon-monoxide spectral analysis showing 
them as P420s instead of P450s. There are no reports of functional P420s in the 
literature so it is possible that with different conditions (such as use of a different 
lysis buffer, or application of some modifications to the sequences prior to 
expression) they may show the characteristic 450 nm spectral shift. E coli expression 
systems have been reported on many instances previously to produce P420 peaks 
with and without sequence modification (Guengerich et al, 2009). It has been 
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suggested that detergents in lysis reagents could at least be partially to blame for 
this (Luthra et al, 2013), however within the current study when sonication was used 
as an alternative lysis technique, neither a P420 nor a P450 peak was evident.   
Four NSAID drugs were analysed in detail with rCYP2C92. These assays were run 
alongside ones involving equine liver microsomes and human recombinant CYP2C9. 
Although diclofenac has been studied with CYP2C92 before (DiMaio Knych et al, 
2009) the other three (ketoprofen, phenylbutazone and flunixin) have never been 
used to characterise this isoform. Despite substrate depletion being evident for 
rCYP2C92 with phenylbutazone and diclofenac, the metabolites 4-hydroxydiclofenac 
and oxyphenbutazone were not produced at any significant levels. To contrast, 4-
hydroxydiclofenac and oxyphenbutazone were detected in equine microsomes and 
the human rCYP2C9 systems. This finding could be used to imply the recombinant 
CYP2C92 is not a fully functional P450, although it is unknown what metabolite this 
enzyme produced instead of those that were monitored. Further analysis will be 
required to determine what the products of this recombinant CYP are by analysing 
the total ion current obtained from incubation samples. 
All NSAIDs showed metabolism by rCYP2C92, although with ketoprofen this was 
only evident at lower concentrations. Interestingly, rCYP2C92 differed in its 
metabolism of ketoprofen and flunixin from the human rCYP2C9 isoform - ketoprofen 
and flunixin showed no metabolism with CYP2C9. Ketoprofen is known to be mostly 
metabolised by phase II enzymes in human (Skordi et al, 2004) however the 
metabolism of flunixin in human is unknown, since this drug is not used in human 
medicine. These findings further emphasize the importance of species differences in 
drug metabolism and the dangers of extrapolating data between species.  
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Addtionally, significant differences were noted between the recombinant equine and 
equine microsomal systems during the Michaelis-Menten analyses. For 
phenylbutazone and diclofenac, substrate auto-inhibition was evident for the 
recombinant equine system but not the microsomal system, and conversely with 
flunixin, substrate auto-inhibition appeared to be taking place in the microsomal 
system but not the recombinant system. This could have been caused by 
conformational differences in the recombinant enzyme – however since other P450 
enzymes are present within microsomes, the concurrent metabolism by other 
isoforms of the probe substrates is also a possibility, as is it a possibility that other 
P450 isoforms produce metabolites that cause auto-inhibition with regard to the 
flunixin microsomal assay. Further studies using inhibitors of various P450 isoforms 
will be required to dismiss or confirm this possibility.  
In future work, the P450s isolated in the current research can be further 
characterised against a greater range of substrates – drug and non-drug. Two P450s 
produced during the current study (CYP2A13 and CYP1A1) were not phenotypically 
characterised at all due to the fact these isoforms are not major drug-metabolising 
enzymes in other species (Galván et al, 2005, Fukami et al, 2007). Potential 
substrates of CYP2A13 and CYP1A1, such as PAHs, could be tested against these 
recombinant enzymes. Additionally, all P450 constructs could be expressed in E. coli 
with N-terminal modifications in order to assess whether this alters the CO spectral 
assay outcome or generates different metabolites with diclofenac and 
phenylbutazone. N-terminal modifications are not a requirement for E. coli production 
of all P450s but have been used to produced functional P450s when native forms 
were not successfully expressed (Yun et al, 2006). A greater range of known CYP2C 
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and CYP2D substrates could also be tested against the recombinant CYP2C92 and 
CYP2D50 enzymes produced during the current study.  
Extrapolation of pharmacokinetic data between species is commonplace, however 
comparative studies have shown significant differences in drug metabolism between 
horse and other species (Chauret et al, 1997, Martignoni et al, 2006), Mössner et al 
(2011)). In the horse, in vivo metabolism studies are much more frequently used 
than in vitro studies, however in vivo research does not allow for specific P450 
isoforms involved in the metabolism of a drug to be determined. Drug-drug 
interactions (DDIs) are a potential consequence of dosing an animal with drugs 
where P450-specific metabolism is unknown and it is only due to the thorough 
characterisation of P450 substrates, inhibitors and inducers in human that these are 
able to be avoided in human medicine (Rendic, 2002).  For substrates and inhibitors, 
recombinant human P450s are routinely used for fast and effective screening of drug 
candidates (hepatocytes cultures are needed to test for induction of P450s), Fasinu 
et al, 2012. At this stage, drugs that may cause significant DDIs will be removed from 
the development process (Zhang et al, 2012). While human recombinant P450s 
have been commercially available (in the form of Supersomes) since the 1990s, 
equine P450s were only first recombinantly produced in 2008 (DiMaio Knych and 
Stanley, 2008) and no isoforms have commercial availability. Many adverse drug 
reactions are known to occur in the horse, enphasizing the importance of P450 
research in this species (Scarth et al, 2010, Brumbaugh, 2001).  
Due to the financial resources and motivations of the horseracing industry, the vast 
majority of pharmacokinetic data in the horse comes from routine drug testing of 
competing animals where samples (particularly urine) are taken on racedays in order 
to detect prohibited substances (Scarth et al, 2010). Although these methods are 
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highly developed, they cannot fully take into account the effect of DDIs on urinary 
metabolite profiles since CYP-specific metabolism of medications is unknown. For 
this reason, knowledge of P450 metabolism in the horse is important clinically as 
well as within the horseracing industry. To date, only the tip of the iceberg has been 
reached in equine P450 research and to fully understand drug metabolism in the 
horse all major P450s will need to be determined with substrate and inhibitors 
elucidated for each. As more research is carried out in this area, differences between 
horse and other species may become more evident and may therefore influence 
treatment regimens as well as allowing for greater sensitivity for doping control within 
the horse racing industry. 
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Appendix A: Primer sites (bold) for primers as highlighted in table 2.2.1. 
>Ecab.P450.1 
AGAATGACCTTCGACCCCACCTCAAAAATCACAAACATTGAATGGATCATAGACCAAAACAGTAAAGCTAAACTAAAGACTGCTAGAAAAAAAGGAAAAA
ATATTTGCAATTTTGGGGTGGGCAAAGATTTCTTAGGTAGCACAAACTATCAAAAAAGGAAAACCATCAAAGAAAAAACTTAGAGGCCAGCCCGCCAGCC
CTTCGACCCCACCTTTGTCCTTGGCGGCGGGCCCTTCAACGTCATCGCCGACATCCTCTTCCACAAGCACTTTGACTACGAGGACAAGACGTGTCAGAGGC
TGATGCACTTGTTCAACGAGAACTTCTACTTGCTCAGCACCCCCTGGCTCCAGGCTTATAATTATTTTTCAACCTATCTGCGCTACCTGCCTGGAAGCCATAG
AAAAGTAATGAAAAATGTGTCTGAAATTAAAGAGTTTACTTCAGAAAGAGTGAAGGAGCACCATAAGTCACTGGACCCCAACTGCCCCCGAGACTTCACC
GACAACCTGCTCATGGAAATGGAGAAGGAGAAACACAGTGCGGAGCCCCTGTTTACGTTGGAAAACATCACTGTGACCACGGCTGACATGTTCTTTGCAG
GGACAGAGACCACCAGCACCACGCTGAGATACGGGCTCCTGATTCTCTTGAAACACCCGGAGGTTGAAGAGAAACTTCATAAAGAGATTGACAGTGTGA
TTGGGCCAAGCCGAATCCCTGCCTTCAAGGACAGACTAGAGATGCCCTACATGGATGCTGTGGTGCATGAGATTCAGCGATTCATCAACCTCGTGCCCTCC
AACCTGCCCCATGTAGCAACCCAGGACACAGCGTTCAGAGGATATGTCATCCCTAAGGGCACAGTCGTAATTCCGACACTGGATTCACTCTTGTATGACAA
CCAAGAGTTCCCTGATGCAGAGAAGTTTAAGCCAGAGCACTTTCTGAACGAAAACGGAAAGTTCAAGTACAGCGACCATTTCAAGGCATTTTCCGCAGGA
AAGCGCGTGTGCGTCGGAGAAGGCCTGGCTCGCATGGAGCTGTTTCTGTTCCTGACTGCCATTCTGCAGCACTTTAACTTGAAGTCTCTGGTTGACCCCAA
GGATATTGACCTCAGCCCCGTCACGATTGGGTTTGGCAACATCCCACCCAATTACAAGCTCTGCATCATTCCC 
>Ecab.P450.4 chr1 
CAGTTGCCTCAGCATTTTGTTGGTGCTTATTTAGATGAGATGGATCAAGGTAAAAATGACCCATCGTCTGCTTTCTCCAAAGAAAAGCTAATTTTCTCTGTG
GATGAACTCATCATTGCTGGAACCAAAACTATAACCAATGTGCTATGGTGGGCAGTTCTTTTCATGGCCCTTTATCCTAACATTCAAGGACGGGTTCAGAA
GGAGCTTGATTTAATTATGGGACCCAGTGGGAAGCCATCTTGGGATGACACATGCAAAATGCCTTATACTGAGGCAGTTTTGTGTGAAGTTTTAAGATTCT
GTAATATAGCGCCATTAGCGATTTTCCATGGAGCCTCTGTAGATGTAGTTGTATGTGGTGATTCCATTCCTAAAGGCAAAGCAGTTATTACAAATCTTTATT
CTGTACACTTCAATGAAGAGTACTGGAGAGACCCAGAAGTATTCTATCCTGAGCAATTTCTGGACAGCAGTGGACTTTTTGCCGAGAAGGAAGCTTTGCTT
CCTTTTTGCTTAGGAAGAAGAGATGGTCCTGGAGAACAGCTGGCTGTGGAAATGTTCCTGTTTTTTACAGCATTGCTTCAGCTGTTTCACTTGCATTCTCCA
GATGAACTGGTTCCAAATCTGAAGCCCAGGTTAGGCATGACATGCCAACCGCAGCCTTACCTCATCTGTGCA 
>Ecab.P450.5 
ATGATGTTGTCCCAGCTCAGTCCCTTCTCGGCCACAGAGCTTCTCCTGGCCTCCACTATCTTCTGTCTGGTATTCTGGGTGGTCAGAGCTTGGCAGCCCCAG
ATCCCCAAAGGCCTGAAGAGTCCACCAGGGCCCTGGGGCTGGCCCTTCTTGGGGCATGTGCTGACCCTAGGGAAGAACCCACATCTGGCTCTGTCGAGGC
TGAGCCAGCGTTATGGGGATGTGATGCAGATCCGCATTGGCAGCACACCTGTGCTGGTACTCAGCGGCCTGGACACCATCCGGCAGGCCCTGGTGCGGC
AGGGCGATGATTTCAAGGGCCGGCCTGACCTCTACAGCTTCACTCTGATCACTAACGGCCAGAGCATGACCTTCAACCCAGACTCTGGACCAGTGTGGGC
TGCCCGCCGGCGCCTGGCCCAGAACGCCCTCAACACCTTCTCCATCGCCTCAGACCCAGCTTCCATGTCCTCATGCTACTTGGAGGAGCATGTGAGCAAGG
AGGCCGAGGCCCTCCTCAGCAGGTTGCAGAAGCTGATGTCAGTGGCTGGGCGCTTCGACCCCTCCAGCCAAGTGGTAGCATCCGTGGCCAATGTCATTGG
TGCCATGTGCTTCGGGCAGCACTTCCCCCACAGCAGCGAGGAAATGATCAGCCTTTTGAGAAGCAGCCATGAGTTCGTGCAGACTGCCTCCTCCGGGAAC
CCCGTAGACTTCTTCCCCATTCTCCGATACCTGCCCAACCCTCCCCTGCAGAGGTTCAAGTCCTTCAACCAGAGGTTCCTGCGGTTCCTGCAGAAAATAATC
CAGGAGCACTATCGGGACTTTGACAAGAACAGCATCCAGGACATCACAGGCGCCCTGTTCAAGCACAGAGAGAAGAGCTCCAGAGCCAGCGGTGTTCTC
ATCCCCCAGGAGAAGATTATCAACATTATCAATGACATTTTCGGTGCCGGATTTGACACAGTCACAACAGCTATTACCTGGAGCCTTACGTACCTTGTGACA
AATCCTAAGATACAGAGGAAGATCCAGGAGGAGCTGGACACAGTGGTTGGCAGGGCGCGGCAGCCCCGACTCTCCGACAGACCCCAGCTGCCCTATATG
GAGGCCTTCATCCTGGAGACCTTCCGACACTCCTCCTTCGTCCCCTTCACCATCCCCCACAGCACAGTAAGGGACACGACACTGAACGGCTTCTACATCCCC
AAGGAACGCTGTGTCTTCATAAACCAGTGGCATGTCAACCATGACGAGGAGTTGTGGGAGAACCCGTTTGAGTTCCGGCCAGAGCGATTCCTCAGTGCTG
ATGGCACCACCATCAACAAGACCTTGAGTGAGAAGGTGATGCTCTTTGGCATGGGCAAGCGCCGGTGCATAGGAGAAGTCCTGGCCAAGTGGGAGGTCT
TCCTCTTCCTGGCCATCTTGCTGCAACGGCTGGAGTTCAGTGTGCCACCAGGCGTAAAATTGGACCTAACCCCCATCTACGGGCTGACCATGAAGCATGCC
AGCTGTGAACATGTCCAGGCACGGCTACGGTTTTCCATC 
>Ecab.P450.17 
CAGGCCAAGGGGAACCCGGAGAGCAGCTTCAGTGATGACAACCTGCGCCTGGTGGTGGCTGACCTGTTCTCTGCAGGGATGGTGACCACCTCGACCACG
CTGGCCTGGGCCCTCCTGCTCATGATCCTGCACCCGGATGTGCAGCGCCGTGTCCAACAGGAGGTCGATGAGGTGATAGGGCAGGCGCGGCGACCAGAG
ATGGGGGACCAGGCCCACATGCCCTTCACCATGGCCGTGGTCCACGAGGTGCAGCGCTTTGCAGACATTGTCCCACTGGGTGTACCCCACATGACATCCC
GTGACGTTGAAGTGCAGGGCTTCCTCATCCCCAAGGGGACCACGCTCATCACCAACCTGTCATCGGTGCTGAAGGATGAGACCGTCTGGAAGAAGCCCTT
CCGCTTCCACCCCGAGCACTTCCTGGACGCCCAGGGCCGCTTCGTCAAGCAGGAGGCCTTCATGCCCTTCTCAGCAGGCCGCCGCTCGTGCCTCGGGGAG
CCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTGCCTCCTGCAGCGCTTCAGCCTCTCGGTGCCCGCTGGGCAGCCCCGCCCCAGCGACCACGGTGTC
TTTGGCTTCCTGGTGACCCCGTCCCCCTACCAGCTCTGC 
>Ecab.P450.18  
TTCTCAAAGATCTTCAGTTTAGATCTTGGAGGTATATCAACTGTGGTTCTAAATGGCTATGATGTAGTGAAGGAGTGCCTTGTTCATCAAAGTGAAATTTTT
GCAGACAGACCATGTCTTCCTTTATTCAAGAAGATGACAAAAATGGGAGGCTTACTCAATGCCAGATATGGCCGAGGATGGGTTGATCACAGAAGATTAG
CTGTAAACAGCTTTCGCTATTTTGGATATGGCCAAAAGTCTTTTGAATCTAAAATCTTAGAAGAAACCAAATTTTTCATTGATGCTGTTGAAACATACAAAG
GTAGACCGTTTGACTTTAAACAATTAATAACAAATGCTGTTTCAAACATAACCAATCTGATCATTTTTGGAGAACGATTCACCTATGAAGATACTGATTTTCA
267 
 
GCACATGATTGAGTTATTTAGTGAAAATGTGGAGCTAGCTGCCAGTGCCTCAGTCTTCCTGTATAATGCCTTTCCATGGATTGGCATCTTACCTTTTGGAAA
ACTTCAACAGCTGTTTAGAAATGCAGATGTGGTCTATGAGTTTCTCTCCAGGCTTATTGAAAAAGTTTCTGTCAACAGAAAGCCTCAGTTACCTCAGCATTT
TGTTGATGCTTATTTAGATGAGATGGATCAAGGTCAAAATGACCCGTCATCTACTTTCTCCAAAGAAAACCTCATTTTCTCCGTGGGTGAGCTCATCATTGC
TGGAACTGAAACTACAACCAATGTGCTACGGTGGGCTATTCTTTTCATGGCCCTTTATCCTAACATTCAAGGACAAGTTCAGAAAGAGATCGATTTAATTAT
GGGACCCAGTGGGAAGCCATCTTGGGACGACAAATGCAAAATGCCTTATACTGAGGCAGTTTTGCACGAAGTTTTAAGATTCTGTAATATAGTGCCATTA
GGGATCTTCCATGCAACCTCTGAAGATACAGTTGTACGTGGTTATTCCATCCCTAAAGGCACAACAGTAATTACAAACCTTTATTCTGTACACTTTGATGAA
AAGTACTGGAGAGACCCAGAAATATTCTATCCTGAGCGATTTTTGGACAGCAGTGGATATTTTGCCAAGAAGGAAGCTTTCATTCCTTTCTCCTTAGGGAG
AAGACATTGTCTTGGAGAACAGCTGGCTCGGATGGAAATGTTCCTGTTTTTTACAGCATTGCTTCAGCGGTTTCACTTG 
>P450.Equ.18 
GCCATTGCCCCCAAGGATGACCTTTTCTATGGCTTCCTGAAACCTTGGCTGGGAGATGGGCTGCTGCTCAGCAAAGGGGACAAGTGGAGCCGGCACCGC
CGCCTGCTGACCCCCGCCTTCCACTTTGACATCCTGAAGCCCTACATGAAGATCTTCAACCAGTGTACCAACACCATGCACGCTAAGTGGCGGTGCCTGGC
GGAGGGCTCCGTGGTCTCCCTGGACATGTTTGAGCACATCAGTCTCATGACTCTGGACAGTCTGCAGAAATGTGTCTTCAGCTACAACAGCAACTGCCAG
GAGAAGATGAGCGACTACATCACAGCCATCATCGCGCTGAGCGCGCTGGTGGTCCGGCGGCAGTACACCCTGCACCACCACCTCGACTTCATCTATTACCT
CACGGCCGATGGGCGGCGCTTCCGGCAGGCCTGTGACACTGTGCACCGCTTCACCACAGAGGTCATCCAGGAGCGGCGGCGGGGGCTACGCCAGCAGG
GGGCTGAGGCCTGGCTGAAGGCCAGGCAGGGCAAGACCTTGGACTTCATCGATGTGCTGCTGCTGGCCAGGGATGAAGAGGGGAAGGAACTGTCAGAT
GAGGACATCCGAGCTGAGGCGGACACCTTCATGTTTGAGGGTCATGACACCACATCCAGTGGGCTCTCGTGGTTGCTGTTCAACTTGGCCAAGTATCCAG
AGTACCAGGAGAAGTGCCGGGAAGAGATCCAGGAAGTCATGAAAGGCCGGGAGCTGGAGGAGCTGGAGTGGGACGACCTGACCCAGCTGCCCTTCACC
ACAATGTGCATCAAGGAGAGCCTGCGCCAGTTCCCGCCCGTGACGCTGGTCTCCCGCCGCTGCACGGAGGACATCAAGCTCCCCGATGGGCGCATCATCC
CCAAAGGAATCATCTGTCTGGTCAGCATCTACGGGACCCACCACAACCCCACAGTGTGGCCTGACTCCAAGGTGTACAATCCCTACCGCTTTGACCCGGAC
AACCCGCAGCAGCGCTCCCCGCTGGCATTCGTGCCCTTCTCCGCAGGACCCAGGAACTGCATCGGACAGAGCTTCGCCATGGCCGAGATGCGCGTGGTCT
TGGCGCTGACGCTGCTGCGCTTCCGCCTGAGCGTGGACCGCACGCACAAGGTGCGGCGGAAGCCGGAGCTCATCCTGCGCTCGGAGAGCGGCATCTGGC
TGAACGTGGAGCCGCTG 
>P450.Equ.23 
CCATTTCTTCTAGTTTCCTTCTGGGACACCTCCCCTACTTTTGGAAAAAGGACGAGGTTTGTGGCCGCGTGCTCCAAGATGTGTTTTTGGATTGGGCTAAGA
AGTATGGGCCTGTCGTGCGGGTCAACGTCTTCCACAAAACCTCGGTCATCGTCACGAGCCCGGAGTCGGTCAAGAAATTCCTGATGTCAACCAAGTACAA
CAAGGATTCCAAGATGTACCACGCAATCCAGACTGTGTTTGGCGAGAGACTGTTCGGCCAAGGCTTAGTGTCCGAGTGTGACTATGAGCGCTGGCACAAA
CAGCGGAGGGTCATGGATCTGGCCTTCAGCCGGAGCTCATTGATCAGCTTGATGGAGACGTTCAACGAGAAAGCCGAGCAGCTGGTGGAGATTCTGGAA
GCCAAGGCGGATGGGCAGACCCCGGTGTCCATGCAGGACATGCTGACCTGCACCACCATGGACATCCTGGCCAAGGCAGCTTTCGGGATGGAGACCAGC
ATGCTCCTGGGAGCCCAGAAGCCTCTGTCCAGGAAGGTGAAACTGATCCTGGAGGGTATCAGTGCCTCTCGCAACACTCTGGCGAAGTTTATGCCAGGGA
AGTGGAAGCAGCTGCGAGAGATCCGGGAAAGCGTCCGCTTCCTGCGCCAGGTGGGCAAGGACTGGGTCCAGCGCCGCCGGGAGGCCCTCAAGAGGGG
GGAGGACGTCCCTGCCGACATCCTCACGCAGATTCTCAAAGCTGAAGAGGGCGCCCAGGACGACGAGATCCTGCTCGACAACTTTGTCACCTTCCTCATT
GCTGGTCACGAGACCTCTGCCAATCACTTGGCATTCACGGTGATGGAGCTCTCACGCCAGCCCGAGATCTTGGCGAGGCTGCAGGCCGAGGTGGACGAG
GTCATCGGCTCTAAGAGGCACCTTGACTGCGAGGACCTGGGGAGGCTGCAGTACCTGTCCCAGGTTCTCAAAGAGTCGCTGAGGCTGTACCCGCCAGCGT
GGGGCACGTTTCGCCTGCTGGAGGAAGAGACCTTGATTGATGGGGTCAGAGTCCCCGGCAACACCCCACTCCTGTTCAGCACCTACGTCATGGGGCGGAT
GGACACATACTTTGAGGACCCGCTGACTTTCAACCCCGATCGCTTCAGCCCCAAAGCACCCAAGCCTCGCTTCACCTACTTCCCCTTCTCGCTGGGCCCCCG
CTCCTGCATCGGGCAGCAGTTTGCTCAGATGGAGGTGAAGGTGGTCATGGCCAAGCTGCTGCAGAGGCTCGAGTTCCGGCTGGTGCCCGGGCAGCGCTT
CGGGCTGCAGGAGCAGGCCACGCTCAAGCCACTGGACCCCGTGCTGTGCACCCTGCAGCCCCGGGGCTGGCAGCCTGCGCCCCCGCCCCCGCCCTGC 
>P450.Equ.30 chr28 
GGCCGTGTCCAACAGGAGGTCGATGAGGTGATAGGGCAGGCGCGGCGACCAGAGATGGGGGACCAGGCCCGCATGCCCTTCACCATGGCCGTGGTCCA
CGAGGTGCAGCGCTTTGGGGACATCATCCCACTGGGCTTGACCCACATGACATCCCGTGACGTTGAAGTGCAGGGCTTCCTCATCCCCAAGGGGACCACG
CTCATCACCAACCTGTCGTCGGTGCTCAAGGATGAGACCGTCTGGAAGAAGCCCTTCCGCTTCCACCCCGAGCACTTCCTGGACGCCCAGGGCCGCTTCGT
CAAGCAGGAGGCCTTCATGCCCTTCTCAGCAGGCCGCCGCTCGTGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTGCCTCCTGC
AGCGCTTCAGCTTCTCGGTGCCCGCTGGGCAGCCCCGCCCCAGCGATCATGGTGTCTTTGGCGTCCTGGTGACCCCGTCCCCCTACCAGCTCTGCGCTGAG
CCCCGC 
>P450.Equ.37 chr6 
TCCCGGCCAGGCATAGCCGCTGTGCTGCTGGGTTCGCGCCTGGGCTGCCTGGAGGCCGAAGTGCCCCCAGACACTGAGGCCTTCATCCGCGCGGTGGGT
TCCGTGTTTGTGTCCACGCTGCTGACCATGGCGATGCCCAACTGGCTGCATCGCCTCGTGCCCGGACCCTGGGGACGCCTCTGCCGAGACTGGGACCAGA
TGTTCGCATTTGCCCAGCAGCACGTGGAGCGGCGCGAGGCCGAGGTCGCCGGGAGGAGCCCGGGAAAGCCTGAGGAGGACATGGGATCTGGGGCGCA
CCTTACCTACTTCCTGTTCCGGGAAGAGTTGTCAGCCTCGTCCATCCTGGGGAATGTGACGGAGCTGCTACTGGCTGGAGTGGACACGGTGTCCAACACG
CTCTCTTGGGCTCTGTATGAACTCTCTCGGCACCCCGAAGTCCAGACGGCCCTGCACTCCGAGATCACAGCTGCCCTGGGCCCTGGCTCCAATGGCCACCA
TTCAGCCACTGCTCTGTCCCGGCTGCCCCTGCTTAAGGCCGTGGTCAAGGAAGTGCTGAGACTGTACCCCGTGGTACCTGGAAATTCCCGTGTCCCAGACA
GAGACATTCATGTGGGTGACTATATTATCCCAAAAAATACGCTGGTCACACTGTGTCATTATGCCACATCAAGGGACCCTGCTCAGTTTCCAGAGCCAAAT
TCTTTTCGTCCAGCTCGCTGGTTGGGGGAGGGTCCAGCGCCCCATGCGTTTGCATCTCTCCCTTTTGGCTTTGGCAAGCGCAGCTGTATGGGGAGACGCCT
GGCAGAGCTTGAGCTGCAAATGGCTTTGGCCCAGGTA 
 
>CYP1A1 
268 
 
ATGTTTTCTGTGTTTGGATTCTCTGTCCCCATCTCGGCCACAGAGCTTCTCCTGACCTCTGCCATCTTCTGTCTGGTATTCTGGTTGGTCAGAGCTTGGCAGC
CCCAGATCCCCAAAGGCCTGAAGAGTCCACCAGGGCCCTGGGGCTGGCCCTTGTTGGGGCACGTGCTGACCCTAGGGAAGAACCCACATCTGGCTCTGTC
GAGGCTGAGCCAGCGTTATGGGGACGTGATGCAGATCCGCATTGGCAGCACACCTGTGCTGGTACTCAGCGGCTTGGACACCGTCCGGCAGGCCCTGGT
GCGGCAGGGCGATGATTTCAAGGGCCGGCCTGACCTTCACAGCTTCACTCTGATCTCTGATGGCCAGAGCATGACCTTCAGCCCAGACTCTGGACCAGTG
TGGGCTGCCCGCCGGCGCCTGGCCCAGAACGCCCTGAAGAGTTTCTCCATCGCCTCAGACCCAGCTTCCATGTCCTCCTGCTACTTGGAGGAGCACGTGAG
CAAGGAGGCAGAATATCTCATCCGCAAGTTCCAGGAGCTGATGGCAGGGGTTGGGCACTTCGACCCCTACAAGTATGTAGTTATGTCAGTGGCCAATGTC
ATCTGTGCCATGTGCTTTGGCCGACGATATGATCATGATGACGAAGAGCTGCTTAACTTAATCAACCTGAATAATGAGTTTGGGGAGGTGGCTGCCTCCG
GGAATCCGGCTGACTTCATCCCTATTCTCCGTTATCTGCCCAACTCTGCCCTGGACACCTTCAAGGACCTGAATAAGAAGTTCTACATCTTCATGCAGAAGA
TGATCAAGGAACACAACAAAACATTTGAGAAGGGCCACATCAGGGACATCACAGACAGCCTGATCGAGCACTGTCAGGACAAGAGGCTGGATGAGAAT
GCCAATATCCAGCTGTCAGACGAGAAGATCATTAATGTCGTCTTGGACCTCTTTGGAGCTGGGTTTGACACAGTCACAACTGCCATCTCCTGGAGCCTCCT
ATACCTGGTGACAAGGCCCAGCATGCAGAAAAAAATCCAGGAGGAGCTGGATACGGTAATTGGCAGGGCGCGGCAGCCCCGGCTCTCTGACAGGCCCC
AGCTACCCTATATGGAGGCCTTTATCCTGGAGACCTTCCGACACTCCTCCTTCGTCCCCTTCACCATCCCCCACTGTACCACACGAAACACAAGTCTGAGTG
GCTTTTACATTCCCAAGGGGCATTGTGTCTTTGTGAACCAGTGGCAGATCAACCATGACCAGAAGCTGTGGGGTGACCCATCTGAGTTCCGACCAGAACG
GTTTCTCAACCCCAACGGCACCATCAACAAAGCACTGAGTGAGAAGGTGGTTCTCTTTGGCTTGGGCAAGCGGAAGTGCATCGGTGAGACCATCGGCCGC
TTGGAGGTCTTTCTCTTCCTGGCCATCCTGCTGCAGCAGGTGGAATTCAGCGTGCCGCCAGGTGTGAAGGTGGACATGACCCCCATCTACGGGCTGAGCA
TGAAGCATGCCCGCTGCGAGCACTTCCAGGTGCAGCTGCAGTTTGCAGTAAACACAGAGGATGAAGAAACACGCTGA 
>CYP2U1-like  
ATGGGTGATCACGTCCTTGAAGGGATTGTATTCGCACATTATGGTCCAGTCTGGAGACAGCAGAGGAAGTTCTCTCATTCAACTCTTCGTCATTTTGGCTT
GGGAAAGCTTAGCTTGGAGCCCAAGATTATTGAGGAGTTCAAATATGTGAAAGAGGAAATGCAGAAGCATGGAGCAGTCCCCTTCAGCCCTTTCCCCATC
GTCAGCAAGGCCGTCTCTAACATCATCTGCTCCTTATGCTTCGGCCAGCGCTTTGATTACAACGATACGGAGTTTAAGAAAATGCTGGATCTTATGTCACGA
GCGTTGGAAATCTGTTTGAACACCCAGCTCCTCCTGGTCAACATATGCTCCTGGCTTTATTACCTCCCCTTTGGACCGTTTAAGGAATTAAGACAAATTGAA
AAGGATATAACCACTTTCCTTAAAAAAATCATCAAAGACCATCGAGAGTCTCTGGATGTAGAGAACCCTCGAGACTTCATAGACATGTACCTTCTCCACAT
GGAGGAGGAGAGGAAAAGTAACAGCGATAGTAGTTTTAATGAAGATTACTTATTTTACATCATTGGGGATCTCTTCTTTGCTGGGACTGATACCACAACTA
ACTCTCTGCTTTGGTGCCTTCTGTATATGTCACTGAACCCCGAGGTGCAAGAAAAGGTTCACGAAGAAATTGAAAGGGTCATTGGTCCTGACCGAGCCCCT
TCCCTCACGGACAAGGCCCAGATGCCCTACACAGAAGCCACTATCATGGAGGTGCAGAGGCTGACTGTGGTGGTGCCGCTCTCCATTCCTCATATGACCTC
GGAGACAACAGTGCTCCAGGGGTACACCATTCCTAAAGGCACAGTGGTTCTACCCAACCTGTGGTCAGTCCACAGAGACCCAGCCATTTGGGAGGAACCT
GATGAGTTCCATCCTAATCGATTTCTGGATGATCAAGGACAACTTGTTAAAAAAGAAGCTTTTATTCCTTTTGGGATAGGGAAGCGGGTGTGTATGGGAG
AGCAACTGGCCAAGATGGAATTATTCCTCATGTTTGCGAGCCTAATCCAGAGTTTCAAGTTTGCTTTACCTAAGGATTCTGAGACGCCCCTCCTGACTGGA
AGATACGGTCTCACTTTAGCCCCACATCCATTTAATGTAATCATTTCAAAGAGATAA 
>CYP3A97 
ATGGACCTGATCCCCAACTTTTCTACAGAAACCTGGGTTCTCCTGGCTACCAGCCTTGTGTTCCTCTATCTATTTGGCACCTATACACATGGACTTTTTAAGA
AGCTCGGAATTCCTGGGCCGACTCCTCTGCCTTTCTTTGGAAATATTCTGAGCTACCGTAAGGGTATTTGGGATTTTGACAAGAAATGTTTTAAAAAGTATG
GAAAAACGTGGGGGTTTTATGAAGGCCGGCTTCCTGTATTGGCTATCACAGATCCAGACATGATCAAAACCGTACTAGTGAAAGAATGTTATTCTGTCTTC
ACAAACCGGCGAACTTTTGGTCCAGAGGGATTTATGAAAAATGCCATCACTCGGTCTGAGGATGAACAATGGAAGAGAATACGAACTTTGCTGACGCCAA
CCTTCACCAGTGGAAAGCTCAAGGAGATGTTCCCCATCATTGGCCATTATGGAGATGTGTTGGTGAGGAACCTAAGGAATGAAGCAGAGAAAGGCAAAC
CCGTCACCTTGAAAAACATCTTTGGGGCCTACAGCATGGATGTGATTACTAGCACATCATTTGGAGTGAACATAGATTCCCTCAACAACCCACAAGATCCCT
TTGTGGACAATGCTAAGAGGCTCTTAAGACTTGATTTTCTTGATCCACTCATTCTCTCAATAACTCTCTTTCCATTTCTTCGCCCAGTTTATGAAGCATTAAAT
ATCAGTGTGTTTCCAAAAAGTGTAACTGATTTTTTCATAAAATCTGTAAAAAGGATGAAAGAAAGTCGCCTCAAAAATAAGGAAACGAACCGAGTGGATT
TTCTTCAGTTGATGATTAACTCCCAGAATTCCAAAGAAATGGACACCCATAAAGCTCTGTCTGATCTCGAGCTTGTAGCCCAATCTATTGTGTTTATTTTTGC
TGGCTATGAGACTACGAGCACTTCTCTCTCCTTCCTTATGTATCTTTTGGCCACTCACCCTGATGTCCAGCAGAAGCTGCAGAAGGAGATTGATGTGACTTT
CCCCAATAAGGTACCTCCCACCTATGATGCCCTGCTACAGATGGACTATCTTGACATGGTGTTGAATGAATCTCTCAGATTATTCCCAGTTGCTGGTAGACT
TCAGAGGATCTGTAAGAAAGATGTGGAACTCAATGGGGTGTTCATTCCCAAAAGGACACTGGTGACTGTGCCAACCTTTGTTCTTCACCGAGCCTCAGAG
TTCTGGCCAGAGCCTGAAGAGTTTCGTCCTGAAAGGTTCAGTAAGGAGAACAAGGACAGCATAAATCCTTATATATACCTGCCTTTTGGAACCGGACCCC
GAAACTGCATTGGCATGAGATTTGCTCTGATGAACATGAAACTTGCTGTCGTCAGAGTGCTGCAGAACTTCTCCTTCAAACCTTGTAAAGAAACAGAGATA
CCCATAAAATTAGGCACTGAAGCAATTGTGAAACCACAAAAGCCCATTGTTCTAAAAGTTGAGCCCAGAGATGGGACCGTGACTGGAGCCTGACTTTCCC
TAAGGACTTCCACTGTTCTTCAAGGAAGCTGTATCCCAGAACACCAGAGATCTTAATTTACTTTGTGAATACAATTCAGAATGAAGGTGGGCTTAACCTACT
GCATGTGATGGATGCCTGAGATTCTTACATTTATTGATTTTCAGTGTCTATGTAGAGTATTACATGTTATGTGATATGAGCAGGACAGTGGTGCGGGTTGT
GACTCAGCTGTGTCCTGCAGATGATCTCCATCTCCCACTTAGACAATTCACTTTGCTGAACCTGAATCGGAAATAAATTTATCACCATTTTTATTAAAACCAC
AAAGGA 
>CYP2C26-like 
ATGGATCTGGTTGTGTTCCTGGGGCTCTGTCTCTCCTGTTGGTTTCTCCTTTCACTCTGGAAACAGAGCTCCAGGAAAGGGAAGCTCCCACCTGGCCCCACT
CCTCTCCCTATTATTGGAAATATCCTACAGTTAGATGTTAAGGACATCAGCAAATCCTTAAGCAATCTCTCAAAACTCTAGAAGAGACAATGGATCTGGTT
GTGTTTGGGCTTGAAGCCCACTGTGGTGCTGCATGGATATGAAGCAGTGAAGGAAGCCCTGATTGATCTGGGAGAGGAGTTTTCTGGAAGAGGCAGTTT
CCCAGTGGCTGAAAGAGTTAATAAAGGACATGGAATCCTTTTCAGCAATGGAAAGAGGTGGAAGGAGATCCGTCGTTTCTCCCTCATGACTCTGCGGAAC
TTTGGGATGGGGAAGAGGAGCATTGAGGACCGAGTTCAAGAGGAAGCCCGCTGCCTTGTGGAGGAGTTGAGAAAAACCAATGCTTCACCCTGTGACCCC
ACTTTTATCCTGGGCTGTGCTCCCTGCAATGTGATCTGCTCCATTATTTTCCAGAATCGTTTTGATTATACAGATCAGACTTTTCTTAACTTGCTGGAAAAATT
269 
 
TAATGAAAACCTCAGGATTATGAGCTCTCCATGGATACAGGTCTGCAATAATCTCCCTGCTCTCATTGATTATCTCCCAGGGAGTCATAACAAAATGCTTAA
AAATTTTGATTATTTGAAAAGTTACGTTTTGGAGAAAACAAAAGAACACCAAGAATCCCTGGACATTGACAATCCTCGGGACTTCATTGATTGTTTCCTGAT
CAAAATGGAACAGGAAAAGCACAATCAACAGTCGGAGTTTACTTTTGAAAACTTGATAGCTGCTGTATCCGATTTGTTTGGAGCTGGGACAGAGACAACG
AGCACCACCCTAAGATATGCTCTCCTGCTCTTGCTGAAGCATCCAGAGGTCACAGCTAAAGTTCAGGAAGAAATTGACCGTGTGATTGGTAGACACCGGA
GCCCCAGCATGCAGGACAGGAGCCACATGCCCTACATGGATGCCGTGATACACGAGATTCAGAGATACACTGACATCGTCCCCACCAACCTGCCTCATGC
AGTGACCTGTGACGTTAAATTTAGAAACTATATCATCCCCAAGGGCACGACCATATTAACATCACTGACTTCCGTGCTGTACGATGCTAAAGAATTCCACAA
CCCAGAGGTGTTTGATCCTGGCCACTTCCTGGATGAGAGTGGCAACTTTAAGAAGAGCGACTACTTCATGGCTTTCTCAGCAGGAAAACGAATGTGTCTG
GGAGAAGGTCTAGCCCGCATGGAGCTGTTTTTATTTCTGACCACCATTTTACAGAAATTTACCCTAAAATCTGTGGTTGACCCAAAGGATATCGACACCACC
CCAGCTGCCAGTGGGTTTGGCCATGTGCCAGCCTCATACCAGTGCTCTGCTTTATTCCTGTGTGA 
>CYP1B1-like  
ATGGCCACTAGCCTCAGCCTGGACGATCCTCTACTGCCGATCTCGCTGTCCACCCAGCAGACCACGCTCCTGCTGTTCCTCTCGGCGCTAGCCGCCGTGCA
CGTGGGCCAGTGGCTGCTGAGGCAGCGGCGGCGACAGCCAGGGTGCGCGCCCCCCGGCCCCTTTGCGTGGCCGCTGATCGGAAATGCGGCGGCTATGG
GCCCTGCGCCGCACCTCGCATTCGCGCGCCTGGCGCGACGCTACGGCGACGTCTTCCAGATCCGCCTGGGCAGCTGCCCAGTGGTGGTGCTGAACGGCG
AGCGCGCCATCCGCCAGGCCCTGGTGCAGCAGGGCGCTGCCTTCGCCGACCGGCCGCCCTTCGCCTCTTTCCGCGTGGTGTCCGGCGGCCACAGCCTGGC
TTTCAGCCAGTACTCTGAGCATTGGAAGGTGCATCGGCGCGCAGCGCACAGCACGATGCGAGCCTTCTCCACGCGCCAGCCGCGCAGCCGCCGCGTCCTC
GAGGGCCACGTGCTAGGCGAGGCGCGCGAGTTGGTGGCGCTGCTGGTGCGCGGCAGCGCCGGCGGCGCCTTCCTCGACCCGGTGCCGCTGACCGTGGT
GGCCGTGGCCAACGTTATGAGCGCCGTGTGCTTCGGCTGCCGCTACAACCACGACGACGCCGAGTTCCTCGAGCTGCTCAGCCACAACGAGAAGTTCGG
GCGCACGGTGGGCGCGGGCAGCCTCGTGGACGTGCTGCCCTGGCTGCAGCTCTTCCCAAACCCGGTGCGCACTGCCTTCCGCGAATTCGAGCAGCTCAAC
CGCAACTTCAGCAACTTCGTCCTCAACAAGTTCCTGAGCCACCGTGAAAGCCTTCGGCCGGGGGCCGCCCCCCGAGACATGATGGACGCCTTCATCCTCTC
CGCTGGAAAGGAGGCGGCTGAGGGCTCGGGCGACGGCGGCGCGCGGCTGGACATGGAGTACGTACCCGGCACTGTCACCGACATCTTCGGCGCCAGCC
AGGACACTCTCTCCACTGCGCTGCAGTGGCTGCTCATCCTTTTCACCAGGTATCCTGAAGTGCAGGCTCGGGTCCAGGCAGAATTGGATCAGGTCGTGGG
TAGGGACCGTCTCCCCTGCCTGGATGACCAGCCCAAGCTGCCCTATGTCATGGCCTTTCTCTATGAAGCCATGCGCTTCTCCAGCTTTGTGCCCGTCACCAT
TCCTCACGCCACCACTGCCAATGCCTCTGTCTTGGGCTACCACATTCCCAAGGACACGGTGGTTTTTGTTAATCAGTGGTCTGTGAATCATGACCCAGTGAA
GTGGCCTAACCCCGAAGACTTCGATCCAGCCCGCTTCTTGGACAAGGACGGCTCCATCAACAGGGACCTGGCCAGCAGCGTGATGATTTTTTCAGTGGGC
AAACGGCGGTGCATCGGGGAGGAGCTTTCCAAGATGCAGCTGTTTCTCTTCATCTCCATCCTGGCTCACGAGTGCAATATCAAGGCCAATCCAGACGAGC
TCTCGAAAATGGATTTTCATTATGGCCTGACCATTAAACCCAAGTCATTTAAAATCAATGTCACCCTCAGGGAGTCCATGGAGCTCCTTGATAGTGCTGTCC
AAAAGTTACAGGCCGAGGAAGACAGCCAGTGA 
 
